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ABSTRACf
The popular media (' 'Media" here referring to newspapers, magazines. television,
internet) adds to confusion and panic when reporting on the risks and benefits of
Hormone Replacement Therapy for women (HRT).
Most reports show bias, cast scientists as villains, or leave the reader more
confused than before about terminology.
The Southern African media does in general aspire to objectivity towards both the
pharmaceutical and natural health industry.
However, shallow or inept reporting, the need to generalise complicated findings
and dramatise what's regarded as cold scientific news, create this bias and
confusion.
Misleading health reporting, in South Africa as much as anywhere else in the
world, can change health behaviour and can even cost lives.
Ethical health reporting can therefore be described as a matter of life and death.
This paper aims to analyse the media for biased, confusing and alarmist reporting.
It then aims to explain reasons for the bias or confusion.
Fourteen reports are analysed. One Time magazine report, and 13 reports selected
from the Southern African media.
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OPSOMMING
Berigte oor Hormoonvervangingsterapie (HVT) vir vroue in die media (' 'Media' ') hier
verwys na koerante, tydskrifte, televisie, internet) dra by tot verwarring en paniek.
Die meerderheid berigte is bevooroordeeld, in die sin dat medici as booswigte uitgebeeld
word. Indien hulle nie bevooroordeeld is nie, is berigte verwarrend, soms juis in 'n
poging om konsepte te vereenvoudig.
Die media in Suider Afrika aspireer wel tot objektiwiteit, teenoor beide die farmaseutiese
sowel as die holistiese (kruie) industrie.
Nietemin, oppervlakkige/oningeligte verslaggewing en die behoefte om ingewikkelde
navorsing te vereenvoudig/interessant te maak, dra by tot vooroordeel en verwarring.
Misleidende mediese beriggewing in Suid Afrika, net soos in die res van die wêreld, kan
mense noop om besluite te neem wat hul gesondheid kan skaad.
Die belang van etiese verslaggewing kan dus as 'n kwessie van lewe en dood beskryf
word.
Hierdie studie ontleed berigte en ondersoek vooroordeel, verwarring of
sensasionalisering.
Redes vir bogenoemde word dan bespreek.
Veertien berigte word ontleed. (een berig uit die Amerikaanse tydskrif Time, en 13 uit die
Suider Afrikaanse media)
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1CHAPTER I
There are only two kinds of medical reporting: New Hope and No Hope.
(Victor Cohn's "First law of medical reporting")
1.1 Introduction
Media coverage is an important source of medical information for South Africans.
Misleading reporting can be risky. People may experience undue hope or fear. They
may even start, or stop, treatment.
Coverage is often alarmist, reflecting misunderstanding or popular social beliefs.
Nelkin (1995: viii) writes in Selling Science:How the press covers science and
technology:
"The increased scale of science has raised questions of social priorities and
research costs; the growing importance of research in human biology has raised
concerns about ethical implications; the many reports of scientific fraud have
increased public mistrust; and the continuing incidents of technological risk have
turned individual events into generic problems. The coverage of science in the
1990s has also been influenced by the growing competition in the media: events
are dramatized and public figures villainized in the endless quest for news. "
Cohn (1989: 5) the former science editor of the Washington Post, stresses in News and
Numbers, how health reporters may make the public quake when they write danger, or
may falsely re-assure the public if they write no danger. He also notes that it is not
what we write; it is what we emphasise that can influence healthy or unhealthy lifestyle
choices.
HR T has been in the news since 1963 when the press proclaimed its extraordinary
benefits and promised miracles. Typical headlines read: "Preventing Menopause,"
"Science Paints Bright Picture For Older Women".
It turned into a feminist debate with some women accusing pharmaceutical companies
of pushing the false quest towards eternal youth to enrich them. On the other hand,
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2many women felt they had a right to the choice of eternal youth and was not going to
be made feel guilty about vanity and accepting their "lot".
Nelkin (1995: 41) asks:
"Who were the experts cited by reporters promoting ET? The major source of
information was Dr. Robert A. Wilson, a gynaecologist, an active promoter of
oestrogen treatment, and the director of the Wilson research Foundation. Funded
by three drug firms, his foundation existed to publish and distribute
recommendations about specific products. Wilson has published a popular book
called Feminine Forever".
Clearly the discovery of a pill that would keep women young forever was a
newsworthy event: Reports of this discovery not only touched on a subject of wide
interest, but also conveyed a message readers wanted to hear. The problem with this
promotional reporting was that it ignored or underplayed the growing evidence
indicating ET's potential risks.
"Media interest in promoting a treatment to keep women lovely and young gave
way to 1980s feminist sensibilities and the desire to be politically correct. But in
the 1990s, as a baby boom generation reaches their fifties and public attention
has turned to women's health, ERT again hit the news -- despite the fact that
there is little new to report on the costs and benefits of a medication sustained as
much by ideology as by definitive research."
Jenni Murray (Murray: 2003: 2), author of several articles and a book on menopause,
writes in a column in The Guardian newspaper:
"There is evidence that the promotion ofHRT, and our willingness to embrace it,
was indeed the result of a male conspiracy born out of loathing and suspicion of
the ageing female. Medical literature of the 18th century refers to the menopause
as a catastrophic tragedy, and post-menopausal women were described as dull
and unattractive. The worst offender arrived in the mid-20thth century. Robert
Wilson, an American doctor, published his book Feminine Forever in 1966. He
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3described menopausal women as castrated by the menopause. He promoted HRT
as the long-sought elixir of life".
For feminists this has sparked many years of bitter debate:
"In the blue comer are women such as former MP Teresa Gorman who, at 70,
gaily reports that she feels and looks as well as she did in her 40s, and claims that
if she were diagnosed with breast cancer tomorrow, she would be grateful for the
years of well-being she attributes to the treatment. In the red comer we have
women such as (well-known feminist author and activist) Germaine Greer, who
in The Change, saw the medicalisation of the menopause as a male conspiracy
that poisoned women and recommended that we embrace our old crone-ness".
Murray agrees that many women have been told lies by the medical establishment.
However, she warns against a modem backlash. She advises a golden mean:
"There is no reason to become a casualty in this war. We can inform ourselves
of the sexual politics and the procedures on offer, balance the risks and decide
what kind of older women we want to be".
She admits that she chose the treatment, after informed consultation with her doctor.
The media should try interpret medical evidence without being swayed by reigning
socio-political beliefs. Reporters should not be afraid of either the medical establishment
or by what their audiences feel is politically correct to hear.
While it's true that there are capitalist motives to sell a product, the benefits of HRTand
ET also certainly hold water. The risks are not to be ignored, but crying wolf might in
the end desensitise the public to dangers. The media should supply informed reports on
the pros and cons.
The current Zeitgeist is distrustful of everything "unnatural".
It seems to have caused a backlash against hormonal supplements. This is often
disproportionate, and can cause action that may be equally detrimental to women's
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4health. In many countries, the natural health industry is, if not fanning the flames of a
backlash, certainly cashing in on the trend against "big bad chemical drug pushers".
Much publicity has been given to the fact that the chemical industry has indeed used
strategies to counter its negative image. Companies have used the media to provide
"facts". Public relations campaigns have been launched against what is known as
"cancer phobia" and "chemo phobia".
Nelkin (1995: 139) writes:
"By 1992 Wyeth-Ayerst Laboratories was spending over 9 million US dollar to
advertise their product in women's magazines that, appealing to their ageing
readership, often feature articles and news reports on the effect of HRT on the
symptoms of growing old".
Now in the 21st century, women feel hoodwinked, while scientists feel a storm in a
teacup is being used to push the herbal industry.
The medical fraternity's general view about the WHI furore is summed up in the
following quote. Calling it a "backlash", Dr John Stevenson of London's Imperial
College (Endocrinology and Metabolic Medicine), writes in the Irish Medical News
(2004: 2)
"You get the feeling that there's an orchestrated campaign against HRT. Is it due to an
industry that thinks if they could destroy HRT it would increase the market for a
particular product?"
The HRT debate has since the 60s been one of the media's favourite headlines.
News about Hormone Replacement Therapy sells well today.
Apart from the politics of feminism, it contains attention-grabbing elements that make
publications fly off the shelves -- death, sex and ageing.
1.2 Explanation of terms
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5Menopause is a natural progression III a woman's reproductive cycle. Levels of
circulating female hormones, oestrogen and progesterone, drop.
This normally starts happening between ages 45 and 50.
Odendaal (Odendaal et al, 2000: 335) describes this period in a woman's life, the
climacterium, as manifesting the following possible symptoms:
Physical -- night sweats, hot flushes, vaginal dryness, loss of libido, insomnia,
fatigue, skin changes and a depletion of calcium, resulting in "brittle bones" or
osteoporosis. This increases the risk of bone fractures. Some women also report
emotional symptoms -- anxiety, mood swings, depression, and memory loss.
Hormone Replacement Therapy (HRT) is a combination of oestrogen and progesterone
used by women who have started to experience discomforting symptoms of
menopause, and who have not had hysterectomies. Women who still have their uterus
intact run the risk of uterus cancer when taking unopposed; oestrogen only supplements.
Progesterone offsets the risk of uterine cancer.
Oestrogens are manufactured from the urine of pregnant mares and synthesised from
plants. Most medical experts agree that the body does not differentiate between natural
("natural" meaning produced by the ovaries) and synthetic hormones.
HRT is used to alleviate menopausal symptoms, and prevention and treatment of
osteoporosis.
Some women say it makes them look younger by improving skin elasticity.
For the purposes of this paper, when referring to oestrogen only supplements, I
will stick to the American-used abbreviation ET.
Phyto oestrogens are the "plant-based" oestrogens that are not used in HRT.
HRT oestrogens are either animal products or synthetic.
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61.3 Background to the WID study and summary of fmdings
The WHI randomly assigned 16 608 postmenopausal women 50 to 79 years of age (mean
63) with an intact uterus to HRT, or a placebo. The WHI study was supposed to last 8
years and examined various health factors connected to HRT. It was stopped three years
short because of a small but statistically significant risk observed for breast cancer in the
HRT group after five years. The study also did not find HRT use added any significant
"lifestyle" benefits (whether women slept better or were less depressed). It did find a
statistically significant reduction in the colon cancer and hip fracture risk category.
The WHI was what Cohn (1989: 38) describes as medicine's "gold standard", a
controlled, randomised clinical trial.
"At its best, the investigator tests a treatment or drug or some other intervention
by randomly selecting at least two comparable groups, the experimental group and
a control group that is observed for comparison. True clinical trials are expensive
and difficult. It has been estimated that of 100 scheduled trials, 60 are abandoned,
not implemented, or not completed, whether for lack of funds, difficulty in
recruiting or keeping patients, toxicity or other problems, or, sometimes, rapid
evidence of a difference in effect (making continued denial or effective treatment
to a control group unethical)."
That's exactly what happened with the WHI trial.
The British Menopause Society ( Newsletter, 2003: 2) summarises how the WHI was
begun in 1991 by the National Institutes of Health:
"More than 160 000 post-menopausal women, ages 50 to 79, were recruited for
various trials designed to find the best ways to prevent heart disease, breast and
colorectal cancers, and osteoporosis. Final results were due out in 2005. One part
of the study, involving 16000 women was halted in May 2002. Half of the 16000
were randomly assigned to receive HRT and the other half were given a placebo,
or dummy pill. Neither the women not their doctors knew who was taking the
HRT. It was halted because the number of breast cancer cases had reached a pre-
specified safety limit. The study had not shown any benefit for cardiovascular
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7diseases, including heart attacks and strokes, although it had shown some other
benefits for hip fractures and bowel cancer. Superficially, the percentage increases
in breast cancer and cardiovascular disease look alarming, but this will depend on
the way that the results are expressed, namely as relative risk or as absolute risk."
The fact that the study was halted early and the fact that details were released early,
added to a sense of alarm.
1.4 How it broke - embargoes and ethics
Scientists are to reporters what rats are to scientists. Would scientists allow their
subjects to check the interpretation of their behaviour?
(Victor Cohn)
Nelkin (1995: 152) explains what's known as the Ingelfinger rule:
"In 1968 Franz J. Ingelfinger, then editor of the New England Journal of
Medicine, decided that he would not publish a scientific article if the details had
been previously reported in another journal or the press. He wanted the Journal
to remain newsworthy. His successor Arnold Relman, perpetuated the rule. He
argued that prior disclosure places a burden on physicians, who should have the
opportunity to read about research in an authoritative source before being
besieged by patients clutching a newspaper article.
However, journalists are appalled by the Ingelfinger rule, arguing that it violates
the public's right to know."
Findings of the WHI study were leaked to the public media before the peer review
report. The reporter who wrote the story had interviewed one of the WHI physician
investigators. Breaking the embargo for the sake of a scoop sparked severe criticism
from medical circles. The way it was broken is believed to have caused undue public
alarm.
Findings first appeared in the Detroit Free Press newspaper in the United States. An
extensive report was then published as cover article in the respected Time Magazine.
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8The WHI study embargo break illustrates how interpretations of urgency can vary.
Scientists try and control press coverage by refusing interviews unless they can review
and correct the copy prior to publication. Reporters, fearing censorship by vested
interests, are reluctant to show their articles to sources.
Here it helps to apply the SAD formula for moral reasoning, devised by Louis A.Day
(Day, 2000: 65-67):
Situation definition: Describe facts, identify values, and state the ethical issue/question.
Analysis: Weigh competing values, consider external factors, examine duties of
various parties, and discuss ethical theories.
Decision: Render moral agent's (editor's) decision. Defend that decision based on
moral theory.
The issue here is whether it was in the public interest to know the facts before
publication in a medical journal. Is there a need to know or is it just nice to know?
Cons: Itmight spark undue panic/alarm.
Pros: It will certainly sell and there is after all a newspaper's need to survive
economically and a duty to shareholders.
But did the WHI findings warrant an embargo breach? The public was going to be
informed anyway.
The moral agents (editors) had a duty to:
1. The public.
2. The doctor interviewed who leaked the findings before embargo time.
3. Competitive interests.
The paper decided to go public.
Therefore, results of the study were first run by the Detroit Free Press on Monday July
the 8th 2002.
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9So detail of the study became public before it was published in any medical journal.
The story was picked up by other news agencies.
The Journal of the American Medical Association (lAMA) felt that the embargo breach
created unnecessary confusion and exaggerated importance of the findings. The JAMA
expressly asked the reporter who broke the story to refrain from publishing it in the
popular press before it was published in the journal.
The JAMA felt that honouring embargoes of this nature helped foster responsible
reporting. Doctors who were inundated with calls from anxious patients were
unprepared to deal with queries since they had not read the findings. (JAMA, June
2002)
It is difficult to judge when best to release information to the press when scientific
research bears on health.
Nelkin (1995: 155) quotes Barry R. Bloom of the U.S-based Albert Einstein
College of Medicine:
"Until data are interpreted and validated, until the experimental design and
significance are reviewed, and until all currently available data on the incidence in
exposed human populations can be integrated, the rush to the press is mindless, if
not unethical".
However, she mentions that total adherence to such constraints would be impractical; the
press would wait indefinitely for medically related science news.
Johan Retief (Retief, 2002: 38) has a word of caution for such situations:
"The conviction that the public has a right to know is of the utmost importance to
the freedom of the media and indeed also to the upholding of democracy.
However, journalists often make the mistake of pointing out to their sources that
they (the media) have a right to know. The media are far from being that special.
Remember that the media are only vehicles through which the public can be
informed. It is in the first instance not the media, but the public, who has the right
to know. It is the individual's right to know that gives the media a reason for their
IJHJVERSiTEIT ST8.I.ENBOSCM
BIBLIOTEEK
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existence. It is only on this basis that the media can function as watchdogs and
that they need ethical guidelines to fulfill their function properly."
The WHI study reports had global implications on markets. News that the United States
government halted an HRT study involving the pharmaceutical product Prempro (the
estrogen/progestin combination used in the WHI study) hit share markets the following
day.
On July the 9th drug maker Wyeth's shares tumbled over 19 per cent. Prempro is a
member of Wyeth's Premarin family of hormone replacement therapies, and accounts for
14 per cent of the company's sales.
Britain's AstraZeneca shares were hit the next day. And the FTSE 100 index closed
sharply lower.
(Business Report: July 9 2002)
The Southern African media picked up the story. Debate flared with contradicting
headlines and reporting.
Thousands of women jammed call-in lines, wanting to quit their medication cold.
My mother, in her seventies, has been on ET for about 30 years.
After a full hysterectomy (ovaries, tubes and uterus removed) in her early 40s -- she's
taken ET (oestrogen only therapy) every day of her life.
She goes for a mammogram once a year and has her cholesterol levels checked.
She has never has osteoporosis-related problems and leads a high-energy life.
When asked to show ID to prove she qualifies for the "over 60" benefits in public
places, she feels flattered. My dad, the same age, is annoyed when strangers think she's
his daughter.
Maybe se simply has good genes, and she's never had unhealthy habits.
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Maybe she is indeed a poster girl for the "elixir of youth" oestrogen-related treatment
was punted to be decades ago.
The media reports alarmed her since they did not make clear to the layperson the
distinction between oestrogen replacement and combination oestrogen/progesterone
Treatment. After several days of worry, she was convinced not to quit cold. She
consulted with her physician and exercised her informed choice to stay on the drug.
Unlike other women who did quit.
In The Guardian article, Murray tells of an elderly relative who took HRT with no ill
effects for more than 20 years and stopped suddenly in her 70s because of fears of breast
cancer as a result of continued and confusing media debate.
"Shortly after quitting, she had a full house of typical symptoms and has so far suffered
two broken hips as a result of the drop in bone density".
CHAPTER TWO
2.1 Methodology
This paper covers the period from publication of principal results from an American
Women's Health Initiative randomised control trial on HRT in July 2002.
My goal was to compare references to the WHI study in medical journals (The Journal
of the American Medical Association JAMA, New England Journal of Medicine NEJM,
the South African Journal of Medicine SAJM, and Medscape), with reports in the
popular southern African media.
Thirteen print reports (including a Time magazine report) and one television report
from between July 2002 and October 2003 were used.
Quotes commented on are in italics. All Reports analysed are in the Appendix.
I scanned text for the following five points:
1. Anti or Pro-HRT bias
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2. The medical fraternity cast as villain
3. The natural health industry pitted against the pharmaceutical industry
I grouped under the following categories the most common errors/omissions that
contributed, intentionally or unintentionally, to the above:
Incorrect reference to WID study, Selectivity, Use of headlines and photos, Use of
statistics, (Relative Risk and Absolute Risk) Generalisation, Dramatisation, Quoting
extreme opposite views, Confusing reporting.
4. I checked whether reports mentioned confounding factors such as:
* Flaws in the study (The women in the WHI HRT study were all over 60, high above
the age at which most women use HRT. Women in their 60s are usually post menopause
or had hysterectomies, and would be on oestrogen replacement (ET) only. Some of the
women were obese and some used to be smokers. These may have contributed to
negative coronary and breast cancer risk factors.).
* The fact that only one HRT brand -- Prempro, was used in the WHI study. and
whether reports mentioned that other HRT brands might not have the same effect.
* The difference between oestrogen only (ET) and oestrogen/progestin (HRT).
* Whether it was pointed out that the period of use might playa role in risk and result.
5. Type of media used
I hypothesised that magazine features have the best "chance" (more space and more
time) to be accurate and give the full picture, with newspapers and television coming
second and third in terms of quality and depth of reporting.
I checked whether the use of by-lines made a difference to quality/depth of reporting.
Chapter three is a discussion of the common errors and omissions.
I found that bias or alarm was sparked more by "well-meaning" but shallow reporting,
than by deliberate manipulative omission.
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I found that bias or alarm was sparked more by "well-meaning" but shallow reporting,
than by deliberate manipulative omission.
Chapter four gives recommendations on avoiding the errors and omissions. "reading"
statistics, and questions to ask scientists.
Magazine features : Sarie (Published by NasperslMedia24) - Target: Afrikaans-
speaking, family orientated women (Higher Lifestyle Measurement)
HealthlFitness magazines -- Longevity and Shape - Targets: Women mid twenties and
up, Higher Lifestyle Measurement.
(The South African Advertising Research Foundation: All Media and Products Survey,
(online) Retrieved from the worldwide web March 2003: http.Z'www.Touchline.co.za)
Newspaper reports from: The Cape Argus, Die Burger, Weekly Mail and Guardian and
The Daily Mail.
News24 website - Health24 -- also part of the Media24 Group.
One television news report about the study was broadcast over the time: Both etv and
SABC3 ran the same report by line agency Reuters as is, and did not solicit local opinion.
CarteBlance, the MNet channel's investigative programme, informed that they never
covered the HRT controversy.
2.2 Analysis
Report 1
Time magazine July 2002
Headline - The truth about Hormones
Comment: The headline implies that a lot of lies abound.
Use of photos: The cover photo shows a middle age-looking woman with an expression
of what seems concern. Other photos are of another 40-plus, unsmiling woman. A third
photo shows an older looking woman staring at herself in the mirror, looking concerned.
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By-lines - Several reporters collaborated on the issue.
The article was the cover story, consisting of several pages of reporting with alarmist
subtitles:
A large federally-funded study provides definitive proof that oestrogen and progestin
are not age-defying wonder drugs. What's a woman to do?
Comment: Oversimplification and dramatisation
In News and Numbers, science writer Victor Cohn (Cohn, 1994: 59) points out that:
"Virtually no single study proves anything. Two or 4 or 15 studies (only) add credence,
especially if the diagnosic and outcome criteria and the people studied are similar."
But a single study rarely proves anything.
The phrase What's a woman to do? Conveys a sense of drama and frenzy.
The reports use anecdotal material, withquotes casting doctors as "bad guys" against
unsuspecting women -- Maybe I've been too trusting.
It kicks off with a case study that says she is confused and angry.
The next paragraph again casts the doctor in the role of villain: I did not have any
symptoms, but he recommended itfor general well-being, bones and heart.
It stresses that women now don't know where to go or whom to listen to.
It interjects: Whom indeed.
That phrase editorialises. The reporters do not merely let the patients or the experts state
the facts. It sets an ironic tone, and adds colour -- that of women left in the lurch.
The feminist debate surfaces in a quote by the International Organisation to Reclaim
Menopause: We need to accept menopause as a natural normal physiological
process ...the idea that our bodies fail us at menopause is ludicrous, extremely sexist and
just plain wrong. It then gives some background history about how hormone
supplements were "pushed" about 40 years ago:
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Like latter-day Ponce de Leans, however, these women are watching their dream of
eternal youth fade away. A large, federally funded clinical trial, part of a group of studies
called the Women's Health Initiative (WHI), has definitively shown for the first time that
the hormones in question-estrogen and progestin-are not the age-defying wonder drugs
everyone thought they were.
Comment: Generalisation and Incorrect reference to published study
It's not sure what's meant by "age-defying". The end point of the study was to examine
effects on health, not lifestyle - not whether it kept skin supple or give that "youthful
glow". Medical Journals in the appendix clearly state that; "estrogen plus progestin does
not confer cardiac protection and may increase the risk of CHD among generally healthy
postmenopausal women, especially during the first year after the initiation of hormone
use. This treatment should not be prescribed for the prevention of cardiovascular
disease."
They also state that HRT is still the best treatment for menopausal symptoms. The
journals report positive findings from the WHI as well. HRT might playa role in
preventing brittle bones (that causes what's known as a "dowager's hump") and it lowers
the risk of cancer of the colon. Should these not be included under age- defying?
Whether it is or is not an age-defying wonder drug has been an open question for many
years. So this is not a finding. The study's findings did not focus or comment on youth as
such.
The paragraph can also be described as selective: ignoring the good news while focusing
on the bad news. It does not even mention in passing that the study has also "definitely
shown for the first time" that it prevents (or lowers the risk of) brittle bones and colon
cancer.
Definitely shown for the first time
Comment: Oversimplification. A single study rarely proves anything so inconclusively.
See discussion in Chapter 3.
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As if that weren't bad enough, the results, made public last week, proved that taking these
hormones together for more than a few years actually increases a woman's risk of
developing potentially deadly cardiovascular problems and invasive breast cancer,
among other things.
Comment: Inaccuracy resulting from a need to dramatise.
As if that weren't bad enough, is editorializing. Additionally; the results were going to be
made public anyway. It sounds as if there was going to be an attempt to keep the findings
a secret. The tone also accuses the makers of HRT of "breaking a promise" of supplying
eternal youth. Again the phrase the results proved is used. Use of the adjectives
potentially deadly and invasive is alarmist and unnecessary. What cardiovascular
problems are not potentially deadly anyway?
The difference between invasive and non-invasive is not explained.
Here at last is a rare moment of clarity. The debate over the long-term benefits and risks
of HRT has lasted for decades. Now we have at least a few concrete answers. The
findings are so striking that the study was stopped three years short of its scheduled
completion. (The other WH] trials, which include a look at how estrogen alone affects
women with hysterectomies, are still proceeding.) And the formal scientific report, which
is being published in this week's Journal of the American Medical Association, was
released a week early at a press conference in Washington.
Comment: Starting the sentence with Here at last is a rare moment of clarity is
overdramatisation. The WHI cast in the role of saviour of the female race. Many studies
before have indicated similar results. One single study rarely provides conclusive clarity
on anything.
The paragraph also contains an incorrect reference to published study.
The study was not stopped because the findings were so striking. Context was
selectively omitted by the sentence.
Researchers set down a predetermined "safe" number of cases. If more cases of a
disease than that predetermined number develop disease, it was agreed that on that
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figure, it would be unethical to continue observing statistics. This is what's called the
"predetermined hazard level". In other words, the safety bar was set very high.
The paragraph also does not present full context. This is omission that is misleading:
The report was released a week early, not because of the staggering findings, but
because it was leaked before an independent peer review (before the medical fraternity
could advise on the findings).
Under the heading Some questions still.
The report does mention that one brand of medication was used in the HRT study group,
Prempro, and that the WHI findings might not be applicable to other brands of
medication. And that so-called natural oestrogens are not risk free.
The Times report is well-written from a statistical point of view.
However, it selectively oversimplifies statistics.
It gives the Relative Risk statistics for the "bad" news (heart attacks, blood clots, breast
cancer) while giving the Absolute Risk figures, in brackets, for the "bad" news.
Though the women on HRT suffered fewer hip fractures (1 woman per 1000 per year
vs.l l/Z women per JOOOper year).
Summary
Anti HRT, presenting no "good news" contained in the medical journal reports, using
adjectives not used in the medical reports.
It casts the medical fraternity in the role of villain.
It uses relative Risk (RR) figures mentioned in the medical journals only.
Confounding factors:
I.Flaws (Study group age and health)
Mentioned that Prempro findings do not
Not mentioned
2.Prempro
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apply to other products
3.HTIHRT difference Explains that the ET leg of the study
continues
4. Period of use plays a big role Mentions that HRT used over many years
increases risk
If I was on HRT this report would have made me feel more nervous, distrustful of my
doctor, and even guilty of vanity for using it.
Report2
Longevity November 2004
Title -To be or not to be, on HRT
Byline - Prevashni Ramsamy
Use of photo - Positive image of 4 happy corporate looking women representing ages
between 20 and 60.
Introduction -Has the death knell sounded for hormone replacement therapy, as we
know it?
It also contains the phrase pains ofmenopause.
Comment: Selective: "Good" news emanating from the study put on the backbumer.
Although put in question form, the first line casts a feeling of doom over HRT use. The
use of the phrase death knell in this context also creates bias. Menopause as a "pain"
strengthens the image of women as choiceless victims at the mercy of pharmaceutical
experts.
The tone setter or introduction starts with what is known in media jargon as a "Johnny"-
- a case study.
Felicity is an intelligent, respected 50something attorney.
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Although this sentence has no direct bearing on the reader's perception of HRT, it
strengthens a stereotype. One detects prejudice - a tone of surprise that 50-something
female attorneys are not intelligent and respected by default.
Sensationalism/dramatisation: Adjectives abound:
In the second paragraph the word concern about the dreaded disease is used three times.
The medical fraternity's onslaught portrays a negative image of the medical fraternity as
villain and women as victims.
The reporter refers to the WHI study and the UK Million Women study as Indicting
HRT as a central cause of increased breast cancer incidents, links to heart disease and
deep vein thrombosis.
The word indict again creates the image of the medical fraternity as standing accused of
pulling the wool over women's eyes.
Wide-eyed women desperately seeking a simple solution to a difficult time in their lives
More sensationalism/dramatisation. The sentence continues the use of adjectives
conveying a sense of panic and stereotyped victimhood. Women are portrayed as
victims of a plot to deprive them of a wholesome solution to their suffering.
The WHI had planned to investigate the long-term effects of HRT over a period of eight
years.
Comment: Selective and Incorrect reference to published study. Reporter omits context
and background. The aim of the WHI study was not merely to "investigate the long term
effects of HRT over a period of eight years".
The study focused on whether or not HRT reduces the risk of coronary heart disease.
According to Dr Phillip Zinn, gynaecologist at Kingsbury Clinic in Cape Town
(personal communication: October 2003), many studies before have investigated the
long-term effects of HRT and it is not staggeringly new news that there is a slightly
increased risk of contracting breast cancer.
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A study in the respected British Lancet medical journal compared the effects of
treatment with HRT.
Comment: Verbally clumsy. It was not a study in Lancet that compared the effects, but a
report on a study in the Lancet that compared the effects.
It is also indeed true that figures indicate a 26 per cent relative risk. However, context is
omitted.
The reporter refers to noted allopathic experts who called the issue media frenzy and
misrepresentation. Allopathic experts" is not commonly used. The reporter could have
used the word "conventional medicine" instead.
It does present an opposing view by stating that the experts believe that hormones are
still the treatment of choice for menopausal complaints.
The media in reporting on the WHI findings is portrayed as "on the side of' women.
It omits to say what the product or the dosage of progesterone/oestrogen treatment used
in the WHI study was (Premorin and Provero), whether this product or similar is used in
southern Africa, or what exactly a fairly high dose means.
The article then attempts to get the views of experts representing the two opposing view.
It quotes Professor Franco Guidozzi, head of the department of Obstetrics and
Gynaecology at Johannesburg Hospital. Saying he is doing damage control on the
findings. He is quoted as accusing the media of again creating an emotive wave of
uncertainty. This repeats the earlier image of a standoff -- doctors versus the media. He
repeats the lower dose advice.
On the other side of the debate is Dr Arien van der Merwe. A holistic sounding quote is
used when she talks about science having finally caught up with the natural wisdom of
centuries. At the bottom of the page is a block containing the doctor's natural
prescription.
It adds that her book on natural remedies is available through Tafelberg Publishers at
bookshops.
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Comment: In presenting two opposing voices on two extreme poles of the argument,
balance is not provided. Simply providing a 50/50 view often does not help provide the
bigger picture.
The main part of the article ends with a quote by the case study. The tone is reproachful -
- somebody got a bad "deal", without her knowledge or consent:
Her cancer, promoted by the HRT pill that was meant to prolong her life.
It is also generalisation. All other possibilities but HRT that "promoted her cancer" (such
as lifestyle) have not been exhausted. The article does not state any conclusive "smoking-
gun" proof that HRT promoted her cancer.
To end, the article summarises the changing beliefs in the remedial qualities of HRT
over the years.
It mentions a few positive effects of HRT "in passing". This is under the subheading
"Benefits and risks ofHRT in context", quoting Professor Guidozzi.
Under the heading "until 2002":
Studies indicate that HRT does prevent bone loss (osteoporosis) after four or five years.
Cognitive functioning, Alzheimer's, sleep disturbances, mood fluctuations and colon
cancer are improved with HRT.
Comment: Selective: When reporting on the positive effects, she omits to add credibility
to the statement by specifying which study.
The reporter does add that bone loss is prevented after four or five years. However,
when reporting on the risk (breast cancer, stroke and deep vein thrombosis) she omits to
mention similar -- after four or five years.
The logical construction of colon cancer improved with HRT is confusing but probably
meaningless error/negligible.
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The WH! study reflected a 26 per cent increase in breast cancer in women receiving
HRT compared to those receiving the placebo is Inaccurate. It should have read: the
study reflected a 26 per cent Relative Risk increase, not an increase in cases.
Meanwhile, the "positive" outcomes (reduced colon cancer and bone fracture risk) are
omitted in terms of Relative Risk.
(When comparing the medical journal report relative Risk figures, one sees that, the
WHI study has likewise proved that:
Risk of hip fractures are down by 33 per cent for women on HRT, and colon cancer
down by 37 per cent.)
Under the heading 2002-2003:
HRT is associated with specific breast cancers - invasive breast cancers, and not with
lesions that start growing and become cancers.
Comment: Confusing terms.
(See discussion by Dr Zinn in Chapter 3)
She also touches upon the UK Million Women Study: The study indicated that the risk
of breast cancer (relative to placebo) is twice as high for those taking combined HRT.
Again, statistics oversimplified. The difference between relative risk and absolute risk
is not explained and only the relative risk figure is given. While the results have been
called statistically meaningful in the medical journals, and should be reported in
responsible media, the findings and statistics should be placed in context, so as not to
spark public alarm.
The rest of the article states advantages of natural healthy therapies, with more quotes
by Dr Arien van der Merwe:
The last point is an attempt at balanced objectivity, but in the light of the general tone of
the article it is almost ironic: Sensationalist statistics quoted in the media must be
viewed with caution and in context if an informed decision is to be made.
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Summary
Anti HRT. Even though an opinion is given by one independent expert that the findings
are not applicable to all women, the general tone is that of the WHI report exposing all
HRT as bad.
Only RR figures applied, good news played down, bad news prominent. Medical
fraternity cast as villain. Sensational.
Confounding factors:
l.Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned that Prempro findings do
not apply to other products
3.HTIHRT difference Mentioned that oestrogen alone IS
different to combined HRT
4. Period of use plays a big role Not explained
Report3
Mail and Guardian October 3, 2002
Headline -Does hormone replacement work?
Byline - Sheree Russouw
The headline does not address the question exactly for what women want it to work.
Picture: Sinister picture association -- a woman with no hair (chemotherapy?) being
scanned before or after a mastectomy.
The picture almost "answers" the question posed by the headline.
Introduction is subjective. It quotes an advertisement by drug maker Ayerst in the
I970s, referring to women's fear of losing their youth and their husbands.
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The tone conveys the impression of drug makers luring women into using chemicals;
then paying a dear price for their vanity and lust.
As quoted by Nelkin earlier in this paper, it is indeed true that in the 70s the medical
establishment did promote HRT on a much bigger scale than now. But since the
90s, Feminist sensibilities and the fact that women are more informed, has changed the
scene. Women are no longer the helpless stereotype.
Second paragraph: Women have optedfor HRT as an instant cure.
Comment: It makes HRT sound like an "easy way out" or a "quick fix". A lot of stigma
accompanies medical quick fixes, and such a phrase might sway any confused reader
towards suspicion.
The next phrase reads: The bad news does not stop here.
This is editorialising for the sake of drama. The image of HRT is already blown; it's bad
news all along
While studies show that HRT can reduce osteoporosis and colon cancer and combat
Alzheimers, the WHl study proved to be a medical tempest.
Comment: Selective. The positive results found by the studies are mentioned almost as
an afterthought.
The article then lists the negative findings of the WHI report.
The way it explains the difference between ET and HRT is also confusing.
The next sentence quotes Dr Theo Kopenhagen of Park Lane Clinic as saying "the
incidence of risk". This is a confusing construction.
Note: It's Dr Kopenhager. The spellcheek probably changed it to Kopenhagen.
Kopenhagen affirms that the majority of the 16 000 were not ideal candidates and that
the hormone taken was not suitable.
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Comment: It's the only report surveyed that mentioned flaws in the study. She could
have elaborated on the flaws: The women tested were all over 67 years of age (Much
older than most women who enter menopause and go on HRT. Women that age usually
have passed menopause or have had hysterectomies and would therefore not be on HRT.
Note: Two of the 3 points listed, as flaws in the study --that some of the women were
obese and some were ex smokers -- are negligible. In a normal society, some people are
indeed obese and ex smokers. The group was representative.
Selective: The word affirms is used. It seems that when a bad finding is mentioned,
doctors admit but when any doubt is cast on whether the study might have flaws that
might paint a brighter picture, the word affirms is used. It's also not clear what is meant
by the hormone not being suitable.
The WH! study used hormones found in pregnant mares, which is not normally used.
Comment: Error. Plant-based hormones as well as mare urine hormones are both still
widely used. 21st Century sensitivities will squirm at the fact that pregnant mares' urine
is being taken orally. This might create revulsion and suspicion.
This links in with another vague quote ascribed to the doctor: He believes that natural
estrogens are the answer. This is wrong - the only "natural" oestrogen is the oestrogen
produced by the ovaries.
The reporter does mention the time period effect on risk:
Various studies point out that if you take HRT for less than jive years there is little or no
increased risk of breast cancer.
Many women refuse to go on HRT. .. the WH! study seems to buffer their belief
Comment: The word refuse induces the image of women force-fed against their will.
The WHI study buffering the belief creates the impression of the WHI and women
versus the medical establishment. This is hightened by (in the 3rd last paragraph) saying
Kopenhager concedes the need for discussion - as if he stands accused of conspiring
against women.
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It reminds of the impression created by the word indicted in the preVIOUSreport
analysed.
This impression is strengthened by the reporter, without sourcing anybody; making the
unsoureed statement: Some people believe that HRT is nothing more than the cunning
product of menopause marketing that plays on women'sfears.
It seems as if the reporter can be counted among those some people.
The last sentence referring to safe therapeutic options is vague. One is left wondering
what specific options.
Summary
A slightly alarmist tone, added to the sinister picture, gives the report an anti-HRT tone.
RR figures used and AR figures omitted. Sensational adjectives. Doctors cast as villains.
I.Flaws (Study group age and health) Mentions the age, smoking and obesity
factor of study group
2.Prempro Reference to mare urine is confusing
3.HTIHRT difference Explains that the HRT leg was halted and
that ET is used for women who have had
hysterectomies only
4. Period of use plays a big role Mentions that taking HRT for 10 years
may increase risk.
Report4
Health24 - November 7,2003
Headline - Hormone Therapy: The latest
By-line - Marl Hudson
As little as jive years ago doctors still hailed hormone therapy as the saviour of post-
menopausal women. A year ago the bubble burst.
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Comment: Inaccuracy resulting from the media's need to dramatise findings .Use of the
words hailed and saviour exaggerates reality. It's old news that there are certain risks
involved in HRT; the bubble has burst many a time before. Doctors examine and instruct
all women before prescribing HRT. HRT is not prescribed for smokers, women with
weight problems, high blood pressure and a whole long list of medical symptoms.
The phrase hailed as saviour is not applicable.
It already does not seem as if this is the latest, as promised in the heading.
Our primary objective is the best interest of women, not the pharmaceutical companies,
nor any other interest group. If a natural product is better we will tell you. If you should
worry about the risks of HT we will tell you. If this whole upheaval has blown the
findings out of proportion, then we will tell you. Now read on.
Comment: Heroic -- the media as saviour.
Paragraph 9 continues the tone of doctors as villains:
They believed their GPs and gyneas. Many women ...took hormones, either in pillform or
as implants and later as patches. They took hormones, whether it was oestrogen alone or
a combination of oestrogen and progestin. Most women did not bother to ask their
gyneas whether it was one hormone or two, they took it.
What goes for a small group is applied to a large group. It paints the alarming picture of
women frantically grabbing hormones in a pill popping frenzy.
(There is not a sudden epidemic of death and disease as a result of HRT. There is a big
scare).
Under the subheading explaining the findings, the reporter could have made a simpler
distinction between ET and HRT. In a quest for simplification, the report loses me when
elaborating under the heading breast cancer risk.
* A 50-year-old woman (regardless of combination HT or not) has a 2.8% chance of
developing breast cancer by age 60.
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Does this mean between 50 and 60 a woman has 2,8% chance of cancer, regardless of
whether she uses HRT or not? However then it says that after 5 years of HT by age 50
she has a chance of 3.5% -- which seems contradictory -- since that means it's not
regardless of. And is that HT? or combination HT?
The article makes inconsistent reference to HRT as either combined ET, ET therapy or
combined oestrogen and progestin therapy.
Incorrect reference to published study in an attempt to simplify statistics for the reader.
Too many statistics.
The article presents balance by comparing the risk ofHRT use with the risk of two drinks
daily or obesity.
The Bottomline is lucid, apart from one inaccuracy. The reporter refers to incidence of
cancer that might be a meaningless error. She should have said risk of cancer.
It is one of few articles that mentions the odd fact that, even though the risk is higher,
actual breast cancer mortality for women on HRT is lower than for women not on HRT,
because of better awareness.
It also mentions how big the natural health industry has become, but it does not elaborate
to what extent there is market competition between the pharmaceutical industry and the
natural remedy industry.
The explanation of the risks for heart disease, stroke and deep vern thrombosis IS
statistically correct and clear. The bottom line section is informative.
In fact this should have been the angle of all the reports on the WHI findings and an
accurate reflection of the angle taken in the medical journal reports:
"HRT is not the heart protector we thought it was".
(Then again, that headline would not even have made Page 4, let alone tumble stock
prices.)
The report talks about More and more women are trying phyto-oestrogens.
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The Bottom line section explains clearly that natural remedies are not as effective in
relieving symptoms of menopause.
The end summary is clear and objective, with two meaningless obscurities:
Under the fifth and sixth point she says: Women with a family history of breast cancer,
heart disease, stroke or deep vein thrombosis should be instead of should not be
considered for (combined oestrogen and progestin).
The word statins is not explained. These are a group of medications used in the treatment
of high cholesterol. They have been suggested to have a beneficial side effect on bone
density but this is not very promising with new information.
It's not clear what's meant by low dose is better.
Summary
Neutral tone. Explanation of difference between RR and AR, as well as risk and
mortality. Not over sensationalised. Tables of statistics confusing.
Media cast as saviour against unsympathetic medical fraternity.
Confounding factors:
I.Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Mentioned but confusing
4. Period of use plays a big role Not noted
Report 5
Die Burger August 20, 2002
Title: Menopause: kuur of skete? (cure or ailments?)
Byline: Thalyta Swanepoel
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Moet jy of moet jy nie? Dis die onsekerheid oor hormoonvervangingsterapie wat vroue
op hol het na skokbevindings oor die kuur wat help keer dat vroue droë ou koeie word.
Comment: The phrase shocking findings is exaggeration. The findings were not described
as shocking by the medical journal reports.
Otherwise, a well-balanced article that touches upon aspects neglected by other media.
The tone is re-assuring and conversational. It clearly states that the reasons why the WHI
study that caused such a furore were stopped were because of the slightly increased risk
of breast cancer.
The article quotes various experts and not just extreme opposing views.
It starts off with two spokespersons for pharmaceutical manufacturer Novo Nordisk SA.
It mentions that many women quit their medication, even though the WHI study used a
different kind of medication -- that the WHI study used only one of an older HRT
combination, and only one dosage.
The statements by the pharmaceutical interest group are backed up by an independent
voice -- a woman gynaecologist from the University of Petoria: Daar was not altyd 'n hoë
uitvalsyfer as dit by HVT kom, omdat vroue bang is vir borskanker .. Nou is almal bang
HVT veroorsaak beroerte en hartaanvalle.
Summary
Neutral, not alarmist, lucid.
The article clearly explains without going into confusing detail:
* That results differ from patient to patient.
* It draws a clear distinction between the two legs of the study - the oestrogen only and
the combination oestrogen progestin leg.
* That it was the first study that clearly indicated HRT may reduce colon cancer
incidence.
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* The difference between cases of and actual deaths of breast cancer.
It also quotes independent experts calling for calm Dit is nie nodig dat vroue so heftig
reageer nie.
It brings in a non-extreme opposing voice, from osteoporosis expert Dr Stanley Lipschitz.
He says that only 30 to 40% of women do get osteoporosis, meaning HRT is often not
needed to prevent bone loss.
Once again the reporter does not present an extreme position in order to appear objective.
She specifies and backs up with simple figures the areas in which the doctor has doubts
about HRT.
The report quotes two women who tell of their experiences with and without HRT. The
reporter refrains from adjectives and merely quotes them in full.
In general re-assuring and duly impartial, with no slant pro or against either HRT or the
natural health industry.
Confounding factors:
1.Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Explained
4. Period of use plays a role Noted
Report6
Die Burger August 20, 2002
Title: Gebruik van HVT raak al hoe meer omstrede
Not Bylined
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The first two paragraphs are factually correct but long-winded. Whereas almost all other
reports analysed in this paper can be accused of over-sensationalising, this one presents
facts like an academic handbook. Sentences are long and one gets confused between the
World Health Initiative study, the HERS study, the South African Association of
Gyneacologists, and the German Menopause Association.
When it states the percentages of risk as well as the percentages of reduced risk, it does
not make a distinction between relative and absolute risk.
It later on translates the percentages in terms of Absolute Risk (cases per year), which
makes it sound less ominous.
While the tone of the article IS objective, it might run the risk of confusing/ losing
readers.
Summary
Neutral, uses RR as well as AR, slightly confusing.
Confounding factors:
l.Flaws (Study group age and health) Not mentioned
2.Prempro Mentioned
3.HTIHRT difference Not clear
4. Period of use plays a big role Vague
Report 7
Die Burger, Apri116, 2003-12-14
Title: Ja en nee nie maklike antwoord
Byline: Petro Bosman
Hokaai eers, sê Professor Stephen Hough, hoof van die departement interne
geneeskunde ....
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Comment: the first paragraph and starting off with "Hang on" is effective in dispelling
panic. It clearly states that common sense must prevail and that what's applicable to a
small group need not be applicable to the whole. The first paragraph lists the "good
news" that HRT does protect against brittle bones, as well as that the "bad news" IS
actually "old news".
Toe is gedink dat vroue wat hormoonvervanging kry, is dalk slegter daaraan toe as wat
eers gedink is ten opsigte van hartbeskerming.
Comment: It raises the issue that many other reports left for much later on: That the study
merely proved that HRT is not as effective for heart protection as initially thought.
It uses Absolute Risk figures instead of using only Relative Risk figures: Normaalweg sal
45 uit 1000 vroue wat geen medikasie gebruik nie, borskanker kry. Met
hormoonvervanging skuif dit op na 47 uit 1000.
Comment: By quoting the independent Professor, it clearly states the crux of the research
-- It was found that of the women in the group on HRT, 47 women out of 1000 extra per
year got breast cancer. While it was found in the group not on HRT, 45 women out of
1000 got breast cancer in a year.
It ends off, touching upon the issue of informed choice. Women are not stereotyped
victims and doctors villains.
Summary
Neutral, non-alarmist. States Absolute Risk figures, not Relative Risk figures. Doctors
not portrayed as villains.
Confounding factors:
l.Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Not mentioned
4. Period of use Not mentioned
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Report 8
Die BurgerIDie BeeldIDie Burger Oos Kaap
(web archives 11/7/03)
Headline - Navorser wat medici skud, was lank in SA (Oos Kaap)
And Hormoonbehandeling nadelig, bevind span in VSA (Beeld)
Byline -Pierre Steyn
Both headlines indicate partiality against HRT, the one by implying that a researcher has
done a study that shook up the whole medical establishment with facts they never knew
before; the other by simply stating that HRT is bad, according to a team in the USA.
The introduction might appeal to patriotic South African sentiment. A "home boy", Dr
Jacques Rossouw, the head of the WHI study, has made waves.
It described how he emigrated to the United States after a long and bitter fight with the
South African Medical Research Council, without stating why he fought with them. It's
not clear why this fact had to mentioned, other than that the WHI findings are Rossouw's
"vindication" .
Rossouwen sy span navorsers het Dinsdag aangekondig dat hormoonvervangings
behandeling wat tans deur meer as 6 miljoen Amerikaanse vroue gebruik word, meer
skade as goed doen.
Comment: Dramatisation leading to inaccuracy. It sounds as if Rossouw was the first to
discover risks involved with HRT. This is inaccurate. It neglects to mention that there
have long been cracks in the belief that HRT is 100% beneficial for all women and has no
risks.
It mentions six million women in a way that creates context of Rossouwand his team
fighting for the lives of millions of women against the nasty medical establishment.
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Hulle het bevind that die middels, 'n kombinasie van estrogeen en progesteroon, tot 'n
klein toename in borskanker, hartaanvalle, beoertes en bloedklonte lei.
Use of the phrase klein toename (small increase) in the next sentence seems almost an
anticlimax -- since the first half of the article created anticipation of something earth
shattering after the years of intensive study that shook the medical establishment to its
very foundation.
Tot onlangs het die mediese owerhede hier dokters aangeraai om elke vrou wat nog nie
'n histerektomie gehad het nie en menopause bereik, aan te moedig om die middels te
gebruik.
Comment: Unqualified statement, not attributed to any source. Gyneacologists such as Dr
Zinn keep stressing how they certainly would not recommend HRT for every woman, and
only prescribe it under certain conditions.
Selective: The report ignores the good news and only reports on the bad news. Itmade no
attempt to solicit any other opinion.
The reporter seems unaware of the history of HRT scares and seems out of his depth in
the field. The report does not give context or background to the study.
Summary
Anti-HRT, alarmist. No statistics mentioned
Confounding factors:
I.Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Not mentioned
4. Period of use plays a big role Not mentioned
Report9
Sarie, February 2003
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Headline -Jonger met hormone?
By-line - Lydia van der Merwe
Use of photo: Positive image of a smiling attractive middle-aged woman
Introductory subheading: Maar dit gaan om meer as net estrogeen en die menopause.
The heading has a pro-hormone treatment tone - it asks the question whether hormones
make women younger.
The focus of the article initially is on the WHI controversy. It can be deduced that the
heading was a good teaser to lure readers interested in the ageing issue.
From the outset the article jumps from oestrogen replacement to combination
replacement without specifying what exactly is meant by hormone replacement or by
making a clear distinction.
Under the subheading Die droom van ewige jeug (dream of eternal youth), there appears
a slight confusing inconsistency when referring to HRT or ET.
Niks gee skynbaar beter gestalte aan die droom van ewig jonk en vroulik wees as
estrogeenervangingsterapie (EVT) nie.
Two paragraphs later it refers to HRT - HVT gee verligting van vroeë menopousale
simptome.
The article then lists the positive benefits from HRT. It quotes a Dr Willem Serfontein, a
medical scientist, and tells the reader where to get hold of his book, by Tafelberg
Publishers.
Later on the article refers to a book by Tafelberg Publishers, Dr Arien van der Merwe's
Kruie met Geneeskrag.
It might cause a credibility issue when a book from a publisher that comes from the same
group of companies as the magazine is promoted.
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The reporter should also think twice before recommending a book by an author with the
same name (van der Merwe), in order to avoid suspicions of nepotism.
Under the "fly in the ointment" the report says the risk of breast cancer is increased up to
35%.
Comment: Incorrect reference to published study and oversimplification of statistics
(failure to explain the difference between absolute and relative risk .. She neglects to say
if this refers to the WHI study she reports on later in the article. If so, this statistic is
inaccurate, since the relative risk increases by 26%.
The article then describes the WHI study.
Nie net was daar 'n klein toename in borskanker nie; die risiko vir hartaanvalle het met
41% verhoog. Aan die positiewe kant, afname van 37% in kolorektale kanker en
aansienlike verlaging in heup-en werwelfrakture. (Die deel van die studie waar oestrogen
gebruik is, word voortgesit).
Comment: Tone is re-assuring and mentions positive findings with the same prominence
as negative findings. One inaccuracy is that the relative risk of heart disease is up 29%,
and not 41%. (See article and tables in appendix ...)
Dr Theo Kopenhager, the Johannesburg gynaecologist, is also quoted in this article. He
says the media does not give the whole picture. This helps to give the reader a view from
an independent expert.
It is one of few articles that specifies that only one HRT combination, Prempro, was
used, and that outcomes with other combinations will be different.
It stresses sensible advice -- informed choice in consultation with doctors.
The rest of the article gets snared in medical and scientific terminology. It does not
sufficiently explain terms such as phyto- or plant oestrogen and hormonale voorlopers
soos DHEA en pregnenoloon and topikale pro-gesteroon.
The article is not clear why the subheading reads : it's about "more than just oestrogen
and the menopause".
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Summary
Neutral, but confusing. Only Relative Risk figures are mentioned for "bad" as well as
"good" results.
Confounding factors:
I.Flaws (Study group age and health) Not mentioned
2.Prempro Clearly explained
3.HTIHRT difference Not clear
4. Period of use plays a big role Clearly explained
Report 10
Cape Argus, July 30,2003-12-14
Headline: Modem day Miracle or Killer Treatment?
Byline: Di Caelers
Use of picture: A graph listing benefits and risks equally.
Introductory sentences set the stage that HRT helps against the symptoms of menopause,
but that there is debate on its safety.
It then strikes a re-assuring note: fortunately, there's plenty of good advice to be had.
The article's focus is on the debate, not on whether HRT is good or bad -- which makes it
duly impartial.
The reporter explains why some women need HRT by letting the expert list health
problems that may arise during menopause She also stresses throughout that it is a
woman's individual choice, in consultation with her doctor.
Itmentions that the study was on combined oestrogen and progestin use.
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But refers to healthy post menopausal women which is inaccurate since the 3 "flaw"
factors (age,obesity, smoking) were not mentioned.
The article lists the "good news" (what HRT is good for) first, and the "bad news" (the
risks of HRT) last.
After listing oestrogen's benefits (talking about oestrogen only), she refers to HRT again,
which the reader might find confusing.
She then summarises the methodology of the WHI research.
The sentence that begins: But in one part of the study a group of 17000 women with a
uterus... is an attempt to explain statistics, but the reader might get lost in too much
detail.
She clearly states the objectives of the WHI study, which was not to test whether it's an
"elixir of youth" as many other articles made it out to be.
Researchers wanted to study the relationship between hormone therapy and its possible
benefits for heart disease and hip fractures, and its possible risk for breast cancer,
endometrial cancer and blood clots.
It's one of few articles that state that the aim of the study was to examine the extent of
benefits and risks, instead of making out as if this study was the first to prove that HRT is
not a wonder cure.
The reporter quotes an independent expert, Dr Stephen Hough, as saying that the study
has proved that protection against heart disease is not a reality. But that it's still the best
treatment available for the symptoms of menopause and osteoporosis.
The reporter asks the question so what does all this mean for the average woman on
HRT?
She lets the expert do the talking, explaining what the results meant.
The end message is that it's up to every individual woman to decide for what and for how
long she wants to use HRT.
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Summary
Balanced, neutral, not over sensationalised or alarmist.
This article accurately reflect medical journal reports on the published study:
*That oestrogen plus progestin does not confer cardiac protection and may increase the
risk of CHD among generally healthy postmenopausal women, especially during the first
year after the initiation of hormone use.
*That the treatment should not be prescribed for the prevention of cardiovascular disease.
In an attempt to "translate" or oversimplify, some confusion crept in.
Confounding factors:
lFlaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Mentioned but confusing
4. Period of use plays a big role Mentioned
Report 11
Daily News 25/4/04
Headline Dispelling the HRT myth
By-line Petra Lee
Headline: This line is normally only used when "debunking" the good myth about HRT.
However, this report gives a fairly glowing account ofHRT. So it's assumed the headline
implies that it's dispelling the nasty myth about HRT.
The headline might also prove that the layout person or the editor finally responsible for
the headline often does not grasp what the report is about.
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If you've heard that HRTwill give you breast cancer, take heart. It won't happen.
Comment: Unqualified generalisation. The study did not find that HRT does not give you
cancer. Just as it did not find that it does give you cancer. The expert quoted later on did
also not explicitly state that HRT would not give you cancer. This is bias towards the
other extreme, which can also be dangerous for readers who change health patters
according to media reports.
The reporter then quotes the eminent and highly respected Professor, as saying HRT
promotes the growth of pre-cancer cells.
The adjectives describing the Professor convey a sense of a star struck and uncritical
reporter. The reporter does mention the fact that he is a representative of a
pharmaceutical company. However, the reporter does not see fit to bring in an
independent source or opposing view.
As regards the discussion of epidemiology, and the question of whether HRT merely
makes pre-existing cancer cells grow, it is uncertain whether the expert was quoted in
context.
Independent experts like Dr Zinn (personal communication: January 5, 2004) explain:
"HRT may accelerate the growth of sensitive cancers -e.g, in the breast but may
also give rise to cancers that would never have occurred. We all have genetic
predispositions that make us susceptible to certain diseases but will not necessarily
get these conditions unless the right conditions arise. In the case of oestrogen
sensitive cancers this is the presence of oestrogen - normally not present in large
quantities in the postmenopausal woman. Unfortunately we do not know which
women are going to become susceptible except by inference from risk factors -
family history smoking, alcohol intake, weight, number of children etc. My
answer to the question would therefore be no. It is likely from current info that
HRT can cause cancer that, otherwise, would not have occurred."
Confounding factors:
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Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Not mentioned
4. Period of use plays a big role Not mentioned
Report 12
Die Burger 18/9/02
Headline - Die waarheid oor HVT
Byline: Valda Jansen
An objective, informed and non-alarmist report. The headline is, however, the same
headline as the Times article. The word waarheid "truth" implying that lies abound.
The phrase facts or info on HRT might have been more neutral.
The report makes a clear distinction between combination treatment and oestrogen-only
treatment.
It mentions that the media had ignored the fact that only one brand of medication was
used in the study, and that other combinations may not carry the same risks.
It does not over sensationalise or omit any of the "bad" findings, and mentions the "good"
findings in the same sentence.
It also spells out that the only "new" finding was that HRT does not offer the high
protection against cardiovascular disease as formerly thought and that it should not be
prescribed for the prevention or treatment of cardiovascular disease.
Summary
Neutral, not alarmist or confusing, No "sides" taken against medical experts, no
stereotyping or editorialising.
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Confounding factors:
l.Flaws (Study group age and health) Not mentioned
2.Prempro Mentioned
3.HTfHRT difference Mentioned
4. Period of use plays a big role Not mentioned
Report 13
Shape Magazine May 2003
Not bylined
Headline - HRT gets a double whammy
The headline is negative, saying that once again HRT has been slammed.
Hot on the heels of the question mark about the safety of HRT are suggestions that the
treatment may offer no real benefit for postmenopausal women.
The sentence is an accurate reflection ofa New England Journal of Medicine report about
HRT and quality of life, even though the positive findings are not mentioned.
The report refers to the oestrogen mystique. This is confusing since it does not
differentiate between HRT and ET.
It does quote an independent expert as saying oestrogen is still the most effective
treatment.
The final message is one of common sense and caution.
It does not explain what phyto-oestrogens are. Some HRT medication is also plant based.
Confounding factors:
LFlaws (Study group age and health) Not mentioned
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2.Prempro Not mentioned
3.HT IHRT difference Not mentioned
4. Period of use plays a big role Not mentioned
Television - Report 14
To make reports understandable for a mass audience, television often has to personalise,
or use a device called "The Johnny".
For television to retain maximum viewer's attention in around 2 minutes - scientific
reports often exemplify people. (What's it going to do to me?)The device in TV jargon is
called "The Johnny".
Nelkin (Nelkin, 1995: 57) believes that:
"The form and content of science information on television is conditioned by what
producer Jeffrey Kirsch calls the marriage of the sales mentality to the electronic
image. Producers have learned what formats, production, techniques, symbols,
and personalities are most likely to succeed."
Constraints of scientific complexity are very difficult for the television medium -- it's
hard to give context to complex science issues.
etv news on 07/1 0103 carried a Reuters news agency piece as is.
It contains almost the whole list of points to examine mentioned in the abstract, in less
than a 2-minutes report--omission, sensationalism, oversimplification and lack of
perspective.
Visual material- Not alarmist. Footage of women walking in the street and tablets.
However, the script, is one-sided.
1. The introduction ("attention grabber") simply says that doctors have issued a warning
against the dangers of HRT .
2. It says a major US study was cancelled, without referring to what study.
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3. It omits to mention that the oestrogen leg of the study carried on.
4. The introduction omits reference to proven benefits.
5. The item itself refers to 17 000 healthy women, omitting to say that there has been
criticism of the selection of the group. (That at average age 63 they were not
respresentative of the normal age of women starting HRT, that some were obese, and
some ex smokers)
6. It says HRT raises the number of strokes by 41 per cent, heart attacks by 29 and breast
cancer cases by 28 per cent. This is inaccurate oversimplification.
(Medical journals clearly state that HRT increases the Relative Risk of the incidents
occurring -- not the number of incidents)
7. One upsound by Dr Rossouw, the "leader" of the WHI study is used. It identifies him
only as "doctor" The report does not solicit any re-assuring or opposing view.
8. It gives no advice or recommendations to women.
9. It gives low prominence that "HRT does lower" incidence of hip fractures and colon
cancer.
10. The piece-to-camera is accusatory, implying that women have been hoodwinked.
Confounding factors:
I.Flaws (Study group age and health) Not mentioned
2.Prempro Not mentioned
3.HTIHRT difference Not mentioned
4. Period of use plays a big role Not mentioned
Chapter three
Summary and analysis of error and bias
Table 3.1 Coverage of the WID HRT study in Southern African newspapers, magazines
and television May 2002 until November 2003
Report and Quote that Neutral Pro Anti Alarmist Confusing
number forms HRT HRT
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"gist" of ("Use
article common
sense")
1. Time Dream 1 1
fade away
2. Longevity Medical 1 1 1
fraternity's
onslaught
3.WMG Cunning 1 1 1
product of
menopause
marketing
4. Health24 Grabbing 1 1 1
hormones,
clung to
HT
5.DieBurger Nee wat, 1
kyk na die
individuele
risiko
6.DieBurger Klein 1
risiko,
maar ook
positiewe
uitslag
7.DieBurger Hokaai 1
eers, kyk
na
individuele
profiele
8Die Burger Meer 1 1
skade as
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goed
9 Sarie. Individuele 1 1
profiel
onder die
loep neem
Neutral Pro- Anti- Alarmist Confusing
HRT HRT
10.Cape Make an 1 1
Argus informed
decision
lt.Daily Take heart 1 1
News - it won't
happen
12.Die Individue 1
Burger verskil -
Maak
ingeligte
besluit
13.Shape Not what 1 1
it's
cracked up
to be
14. TV news High 1 1
increase.
"Bad"
disease,
might be
hurting
you.
3.1 Anti or Pro-HRT
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*Seven out of the 14 reports (50%) show bias
(Six out of 14 reports were anti HRT and one out of 14 was pro HRT.
Time, Longevity, Weekly Mail & Guardian, Die Burger (Report 8) Shape, and the
television report were anti HRT, while the Daily News report was pro HRT).
*Three reports (Sarie, Health24, Cape Argus) were neutral but confusing
* Four reports met the criteria of informative, re-assuring and neutral (Die Burger
5,6,7 and 12)
Therefore, in total, 10 out of 14 were either biased or confusing.
Why the bias? This can be because the authors sincerely believe HRT is extremely
dangerous and warrants a public outcry.
In When MBAs rule the newsroom, Doug Underwood (Underwood, 1995: 11) quotes a
newspaper industry research expert as commenting on the fact that media marketing
trends follow, instead of shape, public taste, in order to make more money. Therefore,
bias, can be a conscious or unconscious pandering to reigning social beliefs.
Recent views about HRT taken from news sources such as the British or
American National Women's health Networks do indeed show that the reigning social
belief of our time is anti-HRT.
British Sociologist Kate Hunt (Wilkinson, Kitzinger, 1996: 152) refers to the notorious
book by Robert A Wilson (Feminine Forever) She quotes feminist sources as stressing
how modem feminist literature tends to be universally suspicious ofHRT.
It might be true that both the medical and feminist presentations of the menopause
exploit the fear of cancer to promote or demote medical control over menopause.
The media reflects this, instead of analysing the trend.
3.2 The villainous scientist, the helpless woman, and the heroic media
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Five out of 14 - Time, Longevity, Weekly Mail & Guardian, Die Burger (Report 8) and
the television report gave a stereotyped impression -- that the WHI trial was "on the
side" of helpless women against the villains in the medical fraternity.
Time -Maybe I've been too trusting.
Longevity - The choices they confront me with.
WMG - Dr Kopenhagen concedes.
Die Burger (Report 8)- (The tone IS "I-told-you-so") Tot onlangs het die mediese
owerhede hier dokters aangeraai om elke vrou wat nog nie 'n histerektomie gehad het
nie en wat menopause bereik het, aan te moedig om die middels te neem.
The report actually mentions the word misdadige (criminal) when quoting the head of
the WHI talking about local doctors prescribing HRT.
The Health24 report (Number 4), while not slanted against HRT, also gave the
impression that the media is on the side of the women, against everybody else:
Our primary objective is the best interest of women, not any other interest group. We
will tell you (the truth), now read on.
Johan Retief (Retief 2002: 393) writes that around 1992 a backlash occurred against
feminist messages of the last two decades. First you had the 50s housewife, then the
assertive independent feminist era and then -- "women who work and leave child
rearing to others are flirting with disaster".
He's referring to the advertising industry but this is applicable to the popular press.
"Undoubtedly, the women's movement, with its harsh assessment of the advertising
industry, has succeeded in diversifying the social roles of female characters.
Nevertheless, images of women as pre-occupied with beauty, sex appeal and youth still
abound in commercial messages directed at the mass audience."
3.3 HRT "versus" the natural health industry
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Three out of 12 reports showed distrust of conventional medicine and advises herbal or
"natural" options.
Report 3 (WMG) -safe therapeutic options
Report 2 (Longevity) and Report 9 (Sarie) list herbal remedies and advise the reader
about what books to buy
But no blatant propaganda for natural health products was detected.
Mentioning the names of the books might seem promotional of the natural health
industry, but it might be excused on grounds that they are good books by credible and
responsible experts and therefore in the public interest. Recommending extra reading
materials is not completely unethical. One can also justify a newspaper or magazine
wanting to promote a sister publication for commercial reasons. The link does not seem
covert.
Dr Zinn (personal communication: October 2003) notes that Black Cohosh, mentioned
in the magazine, has not shown great anti-menopausal symptom relief:
"There has been no evidence so far that it is better than a placebo. Soya is better
but must be concentrated and from soya husks (i.e not dehusked soya). The main
component is genistein which is the most effective of the phyto-oestrogens. They
have only been shown to be effective in 60% of women with frequent hot flushes
as opposed to 40% effectiveness of placebo."
It has been noted that advertisements for natural or herbal medication for menopause
were placed on or near the articles in three magazines - Sarie, Shape and Longevity.
3.4 Common errors and omissions that contribute to confusion or bias
As seen in table 3.1, three reports, in attempting to simplify, became confusing.
Nelkin (1995: 118) says that:
"Studies assessing the extent and possible causes of error have produced mixed
results. They suggest that 40 to 50 per cent of scientists complain about
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inaccuracy. When pressed, however, they usually identify the problem as one of
omission of relevant information and lack of qualifying statements rather than of
error per se."
3.4.1 Incorrect reference to the published study
The reports in medical journals clearly state that HRT is still advised for treating
adverse menopausal symptoms. It is simply not advised to help against coronary
problems, and might carry a slight increased breast cancer risk. Translation of the
scientific report in the popular press, being shorter and written in layperson's terms,
generally omitted that angle.
Most reports neglected to point out that the breast cancer risk posed by HRT is old
news, merely once again proven in a different study. All reports neglected to spell out
clearly that one of the basic aims of the WHI study was to test whether HRT is
beneficial for the heart (the WHI study tested whether HRT reduces the risk of coronary
heart disease) The headline and angle of all the reports should simply have been "HRT
has no proven benefits for the heart".
Only the longer feature articles gave background of research methods.
Even so, they included partial but inadequate information about the method. Some of
the information about methods was erroneous or confusing.
Many discrepancies involve omissions or meaningless changes rather than blatant error.
Figures were generally correct but selectively quoted and out of context. No report
clearly indicated the important difference between Relative Risk (big numbers) and
Absolute Risk (small numbers).
3.4.2. Selectivity
News reports written about lengthy research reports often ignore or downplay the "good
news". Six out of 14 (43%) of the reports did not ignore the bad news.
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Time magazine, WMG, Longevity, Die Burger (Report8) Shape, and the television report
focused on the heart disease and cancer angle while mentioning possible benefits in terms
of colon cancer and osteoporosis much later and much less prominent.
Six reports, Sarie, Health24, and Die Burger (Reports 5, 6 and 12) tried to maintain a
fair balance between good and bad findings.
Only the Daily News (Report Il) gave the good news and downplayed the bad news.
All the reports, when quoting statistics (except Report 6), informed readers of the
benefits in terms of Absolute risk (small numbers) and the disadvantages in terms of
Relative Risk (large numbers) .
3.4.3 Headlines and the use of photos
Science writers complain that if they don't sensationalise the first line, they run the risk
of having their story on a back page, or lower down in the bulletin.
Journalists constantly talk about "headline idiocies and the ignorance of editors,"
(Nelkin, 1995: 108). It is the editor who decides what is published, how each article is
cut, and where it will appear in the paper:
"Journalists, unlike scientists, relinquish virtually all control over the final shape
or presentation of their articles. This editorial control often means that stories are
misrepresented in headlines."
Time magazine and Die Burger (Report 8 - eastern Cape) rate highest in terms of an
anti-HRT headline. The Sarie report (Report 9) headline can be described as positive
even though it is in question form. The Daily News headline sounds negative, although
it's probably meant as dispelling the myth that HRT causes harm. In general, most
headlines were not biased, and in question or rhetorical question form.
When reporting on HRT, the favourite headline seems to contain the words "dispel" or
"myth. Usually this means dispelling the myth that it's good, instead of dispelling the
myth that it's bad.
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It may also simply be a handy alliteration -- myth the first word that alliterates nicely
when you need a quick menopause headline when deadline looms.
In order to help the reader "digest" pros and cons, they are often listed in tables or boxes
with subheadings.
Such lists, albeit well meaning, may add to the confusion, as we have seen in the
Longevity article (Report 2) and the Health24 (Report 4) article.
Photos
Apart from one picture used in Time magazine of an unhappy-looking ageing woman,
and the alarming picture of a woman going in for chemotherapy in the WMG report, the
articles used "neutral" or unalarming photographs.
Unlike the content of the script, the television report used neutral non-alarming images.
Women were shown walking in the street and footage of tablets in bottles was shown.
No sign of mastectomies and cancer wards.
3.4.4 Statistics oversimplified
This table summarises the way the WID statistics were presented in the 14 reports in
terms of Relative Risk and Absolute Risk:
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No stats but Meaningless Only Only Only Both Both RR
alarmist omission of RR AR RR for RR and AR
adjectives stats for bad and but
such as bad news AR confusing
"high" and and and
"shocking" good But AR clear
numbers or nonews
statistic
for
good
news
l.Time 1
2. Longevity 1
3.WMG 1
4. Health24 1
5. Die Burger 1
6.Die Burger 1
7. Die Burger 1
8. Die Burger 1
9.Sarie 1
10. Cape 1
Argus
II.Daily 1
News
12.Die 1
Burger
13.Shape 1
14.Television 1
Some reports deliberately used Relative Risk (impressive) while omitting Absolute Risk
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(low) figures. This is either because of time and space constraints (meaningless) or
manipulative. Sometimes the AR and RR figures are given but in an attempt at
oversimplification, confusion sets in.
Two very important differentiations need to be made between:
(a) Relative Risk and Absolute Risk
Relative risk (Cohn, 1994: 55). compares two rates by dividing one by the other
"If for example the lung cancer mortality rate in non-smokers aged 55 to 69 was 19 per
100 000 per year, the risk in smokers was 188 per 100 000. Divides 188 by 19 equals
almost 9.9. It therefore means that smokers are almost 10 times as likely to die from
lung cancer."
If eight more women per year out of 10 000 might get breast cancer compared to those
not on HRT this means 26 per cent Relative Risk.
"26% Relative Risk increase" sounds far more impressive and understandable than
"eight more out of 10 000".
As seen in Table 3.4.4 -- In the reports analysed, Relative risk figures were not merely
emphasised, but whenever statistics were quoted, only the Relative Risk figures were
quoted in all the articles but one report.
In most cases the text simply read, "Risk for breast cancer was 26 per cent higher in the
HRT group versus the non-HRT group." The difference between Relative and Absolute
risk is never explained.
This is how Dr JC Stevenson, of the American Menopause Society, explains the
difference:
"Relative risks give an indication of the magnitude of the increase in disease end-
points but without reference to how commonly these events were occurring
(absolute risk). Thus a small increase in relative risk for a disease event which
occurs very frequently will result in a large increase in patients affected (large
absolute risk), yet a larger increase in relative risk for a disease event which
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occurs infrequently will have only a tiny impact III the number of patients
affected (small absolute risk). The increases in the relative risk of coronary heart
disease (29%), stroke (41%) and pulmonary emboli (lung blood clots) (213%)
have been widely quoted in the media, yet the absolute risk increases, although
significant, were fairly small. The true increased incidences are 0.09% for
coronary heart disease, 0.02% for stroke, and 0.17% for pulmonary emboli.
Thus, for 10,000 women taking HRT each year compared to those not taking
HRT, there would be an additional 8 cases of invasive breast cancer, 7 heart
attacks, 8 strokes and 8 pulmonary emboli. However, there would also be 6
fewer bowel cancers and 5 fewer hip fractures."
(American Menopause Society letter 28/1 0/02)
Absolute Risk is a person's chance of developing a specific disease over a specified time
period.
It's estimated by examining a large number of persons similar in some respect (such as
age) and counting the number of individuals in this group who develop the disease over
the specified time period. For example if we observe 100 000 women between 20 and 29
for one year, approximately 4 would develop breast cancer during this period. Therefore,
the one-year absolute risk of breast cancer for a 20-to 29-year-old woman is 4 per 100
000 women, or 1 per 25 000 women.
Absolute risk of breast cancer for an individual woman - approximately 0.3 per cent per
year. Prempro use added 0.1 percentage point risk per year.
A note on the importance of understanding statistics :
An example of the grave consequences of misunderstanding probability was given in the
British Financial Times (Matthews:2004)
A mother who was found guilty of murder after two of her babies died.
At the centre was the figure of 73 million to one. '
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The figure came from Professor Sir Roy Meadow, an expert witness at the trial of
solicitor Sally Clark, who insisted that two of her babies had died ct deaths. Meadow told
the jury that research suggested the chances of a single cot death taking place in family
such as Mrs Clark was one in 8 543. The chance of two cot deaths occurring was
therefore the square of this figure -- or one in 73million.
The report describes how even judges fluffed the crucial point - that if an event occurs
once, the chances of two such events are not always far lower still.
(The woman's conviction was quashed later by the Court of Appeal, which expressed
concern that the jury had been misled by the huge odds.)
Crucially, DNA match probabilities are merely the odds of getting so good a match,
given no involvement in the crime. That is not the same as the odds of the accused being
innocent.
Matthews stresses that juries have to put match probability into context, using other
sources as evidence. Only then can they estimate the probability of innocence -- which
may be far higher than the match probability suggests.
The writer gives an example by science writer Gerd Gigerenzer to demonstrate the
pitfalls of using common sense with probabilities:
Gigerenzer and his colleagues set a group of experienced medics the following problem,
outlined in a recent paper in the British Medical Journal.
About 1 per cent of women have breast cancer and a cancer screening method can detect
80 per cent of genuine cancers but also has a false-alarm rate of 10per cent. What is the
probability that women producing a positive result really have breast cancer? Most
doctors reckoned it was at least 70 per cent. The correct answer, found by only two
doctors, is just 8 per cent.
Gigerenzer then repeated the test with another set of doctors, this time giving precisely
the data as hard numbers: they were told that lOin every 1 000 women have breast
cancer and that, of these 10, eight will give a positive screening result; while of the 990
who do not have cancer, 99 will produce a false positive result.
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Asked this time to estimate the probability that a woman with a positive result really does
have cancer, most of the doctors could see that it was about 8 per cent.
The author uses this example to prove what science fiction writer H.G Wells meant by
saying that statistical thinking would one day be as necessary for efficient citizenship as
the ability to read and write.
(b) Causation and association (Also see "confounding factors" section)
Many women will develop breast cancer, whether or not on HRT.
Some women will die from it.
The fact that many women contract/die of breast cancer might not be such a "direct
cause" of HRT use as media reports suggest. The HRT (prempro) used in the study may
also not be representative of all HRT .
The "worst offender" here is the television report that, instead of saying the Relative Risk
of women on HRT to contract the following diseases goes up by the percentages
mentioned, simply said" it increases the number of strokes, heart attacks and breast
cancer cases.
Epidemiology cannot prove causation of a condition, it can only suggest association.
(c) Risk and mortality
Higher risk" does not mean higher mortality. According to Prof Davey, (personal
communication: June 2003) the difference is often overlooked.
In reality, even though there might be a slightly increased risk or more cases of breast
cancer for women on HRT, fewer women on HRT actually die of breast cancer than
women not on HRT. This is because of indirect but related reasons.
This might be because they are more aware. Maybe concerned about the effects of HRT;
they go for regular check-ups, join the gym and watch their fat intake.
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3.4.5 Findings are over generalised and what goes for a small group taken to apply to a
large group
This is best described by Nelkin (Nelkin, 1995: 166)
"Readability in the eyes of the journalist may be oversimplification to the
scientist. Many accusations of inaccuracy are traceable to reporters' efforts to
present complex material in a readable and appealing style."
Overall the study's implications are more pessimistic than the findings warrant.
Cohn (Cohn: P. 59) points out that: "Virtually no single study proves anything".
Two or 4 or 15 studies (merely) add credence, especially if the diagnostic and outcome
criteria and the people studied are similar.
But a single study rarely proves anything.
Media philosopher Herbert J. A1tschull (Altschull, 1990: 1) also mentions the "facticity"
of journalists - their tendency to provide graphic descriptions of a single tree when what
readers need is a wider view of the forest.
3.4.6 Inaccuracies seem to result from the media's need to dramatise research findings
"By their choice of words and metaphors, journalists convey certain beliefs about the
nature of science and technology, investing them with social meaning and shaping
public conceptions of limits and possibilities"(Nelkin, 1995: 11).
Hyperbole and sensational adjectives were found in 11 out of 14 reports analysed, with
the exception of reports 5,6,7:
Bad news, shocking, dreaded, potentially deadly, invasive, bubble burst, confused,
angry. wide-eyed, desperate, onslaught, what's a woman to do? .
3.4.7 In a quest for balance, journalists often represent extreme positions
"Journalists' efforts to maintain objectivity, according to sociologist Gaye
Tuchman, were only a "strategic ritual": subjective perceptions inevitably entered
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their writing, while the tone of objectivity allowed reporters to avoid
responsibility for their views. "
"The polarized presentation of technical disputes also reflects journalists' norms
of objectivity - their belief that verity can be established by balancing conflicting
claims." (Nelkin, 1995: 87 and 166)
Note: In addition to "widening the pool" of experts interviewed, care should be taken not
to promote books published by the same company as the newspaper/magazine in which
the report appears. Maybe a reporter should also not promote a book in her article if she
shares a last name with the author. Both instances might be perceived as nepotism and
can hamper credibility.
3.5 Role of media used and bylines
My hypothesis was proved wrong: Newspaper reports and not magazine features proved
to be more neutral and les confusing. (See Table 3.3)
Television fared worst: SABC3 and etv used the same report by Reuters news agency
network CNN as is, without adding local, or second opinions. No local angle or opinion
was sought.
Compared to by-lined reports, the non-by-lined reports in the study did seem more
superficial with a lack of balance or "the other side". By-lined articles were more
responsible and sourced than non-by-lined reports. When a reporter gets by-lined, it
seems as if more care is taken in gathering detail and seeming objective. But the
hypothesis was not as correct as expected.
3.6 Confounding factors
Table 3.6 - The fmal score of how the media reported confounding factors
Report 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Number
Flaws in 0 0 1 0 0 0 0 0 0 0 0 0 0 0
study
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Prempro 1 0 0 0 1 1 0 0 1 0 0 1 0 0
HTIHRT 1 1 1 0 1 0 0 0 0 0 0 1 0 0
difference
Period of 1 0 1 0 1 0 0 0 1 1 0 0 0 0
use
This table adds up the results to calculate:
How effective was the media's communication of risk versus benefit in terms of the
following?
*Did it explain adequately the difference between oestrogen only (ET) replacement and
combined replacement (HRT)?
Five out of 14 -about 36%.
*Did the media surveyed point out that only one brand of HRT, Prempro was used and
that other combinations might not have the good or bad results?
Five out of 14 -reports 1,5,6, 10 and 12 mentioned that the HRT (Prempro) study ended
but the ET (Prernarin) leg continued. Only two explained that different brands could
have different risk factors.
*Was a clear distinction made over safety of short-term versus long-term use?
Again, Five out 14 quoted health experts as saying HRT use should be used for short-
term relief or discontinued after 5 years or stated the WHI findings over 5 years.
* Regarding flaws in the way the study group was selected -- Only one report -- the
Weekly Mail and Guardian (Report 3), mentioned that sixty per cent of the women were
over 60, some were obese or ex smokers.
This is how the British Menopause Society (Newsletter: 2003) explains confounding
factors:
"The small increase in breast cancer cases is in line with what previous population
studies have suggested, as are the increases in blood clots, and the decreases in
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fractures and in bowel cancer. But, knowing the effect of oestrogen on the function
of blood vessels, the lack of benefit on heart attacks is more surprising. However,
it must be remembered that these findings apply only to this particular HRT
regimen, conjugated equine oestrogens 0.625 mg daily plus medroxyprogesterone
acetate (MPA) 2.5 mg daily (similar to Premique in the UK). The findings may not
be the same for other types of HRT, a point acknowledged by the study authors. It
is quite likely that the effects of HRT regimens using different oestrogens and
progestogens, and different routes of administration, would be similar in their
effects on the breast, bowel and skeleton. But the metabolic effects of such
different HRT regimens are clearly different, and this is most likely to impact on
their cardiovascular effects. It is most unhelpful that this point was not appreciated
by the recent recommendations of the Committee for Safety of
MedicineslMedicines Control Agency, which were inappropriate with respect to
cardiovascular disease. It is thus possible that this particular progestogen (MPA)
had a harmful effect on breast cancer and on cardiovascular disease incidence.
Particularly for the heart, the dose (and possibly type) of oestrogen and the type of
progestogen may be crucial. It is therefore imperative that similar studies are
carried out using different types of HRT than that used in WH!."
Chapter4
Conclusion
4.1 Deliberate manipulation or inept omission?
The media seems to have made up its mind whether the glass is half full or half empty,
and it shows.
Instead of giving the facts, background context, and letting experts or victims speak for
themselves. -- Facts and figures were selectively omitted to create context. Such methods
of presenting risk information might sway the reader/viewer into changing health
patterns.
However, examination has not unearthed blatant bias in favour of natural medicine.
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The media seems aware of their ethical duty to the public good. Statistics in the WHI
were significant and any responsible reporter should have mentioned these.
However, there are also risks involved in crying wolf, over sensational ising or pandering
to reigning stereotypes.
In southern Africa none of the reporters interviewed mentioned being blatantly
pressured by "either side" (pharmaceutical or natural) to pitch stories in specific ways.
Reporters also claim that they are wary of propaganda. Magazines and newspapers mark
articles from advertising agencies about health products under "advertorial". Although,
this may not even be sufficient since many people in the region do not know what
"advertorial" means.
It takes a lot of effort and skill to convey facts and statistics clearly. A lot of the
omission is 'innocent"-- merely reporters trying to jazz up "cold facts" or get a space on
the front page. Some of the sensation !inaccuracy might have crept in during final
editing and layout.
But locally, even though anti HRT, the press does not seem in "cahoots" with the natural
health industry.
4.2 What editors say
Apart from mentioning the need for specific training of health reporters, editors and
journalists (personal communications: September 2003) pointed out the following:
*Mari Hudson for Health 24 said her editorial policy applies a "healthy pinch of salt".
Health24 does receive press releases from pharmaceutical companies as well as natural
health companies advertising their product. However, a verbatim report will rarely be
published. The opinion of independent health experts is always solicited. She added that
companies such as Wyeth might call media briefings about certain products. But the
floor is open for questions afterwards, and once again backed up by "outside' medical
opinion.
*Robyn Von Guesau from Shape magazine made these points:
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• Pharmaceutical companies and natural product companies are like any other; they
want to sell their products. In doing so many of them actively market it to the media,
often with presentations by people in the medical field.
• Any good journalist should be aware that these people are paid, in whatever
manner, to say what they say and should, therefore, approach such presentations with a
barrowful of scepticism.
• Journalists should take the material to a neutral source for their input.
• Unfortunately, there are journalists who seldom ask questions and simply soak up
information only to regurgitate it onto health pages as fact - often this has more to do
with lack of training than anything else.
* Prevashni Ramsamy, Longevity magazine's features writer, says that pharmaceutical
companies try to sneak in promotion of their products all the time.
"We only get to hear professional opinions via press conferences, workshops etc hosted
by the huge pharmaceuticals. When the controversy arose over HRT, Wyeth, for
example, immediately hosted the press conference and a medical specialist presented us
with the "information" we required to write our stories. Even the natural health
companies send through their products with "information" selling their product to us.
Obviously, going to these presentations requires an objective approach - use the
information they present as just a segment of your research in a story and go in search of
the opposing view to ensure you receive a balanced account of an issue.
Independent research is necessary because an obvious bias exists even among
professionals who wish to secure their patient base, and reputations by declaring the
questionable drugs they have been recommending for years as safe."
* Chris Nicklin, etv news editor, says it's easy to tar all media with the same brush, but
he believes that local news organisations, with a few notable exceptions, fall woefully
short when it comes to competent health/science reporting.
"This is due to a number of reasons, not least of all the widely held view that science
writing is not mainstream reporting and that any specialism in this field does not need to
be encouraged. As a consequence, important debates in the media around issues, like
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the efficacy of ARVs for HIV treatments, have been obscured by superficial, uncritical
reporting by inexperienced journalists.
Most journalists have a humanities background which often results in the misguided
belief that if they haven't studied science, they cannot write about it. This is unfortunate,
as I believe any good health/science reporter simply requires the same qualities as any
other good reporter, namely
Curiosity, the ability to recognize a story, the desire to get it right, a determination to
convey significance and the ability to right well.
But reporters showing an interest in health/science Issues also need strong
encouragement from editorial managers. The problem with medicine/science is not
finding the stories, but in deciding which of the plethora generated by labs and journals
are significant. Journalists with a strong interest are likely to be the only ones who take
the time and trouble to find out, and who are prepared to go through the necessary hoops
to establish whether a development is a genuine "breakthrough". It's all too easy to
sensationalize health/science stories. What I think I'm arguing for is health/science
reporting to be taken as seriously as other fields of journalistic specialism, such as
political or financial reporting.
Health/science writing makes demands on our intellect and is not for the lazy. General
reporters assigned a medical/science stories seldom apply the necessary checks to
establish whether something is genuinely ground breaking and will often recycle press
releases, media handouts etc. at face value. In my view, any self respecting news
organisation should have a dedicated health/science reporter, especially in this age of
rapid technological advance."
It's clear from the above that reporters are, if not objective, at least aware of a clash of
interests between the pharmaceutical and the natural health industry. It also seems as if
reporters are aware of their duty to aspire to objectivity for the sake of public interest.
However, there are reasonable constraints to be taken into account. Deadline pressure and
competition between institutions should not be underestimated.
Medical experts such as Dr Zinn and Professor Davey agreed that, to be fair, the
following should be taken into account:
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The WHI was a meticulous study and the findings were significant. There were positive
results (about HRT use) as well as negative results.
1. However, bad news sells and the media, in order to be commercially viable, has to
focus the reader/viewer.
2. Well-intended but uninformed reporting, or personal bias will always playa role.
3. Attempts at simplifying, in the print as well as electronic media, add to inaccuracy or
confusion.
It is indeed naïve to imagine there is such a thing as 50/50 impartiality.
"Make no mistake: objectivity is an indispensable journalistic ideal. The reality
however, is that all people are subjective, partial and biased - and journalists are no
exception," says Retief. (Retief,2002:99)
It is evident that reporting is a process of "selection". Journalists decide which aspects
are more important than other aspects. As Retief puts it, ''It is immediately clear that
nobody can be objective. Nobody can interpret objectively. In fact those words are
contradictory to another." (Retief, 2002: 100)
The BBC refers to the term "due impartiality" and acknowledges that it does not exist.
According to the BBC Producer's guidelines, the term "due impartiality" can be defined
as "adequate or appropriate to the nature of the subject. It is better to realise your own
subjectivity than foolishly to pretend otherwise. However, this does not exempt
journalists from the responsibility to "report truthfully, comprehensively,
intelligently"(Retief, 2002: 102).
4.3 Summary
"If I deal with the politics of an issue, I stop being a science writer" or "I want
good science, not moralizing."
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Nelkin (Nelkin, 1995: 98) uses this quote to illustrate how SCIence writers try and
separate science from politics. She talks about the language of "magic and wonder" that
expresses their pleasure in describing science.
However, she warns that the assumption that politics is incompatible with science can in
fact undermine norms of journalistic neutrality.
Nelkin writes how the younger generation of journalists is more cynical.
"Reflecting broader trends, they are more conscious of the social, ethical and economic
costs of science and technology".
Journalists in the 21 st century are no longer merely retailing science rather than
investigating it.
Wilson's book Feminine Forever is now "notorious".
A backlash has set in. One can say that what Nelkin refers to as the language of magic
and wonder has been replaced by horror and suspicion.
Over the years reporting has become more cautious. Reporters no longer pander to the
social belief that women should feel guilty for using it as an "elixir of youth" out of
vanity, and accept their lot or bear the "deserved consequence" of cancer.
Or, on the other hand, that women are under an obligation to stay young and fulfil their
sexual obligations.
However, if health reporters maintain a reputation of being swayed by reigning social
beliefs, instead of going after sober scientific facts, credibility will suffer.
This paper's aim was not to establish whether HRT is good or bad -- merely to reflect
the media.
Journalists have a public responsibility to point out to women the risks of unnecessary
or harmful medicine. They should keep up-to-date with latest developments and
scientific concepts so as not to seem biased or cause alarm that changes health
behaviour.
Stellenbosch University http://scholar.sun.ac.za
68
In order to make readers read useful information (instead of preaching to the converted)
it is often necessary to write a dramatic headline or intro. Facts must be presented in a
digestible format.
However, "jazzing up" "boring or difficult to understand material often feeds public
fears, and might cause suffering.
Errors of omission were more frequent than blatant inaccurate statements.
In the process of reporting on HRT in a lively and understandable manner, most media
reports introduce some errors of omission emphasis or fact. The errors are more often
omissions and subjective emphasis rather than blatant incorrect facts.
Omissions -- of qualifying statements, details of methods and results, as well as shift in
emphasis, less precise wordings and "translations" were widespread.
Fifty per cent of the reports seem to aspire to objectivity. It was oversimplification!
misunderstanding of statistics that contributed to confusion and misrepresentation of
facts.
Television and magazines are the most likely sources of information for most people.
They are crucial in shaping public perceptions of risk.
Scientific findings are often treated with more credit than warranted in the popular
press.
Cause for concern is that this shallow reporting was found in widely read, established,
credible media.
However, it might be too simplistic to portray journalists as ruthless and seeking
sensation or meeting deadlines at any cost.
Chapter 5
Recommendations
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Know the jargon and statistics. In this paper the most important distinction journalists
missed out on was the one between Relative and Absolute Risk, malignant and non-
malignant, invasive and non-invasive, cases and mortality.
- Itmight have been useful to ask more questions about the background and design of the
study.
Cohn (1994: 58-62) has a handy list:
* What specific questions and hypotheses did you set out to test or answer?
*Do you have reason to believe that your subjects were representative of the general
population?
*Does the investigator frankly document or discuss the possible biases and flaws in the
study?
*Is there any basis in these findings for any patient to ask his doctor for a change in
treatment?
*How much weight should your work be given?
*Has there been peer review of the material?
- Reporters should get a wider "pool" of independent experts. The material surveyed
often quoted Dr Theo Kopenhager. He might be a credible and respected medical
expert, but is linked to the pharmaceutical company NovoNordisk's opinion group
according to a newspaper report (La Femme: The Herald 11/9/02).
The article elaborates how the Prempro used in the HRT leg of the WHI study is made
by pharmaceutical company Wyeth, which markets Prempro in South Africa under the
name Premelle. Wyeth and its competitor NovoNordisk each have nearly a third of the
extremely lucrative HRT market here.
More than one article used Dr Arien van der Merwe as natural health expert and at the
same time recommended buying her book.
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- It is crucial to know how to communicate risk and the difference between Absolute
and Relative Risk figures, or whether the risk can be compared to anything else - For
instance: compare taking HRT for 5 years to driving in your car for 5 years or drinking
two units of alcohol a day for the same time.
- Sub editors should take care that the headline, photo and caption are fair reflections of
the report.
- Follow-up research that negate today's headline reports should be published with the
same prominence. For example, the oestrogen leg of the WHI study has produced very
positive "good news" health results.
The fact that by the time this paper is published more than a third of the women who
quit HRT are back on it since they cannot bear the symptoms of menopause, and
advances in HRT (e.g a device inserted in the uterus called the "mirena" combined with
low-dose estradiol patches) will make for another 15 000 words.
Cause for comfort is that half the reports attempted to remain critically objective, and
that editors interviewed aspire to ethical objectivity.
In reporting health, the best reporter is the one who ignores the politics and knows the
jargon -- who reflects all angles and interpretations of "truth".
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Susan Pierres, 'a Miami photojournalist who just turned 60, is
confused and angry. Ten years ago, when she was approaching
menopaus~, her doctor started her on honnone-replacement therapy,
or HRT."I didn't have any symptoms," she recalls, "but he
recommended it for general well-being, bones and heart." Many years
and pills later, her gynecologist suggested that perhaps it was time to
stop. After all, there had been reports that HRT might increase a
woman's risk of breast cancer, a disease that had afflicted Pierres'
mother and aunt. She turned to several other physicians for advice.
They couldn't seem to agree. Now comes word from a really big study
that taking HRT for years at a stretch isn't such a great idea after all.
Should Pierres believe these latest results or go back to her doctor for
an explanation? Which doctor? It's not as though she's all that eager
to get off honnones: "You feel it is your last vestige of youth. What if
my skin turns scaly and my hair falls out?" she worries. "These are
complicated matters. People like me don't know where to go or whom
to listen to." .
Whom indeed. For decades, millions of women like Pierres have been
told that HRT is a veritable fountain of youth. It kept the skin supple,
held back heart disease, boosted old and brittle bones and miQht even
have staved off senile dementia. More than 40% of all women In the
U.S. start some fónn of HRT in their menopause years. Many of them
continue well into their 70s and 80s, convinced that the little pills give
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"These are complicated matters. People like me don't
know where to ga or whom to listen to. II
- Susan PIerres
: ; :
Like latter-day Ponce de Leons, however, these women are watching
their dream of etemal youth fade away. A large, federally funded
clinical trial, part of a group of studies called the Women's Health
Initiative (WHI), has definitively shown for the first time that the
hormones in question-estrogen and progestin-are not the age-
defying wonder drugs everyone thought they were. As if that weren't
bad enough, the results, made public last week, proved that taking
these hormones together for more than a few years actually increases
a woman's risk of develop'lfïg potentially t1éaclIy caraïovascular
problems and invasive breast cancer, among other things.
As with any majormedical announcements, there are caveats and
complications. The, WHI wasn't designed to look at short-term use
during menopause, for instance. But the principal message is this:
taking estrogen and progestin for years in the hope of preventing a
heart attack or stroke can no longer be considered a valid medical
strategy.
Here at last is a rare moment of clarity. The debate over the long-term'
benefits and risks of HRT has lasted for decades. Now we have at
least a few concrete answers.
The findings are so. s~riking that the study was stopped three years
short of its scheduled completion. (The other WHI trials, which include
a look at how estrogen alone affects women with hysterectomies, are
still proceeding.) And the formal scientific report, which is being
published in this. week's Joumal of the American Medical Association,
was released a week early at a press conference in Washington.
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The phones haven't stopped ringing since. Women across the U.S .
immediately started calling their doctors, their mothers, their
daughters, their friends. Are you still taking your' pills? Do you think
plant-based.hormones are any better? Would lowering the dosage
make it any safér?
"Maybe I've been too trusting. I still don't feel like I have all the facts
and details," say's Jodi Simma, 55, a homemaker who engaged nine
friends in a spinted discussion over salads and lemon dessert in New
Richmond, Wis., last week.
"We're all concerned," says Muriel Smith, membership coordinator at
the Dave and Mary'PJper Jewish Community Center, south of Miami,
which is organiZ,h'lg,a panel discussion on the topic. "Everyone wants
to know what to do." .
Some, Iike,Ellen Robin~n, 58, a commercial litigator who works in
Chicago, ha,,~ ~Irea~y made up their minds. Robinson decided last
week to stop ,taking; h'l3rhonnones cold turkey. "I haven't had breast
cancer, a stro!<ifqr~. heart attack," she explains, "but now I'm
nervous. Everyone ~as been in the dark about the risks."
Others who were sképtical of honnones all along feel vindicated. "I'm
not antiestroQen, but we need to accept menopause as a natural,
nonnal, physiological process," insists Vicki Meyer, founder of a '.
cybercommunity called the International Organization to Reclaim
Menopause. The idea that our bodies fail us at menopause, she says,
is "ludicrous, ex,tremQly sexist and just plain wrong."
Physicians are scrambling to keep up. A gyneccllogist in Dallas has
written a script':tb;help her office staff deal with the deluge of calls.
The American ColI~e of Obstetrics and Gynecology has created a
task force to rethink Its guidelines on HRT. "The bubble has burst,"
says Dr. Isaac Schiff of the Massachusetts General Hospital in
Boston, who is chair:in~ the task force. Schiff admits that in the
aftennath of. last week s news, doctors need as much guidance as
their patients. "$ome physicians sar they are not going to change
things in their practice at all and wil be as proactive for HRTas
they've ever been," he says. "Others say this will change their thinking
dramatically.~'·: .: "
~!,·t:",: V:-,;"':;-~-
The Estrog'éN:~~tê~s'
To understand how we got to this point, it helps to know a little
medical history. AbOc~40 years ago, attention was focused on just
one female hérmone,' estrogen. Its greatest popularizer was a
gynecologist name,d ~obei1: Wilson, who thought the honnone could
serve as an:all-purpO~e rejuvenator for women of a certain age. There
was, it mustbeedrnltted, more than a little sexism, not to mention
ageism, in his point of view. In his hugely successful book, Feminine
Forever, published in 1966, Wilson wrote of menopause as a "living
decay" in which women descended into a "vapid cow-like" state.
Supplemental estrogê:n; Wilson insisted, would almost magically
transfonn th~ d~,II'co\:Vinto a supple, younger-looking wife and mother.
She would nqt ohly.Jeél better but also make those around her feel
better--espeGi~IIYi i~:#as implied, her partner in bed. ' '
Those were different times, of course. But the idea that a single pill
might tum b~~k,~~ clock quickly caught the popular imagination. It
~,dn't hurt ~.at ~e. ho~on~'s No. 1 ma~ufacture~,. Wyeth .
"f ....~... '~
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Intriguingly, the part of the WHI study that focuses on the long-term penefits of estrogen alone
among women who have undergone hysterectomies is ongoing. So far, the safety board has not
detected any excess risk of breast cancer in this group. Apparently, estrogen plus progestin has a
negative cumulative effect on the breast that estrogen by itself seems not to have.
Some Questions Still
So much for the major conclusions. Now for the caveats and complications. The WHI study looked
at the most popular brand of estrogen and progestin, which is called Prempro and is made by
Wyeth. Technically speaking, the WHI findings do not apply to other products. Some doctors have
speculated that lower-dose hormones or estrogen-progestin patches and creams might somehow
avoid some of the risks associated with Prempro. That has yet to be proved. Even so-called natural
hormones (those derived from plants) aren't necessarily risk free. For one thing, they haven't been
as carefully tested as Prempro. There is preliminary laboratory evidence, says Dr. Wulf Utian, who
heads the North American Menopause Society, that natural hormones may promote tissue growth
in the breasts and thereby contribute to a cancer risk.
There is also a chance that certain estrogen-like compounds may be developed that will capture all
the hormone's benefits without any of its risks. One such drug, raloxifene, has been shown to
prevent fractures, so far without increasing a woman's risk of breast cancer. But a number of .
women suffer hot flashes and even blood clots while on raloxifene, making it an unlikely candidate
to replace estrogen completely.
Though last week's news raises big questions for anyone on hormone-replacement therapy, women
taking birth-control pills shouldn't panic. True, these pills also contain estrogen and progestin, but
most women take them before menopause, when their bodies are making more of their own
hormones. So it's quite possible that their bodies are better able to handle the excess. In any case,
it's impossible to extrapolate from the WHI study. , • .
Nor should women panic if they are using HRT for short-term relief of menopausal miseries. For in
a strange sort of way, the study brings HRT back to the basics, doing what it always did best-
alleviating intense hot flashes, night sweats and mood swings during the limited period in which
they occur. "Estrogens," says Dr. Howard Judd of UCLA, one of the WHI principal investigators,
"are still the best, and in many ways the only, way of treating menopause."
Is it worth a very slight, short-term risk. of blood clots to battle hot flashes? You bet, says Christine
Fulbright, 53, who runs her own hair salon in Venice, Calif. Fulbright's menopausal symptoms;
which started a year ago, were so bad she thought she was dying. "I was aching all over and crying
all the time," she recalls. "At one point I was cutting a man's hair when, out of the blue, I had to fight
back tears." Fulbright tried alternative remedles, like yam creams, but relief came only when she
tried Prempro four months ago. "It was like a miracle," Fulbright says. "I was back to my normal
self."
The tricky part is going to be figuring outjust how long women like Fulbright need to stay on HRT,
how best to wean them off the treatment. and then how to protect them from osteoporosis and other
ravages of age without resorting to old- fashioned hormones. "The world of menopause
management," says Utian of the North American Menqpause Society, "has just become a lot more
complex." , .
And part of that complexity is dealing with the emotional attachment that some women have to their
HRT regimen. Many like the way they look and feel on the stuff. Change is scary.
And that, perhaps, is why Susan Pierres, the angry and frustrated Miami photojournalist, has yet to
make her move in the wake of last week's news. Along with so many other women, she continues.
to fret over whether she really has to part with her pills.
-With reporting by Amanda Bower/New York, Wendy Cole/Chicago, Jeanne DeQuine/Miamiand
Jeanne McDowell/Los Ange/es
112.1 ~ 14
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I-'narmaceutlcals, rauncneo an aggressIve rnarxennq campaiqn,
Thank goodness today's spots have been updated to feature the
dulcet tones of singer Patti LaBelle and have abandoned patronizing
messages like the ope in a 1975 ad-"Almost any tranquilizer might
calm her down ... but at her age, estrogen may be what she really
needs." ,.. ,.,:, ..
•Over the years the medical arguments for prescribing estrogen were
also updated. "Thé vapid cowlike state was gone, and there was very
scientific lal"\guáge about bone density and heart disease," explains
Cynthia Pearson" executive director of the National Women's Health
Network, a lonqtime-skeptlc of HRT .
- ;_ -' : _: • ,~t-'
It all seerned ~oJogii;al and convincing. Women are much less likely
than men to suffer heart attacks and strokes in their 30s and 40s. But
when natural eW9gëris stop flowing after menopause, women's risk
quickly catches UR to men's. Clearly estrogen has some kind of
positive influeQce. Aod .sure enough, a number of studies in the 1980s"
showed that women who took. the hormone at menopause had lower
levels of LDL cholesterol, the so-called bad cholesterol, and higher
levels of HDL, the so-called good cholesterol, than those who didn't.
The benefits of supplemental estrogen couldn't be more obvious.
" ~',"). .
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DEBATE
Has the, death knell _sounded for hormone
replacement therapy as we know it? Should we
be looking to newer approaches to ease the
pains of menopause? The medical fraternity still
seems divided on this issue, but stay tuned,
more's to come. By Prevashni Ramsamy
F·elicity is an. intelligent, respected 50somethingattorney) She R-é"êpSa:5rêaStOnsSi:Ies'i'ëralTfï9'tormr~nd that of her family. In the past year, likemany women of similar age, she has familiarisedherself with the latest developments in the .\,:ver-
continuing hormone replacement therapy (HRT) controversy. t\
\__'-Bfjfirlré'cent months, Felicity's concerns ha;~- iAêreased .:»
dramatically. Unlike her female cou~PártS, whose fears of
contracting breast cancer from HRT usage form only a,' ,.~
distant but n,agging concern, Felicity has already contracted'. <,
the dreadeclCliSease.-Tflis means that the continually ._
challengingrep~m respected medical journals are a ,--::~~
very real concern for this mother of four. \.,:-
Homec5Pathiê'iternatives to conventional HRT do exist in
the form of natural remedies. But these too have experienced
their share ofcontroversy and, as Felicity has learned, being
presented wit'ilaltemai~is not always the easiest route. "I
wanted to devour every bit of information about every available
treatment to make up my mind about which form of therapy
would be best for me," she says now. "But the choibes they
confronted me with only increased my uncertainty". :'
The 'they' Felicity refers to is the medical fraternity's
, onslaught of information on menopausár~'ome~"'_sTncê-the
'--r~the past year, of not one but two studies .indicting----~HRT as a central cause of increased breast cancer incidents,
~-~~"\'\"..--~
links to heart disease and deep vein thrombosis.
Medical circles are steeply divided over these reports and
their furiously raging debate demands the attention of wide-
\...--..._~ '-~'."'\¥/"
,~~ women ~seeking a simple solution to a
difficult time in their lives.
The study that first sparked the current furore was The US
Women's Health Initiative (WHI)study. Initiated inJ_?_~.ê~.the WHI
had planned to investigate the long-term effects of HRT over a
period of eight years. Over ,160000 post-menopausal women,
on average 67 years old, ~reêilrOii8dTrifc)-thê~study. The~
women were divided into five major groups and every aspect of
lifestyle, from diet to exercise to horrnonallevels, was examined. -...
Last year, three years from completion, a study in thet..-",,-,",-. ___
respected British Lancet medical journal compared the effects of
treatment with Co~fïn the WAfSru'dito'placebo (or
dummy) treatment in two groups of women. It was found that
the numbers of breast cancers in the HRT group had reached a
"-._.\...'......_.'---~--,-----'~-_"' ..---_ -- -----31
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predetermined 'hazard' level. Figures indicated a 26 percent.
i.'1e1aUvê1lskli1Ci'eaSêTn breast cancer incidents'· in 'wo~en' .
'-_ -... •..._ ..~ ~ -.,-_ ~_.-...._...-..-.---
'receivingthe combined HRT compared to those on placebo.
Further, it was decided that risk exceeded benefits. Another
group of the study, comparing synthetic oestrogen only to
placebo, continues; results of this study are not yet known.
The second study, called The One Million Women study,
was initiated by the UK Cancer Research Epidemiology Unit
in Oxford, England. In August this year, findings in the Lancet
confirmed previous findings that "current and recent use of
HRT increases the risk of breast can6~r". Ihe study indi9\\ted
that the risk of breast cancer _[§l!ê.1lY13_io_pfSëë5êfTstwiceas
higfl'fortfïosetaking ~·~e.dJ:!BL -.-------.,.,
NeéCllês!:; tcJsáy,the combined impact of both studies has
resulted in pretty explosive debate surrounding the safety and
efficacy of conventional HRT. To quell the. "media frenzy and
misrepresentation", 25 noted allopathic exPêiis-fromaround
t~ê';orïd;eri~adeira in February this year to discuss clinical
relevance to HRT today. This forum concluded that honmones
are still the treatment of choice for menopausal complaints.
According to their recommendation, HRT should be ini-
tiated early when symptoms occur and at the lowest effective
dose. They also concurred that not all hormone replacement
therapies are the same and that treatment should be
individualised for each woman.
Professor Franco Guidozzi, head of department of
Obstetrics and Gynaecology at Johannesburg Hospital and a
University of ther Witwatersrand Medical School academic,
was a South African representative at the Madeira convention
\
\
"\
. ..•...•
and is one of the first to perform damage control on the
studies' findings. "The media has agaTncreaiecfan emotive
wave of uncertaintY-f6Y-palfënts-ánd'ëf6'ëtors:"he-saTd 'aF'a' ....
.recenfT6ngevity-workshop on the topic, referring to the
release of the One Million Women study.
"Once again, data has been presented out of context and
without reference to subject profiles. Personally, I feel that from
the late 90s to the present time, no new real data supports the
overwhelming emotive concerns. There is no reason to believe
that there should presently be any radical changes." .,/'
Regarding the findings of both studies, Guidozzi does il"
'¥
admit: "What has emanated from recent studies is that there
is potential to consider lower-dose forms of HRT, which are
effective and may minimise the likelihood of adverse events".
US professor of obstetrics and gynaecology at the New York
Center in Manhattan, Dr Steven Goldstein, advises a similar .L/
approach to women questioning their dose of HRT: "If a patient
tapers her dose on HRT over a few months and she feels okay,
I would recommend going off it. If, on the other hand, she
doesn't like the way she feels, she can have her HRT back."
But to another group of medical practitioners, the recent
findings place an entirely new spin on HRT. Medical doctor and
natural medicine expert Dr Arien van der Merwe even argues
that the hormone debate may mean good news for women,
allowing for a totally new approach to menopause treatment. 'J'
"Science has finally caught up with the natural wisdom of
centuries. HRT comprises of potent hormones given to women
at a time in their lives whên nature dictates that hormone
levels should decline because reproductive years are over."
DR ARlEN VAN DER I\t1ER\;VE'S NATURAL PRESCRIPTION ... ~' ::. :'. :
• Take isoflavone phytoestrogens.
They are found abundantly in soy foods
and soy protein-extracted supplements
(also in chickpeas, red clover, linseed,
most nuts and seeds). Try to eat at least
one portion per day.
• Eat ttbsp crushed linseed every day.
Flaxseeds contain lignans, another
group of phytoestrogens that balance
oestrogen and progesterone levels and
reduce symptoms of menopause while
protecting breast tissue from cancer.
• Take a teaspoon of sesame and sun-
flower seeds daily with your breakfast
as well as a handful of various nuts to
nibble on (fibre, essential fatty acids,
plant oestrogens and many more).
• Dong quai (Angelica sinesis) balan-
ces the female hormones. This herb
I'
stands midway between the very weak
plant oestrogens and the progesterones.
• Sage reduces hot flushes (make a
tea using fresh or dried sage leaves).
• Black cohosh has also been shown
to reduce hot flushes and prevent
osteoporosis and vaginal dryness.
Dietary and lifestyle advice:
• Eat foods low in refined sugar, in
saturated fat and in salt
• Avoid stimulants such as spicy food,
too-hot drinks and alcohol
• Increase daily intake of fresh or lightly
cooked vegetables and fruit
• Reduce intake of red meat to a
portion the size and thickness of your
palm once or twice a week.
• Increase intake of cold-water fish like
salmon, sardines and trout, also poultry -
at least two to three times a week.
• Include 600ml low fat or fat free dairy
products or alternate with soy milk.
• Drink at least eight glasses of water a
day.
• Don't smoke; it accelerates bone
loss and ageing.
• Refer. to Van Der Merwe's book
called Herbal Remedies, Health and
Happiness (Tafelberg Publishers), avai-
lable at bookshops
.·32
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A new approach would mean that the 470 million women
worldwide aged 50 and above can target menopausal
symptoms in other ways, either through lifestyle changes or
different drugs. "People are not satisfied by being told what
to do any longer. They don't want to experience the side-
effects of drugs or take the risks associated with them. They
want to take responsibility for their own health by exploring
other options," asserts van der Merwe.
These options include the many alternative treatments
available. ~ut they, too, are in their own maeistrom as constant
ch~II~_Qg~_rs.~:q0ii§ifóii.lli~J§ëE~(i~~E3_~~~§piïau~f~?-irltoth~
safety and efficacy of these products. Van der Merwe says:
"Actually, there has been substantial research done on some of
the HRT alternatives - like soy, black cohosh and antioxidants.
"Black cohosh is one of the most widely studied herbal
remedies for menopausal symptoms. Germany has a special-
ly assigned commission that has investigated and approved
extracts of the root stock of black cohosh for the treatment
of menopausal symptoms. Similar intensive studies are being
carried out on other therapies as well."
Dr Barbara Lewis, another campaigner for natural meno-
pausal relief, recommends dietary as well as exercise inter-
vention. "A healthful diet of large amounts of fresh fruit and
veggies, soy products and natural grains and cereals should
aid a smooth menstrual transition. Regular weight-bearing
exercise is necessary for bone and cardiovascular health."
For Lewis, it all comes down to each individual choosing the
best solution to her menopausal angst. "A responsible position
is to use the lowest possible dosage available that gives a
woman symptom relief at menopause, and use this in the most
natural form possible in line with the basic premise that
menopause is a natural body transition, not a disease process."
For Felicity, the challenge of fighting her cancer (potentially
: promoted by the HRT pill meant to "prolong her life", as was
claimed) remains the only concern. "I've read that chances of
_.,~urvival are greater because the disease is hormonally linked.
But wharklndofïife would-it be IfThave--nobreasts?'-An-alf
that life is lived fearing a relapse in my condition?"
-"-_ ..__ ..•.-." ... _. __ ...~"-_._---_..- .~--_._"---_.
BENEFITS AND RISKS OF HRT IN CONTEXT
Guidozzi's summary of events
Unti12002: L//
• HRT is the most effective treatment for early menopausal
symptoms. It improves quality of life in symptomatic women
• Early cardiovascular disease studies showed that
oestrogen did have a protective effect against cardiovascular
disease in postmenopausal women. Later studies, like WHI,
indicate a 29 percent increase in risk of cardiovascular events
in women taking combined' HRT compared to those on
placebo drugs, i.e. there is a 29 percent increase over what
Stellenbosch University http://scholar.sun.ac.za
.....
is expected if the patient was not taking HRT. There was,
however, no increase in death due to cardiovascular events
in the HRT group compared to the placebo group.
• Studies indicate that postmenopausal HRT does prevent
bone loss and osteoporosis after four to five years of treatment.
• Cognitive functioning, Alzheimer's, sleep disturbances,
mood fluctuations and colon cancer are improved with HRT.
• In the WHI study, a two- to 2.5-fold increase of blood-
clotting events. This equates to an absolute risk of one in
5 000 users of HRT per year extra than what was expected
in non-HRT users.
• Medical studies do not show consistent results for the
effect of HRT in stroke. In the WHI study, there was a 41
percent increase in stroke risk compared to placebo users.
• The WHI study reflected a 26 percent inc~aase in breast
. cancer in women receiving combined HRT compared to those
receiving the placebo, an increase that is similarly seen in
women who are obese and who use alcohol. The One Million
Women study also found a breast cancer risk increase.
2002-2003:
• Oestrogen alone does not apparently increase the risk of
breast cancer. Combined HRT appears to increase risk of
breast cancer. It may be progestagens and not oestrogens
that increase the risk of breast cancer.
• The risk of cancer only appears to be increased after five
years of HRT use. This risk disappears after five years or
more after discontinuing HRT use.
• HRT is associated with specific breast cancers - invasive
breast cancers, and not with lesions that start growing and
become cancers. So HRT is thought to promoteing existing
breast cancers - not causing new breast cancers.
• Women who get breast cancer while on HRT tend to have
a lower mortality rate than women who get breast cancer
without being on HRT.
What Guidozzi advises
• Oestrogen replacement is the best treatment for meno-
pausal complaints.
• Length of treatment with HRT.should be individualised.
• The lowest effective dose of HRT should be used.
• All women should have an annual mammogram and an
annual examination by their gynaecologist. Each separate
exam must be at six-monthly intervals: in other words, see
your doctor and six months later, have a mammogram.
• All women should be taught to perform a clinical self-
examination of their breasts and this should be done regularly.
• Healthy lifestyle modification is important - stop smoking,
limit alcohol intake and maintain a healthy body weight.
• All women offered HRT must be informed of HRT's risks and
benefits so they can decide about their quality of life. A
baseline mammogram must precede commencement of HRT.
• Sensationaliststatisticsquoted in the media must be viewedjVith
caution and in context if an informed decision is to be made.•
atural relief
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gged fee ing
I is a natural diuretic that relieves water retention or blaatedness, a
. symptom of many conditions including PMS, menopause and obesity.
Waterfall contains three natural ingredients: boldo herb, celery seed and
asparagus, which in combination, promote urine secretion and reduce water
retention. In addition Waterfall contains vitamin B6 which helps treat
moodiness and depression, as well as Lecithin, which assists in overall
digestive processes.
Available from leading health shops and pharmacies. For more
information, visit www.peppina.co.za. or phone (011) 466 4095
GIVEAWAY! 25 readers stand to win a pack of
Waterfall. Send your contact details by 30 November
2003 to Peppina Sales, Private Bag X11, Postnet
Suite 161, Halfway House, 1685.
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D a woman develops hot
es, sweats, and wrinkles on her
she is quite concerned that she
ng her youth - that she may
d be losing her husband."
r menopausal women hearing
erdict, aired in a film commis-
d.bythe United States drug
r Ayerst in the 1970s, would
probably rushed out for a
ription for Hormone Replace-
Therapy (HRT).
ay, menopausal women world-
bave opted for HRT as an
It cure for hot flushes, poor
is,memory loss and skin age-
[RT replaces the female hor-
s that decrease as women age.
believed that every woman
pend 30% to 40% of her life-
Dmenopause, during which
illbe increasingly vulnerable
eoporosis, coronary heart
le, strokes and colon cancer.
!bad news does not stop there.
:-Studies{)~ HRT show thá'ti!
.educe osteoporosis and colon
r and can combat debilitating',
les such as Alzheimer's, a )
t study by the Women's Hel!lth
tive (WHI) in the US provéd to
iedical tempest. ./' ,
study, which foeusedon the '.,',
ernruse;gf.hornlones, came to .
in July because participants
zere taking a combination of
;en and progestin hormones
1increased risk of breast
r,heart disease and stroke.
~enis mainly used for women
ave had hysterectomies, and is
meally referred to by critics of
IS the "youth pill" while
stin, once combined with
;en, is HRT. Coronary heart
:eis the leading cause of death
gwomen.
Dr Theo Kopenhagen, a
co10gist a.t Park Lane Clinic,
esthe incidence of risk of
Mail&O!
Many women refuse to go on hormone replacement therapy as they assoCiate breast cancer with it
heart disease is small, especially
with low-dose HRT. He affirms that
the majority of the 16 000 partici-
pants in the study were not ideal
candidates, and that the hormone
takéxi was not suitable.' ' ,'.
'. 4lle WH! studyused hormones - .Ó
found in pregnant mares, which is not
nqrmallyused. Sixty percent of the
women were overthe age of 60,50%,
'Were current br past smokers and a
large number of them were obese. The
study completely ignored the quality
oflife aspect - those symptoms
associated with menopause such as
hot flushes, skin ageing, atrophy'of '
the vulva and memory i6r.-
Kopenhagen believes that
natural estrogens, or low:a~se HRT,
are the answer as they hlivethe ability
to reduce the risks of cancer and
counter the sidé-effects of normal
dose iIRTh - side-effects such as
weight gain, headaches, vaginal HRTs for more than 10 years may
bleeding and swelling of the breasts. increase your risk. Kopenhagen sai
Many women refuse to go on HRT some women have taken HRTs for.
as they associate breast cancer with more than 20 years, but he coneed.
it, and the WH'lfltudy seems to buffer" that there is a need to discuss the
this belief. However, Kopenhagen issues in an annual assessment risl
-affirms that the-risk ofbre.astcancer if a patienthas been on HRT for
increases in aliwomen as they age, more than five years.
regardless of whether theytalre HRT . '. Still, some peOp1e'believe·that
-er not. HRT is nothing more than the
"The risk of breast cancer after the cunning product of menopause
age of 65 is 12 times less than the risk marketing that plays on women's
of heart disease, After 50, deaths fears. However, Kopenhagen says
from breast cancer decrease, while women who take HRTs are new
dea1fsfróm Cardiovascular disease women. "They feel great. Itmakes
mcrease," He believes that the .risk of women feel so much better. But no
. ~ cancer is small in comparison every postmenopausal woman nee
to the>be';lefits, but that the period in HRT. Ithink that the most impor-
which you take HRTs may playa role, tant thing is that women watch the
Various studies point out that if diets exercise and just take care of
you take HRTs for less than five themselves, Ifyou do, there is
years, there is little or no increased convincing data that points to safe
risk cf breast cancer, but taking therapeutic options," he said.
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Hormone Therapy: The latest
As little as five years ago doctors still hailed hormone therapy (HT) as the
saviour of post-menopausal women. A year ago the bubble burst when a
huge study, known as the Women's Health Initiative (WHI), was
prematurely halted in the USA due to concern about the risks of long-term
use of combined progestin and oestrogen.
The publicising of the findings has had a ripple effect. New studies in the
USA and New Zealand have shown that more than half of women on HT
stopped their therapy immediately. In general, menopausal and post-
menopausal women are. left with a sense of unease and confusion
concerning HT.
Health24 investigated. After attending a lecture by Dr Alan Alperstein from
the Department of Obstetrics and Gynaecology, University of Cape Town,
and private practitioner at the Kingsbury Hospital in Cape Town, an
interview with Dr Jacques Rosseau from the WHI and National Institutes of
Health (NIH) in the USA, and scanning medical journals for the latest
articles and reports on HT, we bring you the latest findings. Dr Alperstein
reported back from the very recent North American Menopause
Association's (NAMA) congress.
Ve
Me
du
oe
ov
Our primary objective is the best interest of all women, not the
pharmaceutical companies, nor any other interest group. If a natural
product is better, we will tell you. If you should worry about the risks of HT,
we will tell you. If this whole upheaval has blown the findings out of
proportion, then we will tell you. Now, read on.. f#;rQ
The Initial euphoria of a "fountain of youth" ~
Five, ten years ago doctors presented the option of HT almost as a
"fountain of eternal youth" to their post-menopausal patients.
http://www.health24 ..../centre.asp?subcontenttypeid=43&show=main&conditionID=403 11/7/2003
Many women face menopause and the post-menopausal time of their lives
with dread. Not because menopause is a deadly disease - in fact, it is a
natural phase in the ageing woman's life. And that is just it: ageing is very
natural, but not quite on everybody's wish list. Neither are the symptoms of
post-menopause. Does any woman in her right mind like to deal with hot
flushes, mood swings and vaginal dryness when she still wants to feel
attractive, sexy and wanted? .
With oestrogen production dropping due to declining ovarian function (they
are no longer needed for reproduction, translated to: sorry, you are now
really too old for another baby), the protective effect of the woman's own
oestrogen against heart disease, osteoporosis and Alzheimer's disease
gradually disappears and the risk of these diseases and breast cancer will
increase with age in the post-menopausal woman.
Stellenbosch University http://scholar.sun.ac.za
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It made sense and sounded logical that replenishment of lost oestrogen will I·.·· .
keep all the symptoms of menopause at bay, keep the risks for diseases of .
old age low, will keep the distraught, red-faced women happier and more
even-keeled and their partners sane.
The logic went further: if a little bit of a good thing is good for a year or C.··.1
two, why not stick to hormones till you are 65 or maybe eighty? Why
shrivel up, get Alzheimer's and osteoporosis, and lose your protection
against heart disease?
Who can blame women that they dun
protector against diseases of old age? hey believed their GPsand gynae ~
Many post-menopausal women - especia ecto rus
surgically removed) or ovarectomy (ovaries surgically removed) - took ~
hormones, either in pill form or as implants and later as patches. They took
hormones, whether it was oestrogen alone or a combination of oestrogen
and progestin. Most women did not bother to ask their gynaes whether it
was one hormone or two, they took it.
The new studies
Between 2001 and 2002 the results from the WHI and other similar studies
were published, showing an increased risk for breast cancer and
cardiovascular disease for women on combination therapy. Women got
scared and more than half stopped taking their hormones.
However, one out of four couldn't tolerate their symptoms of hot flushes
and mood swings and grabbed their hormones again.
~
Right now women are confused. Should one take hormones at all, and for
how long? What about the risk for breast cancer? What about long-term
use, what about plant. hormones?
With female life expectancy on the increase and~idence of post-
menopausal women, it is important to establish the status quo.
Explaining the findings
The first important aspect of the findings is that there is a difference
between the risk due to the use of double HT (a combination of oestrogen
and progestin) and the use of oestrogen alone.
Women should note that the findings are based on the use of oestrogen
and progestin simultaneously. The preliminary findings of the trial in which
women are receiving oestrogen alone (without progestin), have shown no
increase in health risks. This arm of the trial is still continuing.
Breast cancer risk:
• A 50-year-old woman (regardless of combination HT or not) has a
2.8% chance of developing breast cancer by age 60.
• No increase in the risk for breast cancer was seen in the first four
years of oestrogen and progestin treatment, according to the WHI
study.
• The WHI study reflected an bsolute ance of breast cancer by age
50 after five years of HT of 3. er five years on HT therapy, a
woman's chance will be 0.7 % higher to develop breast cancer by
age 60. Dr Rossouw of the WHI described the increased risk as
small. .
• If a 1000 women have two drinks daily, or have their first child at
age 30 or older, or are obese, but are not taking any HT after age
50, 35 of them are likely to develop breast cancer at age 60.
• Using another calculation called the "estimated cumulative incidence
of breast cancer", 45 out of 1000 women between 50 and 70 years
and not using HT will develop breast cancer. After five years of HT
IIC:p47 nllt nf 1nnn wnmpn will r!p\lplnn hrp~c:tr~nrpr (twn p'I(tr~npr
http://www.health24 ..../centre.asp?subcontenttypeid=43&show=main&conditionID=403 11/7/2003
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1000). After 10 years of HT use, 51 out of 1000 women will develop
breast cancer (six extra). After 15 years on HT, 57 out of 1000
women will develop breast cancer (12 extra).
Bottomline: There is an increased risk for breast c eer, especially after
four years of HT use. Despite the increase in breast ancer incidence, th
mortality is unchanged. It seems that breast cancer is~~cte~iIaf"tTe"F
women on double HT because of increased awareness and annual
mammography.
Risk for heart disease, stroke and deep vein thrombosis:
oAbout 37 out of 10 000 women older than 50 and who are taking HT
are likely to develop heart disease, instead of 30 out of 10 000.
Therefore, for every 10 000 women on HT, seven more are likely to
develop heart disease.
oAbout 29 out of 10 000 women older than 50 and taking HT are
likely to suffer from a stroke instead of 21 out of 10000. This is an
increase of eight per 10 000 women.
oAbout 34 out of 10 000 women older than 50 and taking HT are
likely to suffer from deep vein thrombosis instead of 16 per 10 000.
This signifies an increase of 18 per 10 000.
o The risk for stroke and pulmonary embolism appeared to increase
within the first two years of use in the WHI study. This increase may
be followed by a decreased risk. According to Dr Alperstein the
decreased risk after two years does not sound enticing enough for
women to put their health and life on the line in the first two years.
Bottom line: This so-called protective benefit against heart disease and
stroke is now recognised as an increased risk. There should be no combined
therapy for women with a family or personal history of heart disease,
stroke, hypertension, elevated cholesterol or lipid levels. No combined
therapy with the objective to reduce the risk for heart disease. Delete this
idea. The American College of Obstetricians and Gynaecologists (ACOG)
states: Combined oestrogen and progestin is not recommended for the
prevention of heart disease in post-menopausal women.
for colorectal cancer, hlp fractures and Alzheimer's:
The use of HT decreases the risk for cancer of the colon and
endometrium.
o The risk for colorectal cancer may drop from 16 per 10 000 women
to 10 per 10 0000 wamen using HT.
o The risk for hip fractures, an indicator of osteoporosis, may decrease
from 15 per 10 000 to 10 per 10 000. HT can be regarded as a bone
protector.
o HT can be regarded as a protector against Alheimer's disease.
Bottom line: Protection against cancer of the colon and endometrium, and
against bone loss (osteoporosis) is real.
What about alternatives?
According to Dr Alan Alperstein women are desperately looking for
alternatives to HT because of the "scare" stories, and because of some side
effects of HT (including headache, nausea, breast tenderness and weight
gain).
In the USA, the trend towards natural remedies is so huge that the public's r7
expenditure on alternative therapies is approximately four times its l
contribution towards all pharmaceuticals. ).
More and more women are trying phyto-oestrogens derived from plants.
Studies on phyto-oestrogen from the Black Cohosh specie Cimicifuga
racemosa has shown relief of meneoeuse svmotoms. accordina to
http://www.health24 ..../centre.asp?subcontenttypeid=43&show=main&conditionID=403 11/7/2003
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naturopath Dr Chase Webber. Phyto-oestrogens do not act in the same way
as HT. It may relieve some of the menopause symptoms, with no additional
health benefits.
Studies have also shown that high amounts of soya in the diet is effective
to treat some menopause symptoms, but that phyto-oestrogen extracts
from soya supplements are not. Other herbals that may be effective in
providing some relief from menopause symtoms are Dong Quai (Aelica
sinensis), licorice root (glycyrrhiza glabra) and chaste berry (vitex agnus
castus).
The bottom line: Some natural remedies do relieve some symptoms. They
do not act like HT and are not as effective in' relieving symptoms of
menopause as HT.
The ultimate bottom line for all post menopausal women
Menopause is not an illness, but a discomfort.
The following applies to the use of combined oestrogen and progestin
therapy (not to the oestrogen therapy alone - that seems to be fine and
without the health risks involved in combined HT.)
• HT (oestrogen plus progestin or oestogen alone) should be
prescribed primarily for the treatment of menopause symptoms such
as hot flushes, mood swings and vaginal dryness, and not primarily
to protect against heart disease as was previously the case. Rather
treat women with heart disease with statins.
• Combined oestrogen and progestin treatment can be prescribed with
relative safety for four to five years to women without a personal or
family history of breast cancer and heart disease. If prescribed for
longer than five years, re-assessment of the benefits and risks is
recommended, because the risk of breast cancer seems to increase
after four years.
• The short-term use (up to five years) of combined oestrogen and
progestin to manage menopause symptoms is regarded as
appropriate treatment. Added benetlts will include protection against
osteoporosis, Alzheimer's disease and colorectal and uterine cancer.
• If a woman still suffers from menopause symptoms after five years,
and she needs the protection against bone loss, Alzheimer's or
colorectal cancer, the doctor should discuss the benefits and risks
again before continuing with the long term use of HT. She may need
annual mammography. ~
• A woman with a famil~istOry of br st ancer or a personal history
of breast lumps shoul e considere for. combined oestrogen and
progestin therapy.
A woman with a family r personal history of or increased risk for tf
heart disease, stroke or deep vein thrombosis, or 0 has C
hypertension, should be considered for oestr plu progestin
therapy. These women should be treated wi h .tatins Studies show
that women are under-treated in this regar .
• It is important to use the most effective dose of the purest hormones
for the shortest duration. In older women using HT for more than
five years, it maybe best to change to low dose oral or transdermal
preparations (skin patches). '--'--
• The oestrogen alone trial should bring even more insights.
- (Mari Hudson, www.health24.co.za)
Health24 retains editorial freedom regarding content. Sponsors of this Condition Centre have no e
on the content thereof.
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Menopouse: kuur of skete?
Thalyta Swanepoel
Moet jy of moet jy nie. Dis dié onsekerheid oor hormoonvervangingsterapie (HVT) wat vroue. .
wêreldwyd op hol het ná skokbevindings oor dié kuur wat help keer dat ouer vroue "droë ou .
koeie" word. Thalyta Swanepoel berig. HVT doen dit vir jou vrouwees as die menopouse-wolfby
die deur staan. Daarsonder gaan jy gebuk onder baie skete, sukkel jy met gloede, val jou hare uit,
lay jy hare op die gesig selfs 'n snorretjie, sê vroue wat weet. Jy kwel jou ook meer oor siektes
soos osteoporose, blaasbeheer, kanker. Enjy~erouder. Vinnig.
Sowat 40' jaar gelede het die ginekoloog Robert Wilson die wêreld se aandag op 'n veeldoelige
"verjongingskuur" vir vroue van 'n sekere ouderdom gevestig: die hormoon estrogeen.
ill syboek Feminine forever skryf hy in 1966 dat die menopouse 'ntydperk is waarin vroue met 'n
droë ou koei vergelyk kan word, luidens 'n berig in Time van 22 Julie. En dat estrogeen haar weer
'n jeugdiger en wulpser vrou en ma sou maak.
, '., .
Minder estrogeen maak vroue vatbaar vir osteoporose, laat die risiko vir hartsiektes styg;
veroorsaak gemoedsversteurings en warm gloede, maak seks ongemaklik omdat die wande van
die vagina uitdroog en verdun, en vat aan jou blaasbeheer.
Maar menopouse is 'n natuurlike proses en baie vroue verkies om die natuur sy gang te laat gaan.
Die gloede en gemoedsversteurings bedaar tog met verdrag. Tog maak HVT die lewe net
maldiker en teerheid van die borste en ander newe-effekte is 'n klein prys om dáárvoor te betaal.
Talle voordele is toegeskryf aan HVT estrogeen vir vroue ná 'n histerektomie en 'n kombinasie
van estrogeen en progesteroon vir dié met 'n baarmoeder: dit verhinder én behandelosteoporose,
dit doenjou hart goed, stuit die verlammende simptomevan die menopouse, en as jy gereeld 'n
mammogram ondergaan, hoef jy jou nie te veel te steur aan die effens hoër risiko vir borskanker
nie. .
Toe, einde Mei vanjaar, het navorsers 'n kat in die duiwehok kom gooi deur die Amerikaners se
Women's Health Initiative-studie (WHI) voortydig op te skort. Die redes? Dat HVT op die duur
die risiko van borskanker verhoog en dalk nie soveel doen om hartsiektes te voorkom as wat
voorheen gemeen is nie. .
Dithet vroue wêreldwyd nóg meer verward gelaat. Me. Cynthia Stoltz, bestuurder van vroue-
gesondheidsorg by die farmaseutiese vervaardigerNoso Nordisk SA, sê die maatskappy se
telefone gons behoorlik. "Vroue weet nie wathulle moet doen nie. Hulle is nie net verward nie,
hulle is bang. Talle staak selfs hul behandeling" al is dit ander middels as wat in die studie gebruik
is, sonder om 'n dokter te spreek." .", , " .
_ NEE wat, sê_dr. Timmy Kedijang, mediese direkteur van Novo Nor disk SA. Mense jaagnou
spoke o~"Die Wlfl-studie het net een van die ouer HVT -komoinasies wat.in Suid-Afrika
beskikbaar is en ook net een dosis ondersoek. .
. "Boonop is net een vertakking van die studie, met 'n spesifieke kombinasie van estrogeen en
.progesteroon, gestaak."
Dr ..Greta Dreyer, ginekologiese onkoloog aan die Universiteit van Pretoria, stem saam. "Daar.
was. nog altyd .'nhoë uitvalsyfer as dit by HVT kom, omdat vroue bang is vir borskanker, .
simptome soos veral borsteerheid en die kostevan die behandeling. Nou is almal bangHVT
veroorsaak beroerte en hartaanvalle." .
. Sy raai vroue aan om HVT te gebruik net vir.spesifieke indikasies soos die verligting van die
http://152.l11.1.251/argieflberigte/dieburger/20O'2/08/2O'/917.html 10'/24/20'0'3
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simptome van die menopouse en die voorkoming van spesifieke siektes. "Die voor-en-
.' nadeelverhouding is vir elke pasiënt anders. 'n Mens moet kyk na die individuele siekterisiko.
Vroue moet liefs hul dokter spreek voordat hulle die behandeling staak."
Dreyer sê verdernie 'n enkele probleem wat deur die WHI-studie bespeur is, is van toepassing op \,/
vroue wat nié 'n baarmoeder het nie en wat net estrogeen gebruiknie. "En as jy enige ander
progesteroon en estrogeen gebniik as die middels wat in die studie gebruik word, is dit ook nie
noodwendig op jou van toepassing nie." .
Sy meen daar is heelwat positiewe bevindings in die studie wat nou oorskadu word. "Dit is die
eerste studie wat duidelik wys hoe doeltreffend hormone is in die voorkoming van osteoporose.
HVT is ook die kostedoeltreffendste behandelingsmetode. Dit is dus 'n wesenlike punt. En die
vroue in die studie is nie eens vir hierdie risiko gekies nie; anders sou die uitslag nog beduidender
gewees het. . .' • ..' '. . ....
"Dis ook die eerste studie wat duidelik toon dat HVT die voorkoms van dikdermkanker verlaag.
En daar sterf nie meer vroue aan borskanker nie, daar is net meer gevalle. Dit isnie nodig dat ..'
vroue so heftig reageer nie." .
KENNERS is dit verder eens dat HVT nie 'n lewenslange' 'vonnis" is . ",na .~ ~
waarvoor jy dit gebruik. As dit is om simptome te verlig, is dit gewoonl korter as vyf' .aar en as
dit kom by beskerming teen siektes, is dit langer as sewe jaar, sê Dreyer. me vroue an ook
voortgaan met 'n laer dosis heelwat aandag word tans aan hierdie denkrigting geskenk."
.Dr. Stanley Lipschitz, osteoporosekenner van Johannesburg, sê egter hy behou uitspraak voor oor
HVT. "Daar is bewys dat HVT teen die menopouse beenverlies in 70% tot 80% van alle vroue
verhinder. Maar as jy kyk na 100% van die vroue, sal net 30% tot 40% wel osteoporose kry, Dit
beteken talle word onnodig behandel. As jy. 'n uiters veilige middel gebruik, maak dit nie saak nie,
maar as daar probleme is soos die WHI-studie nou uitgewys het, moet jy weer dink En daar is
ander selfs beter middels op die mark. " .
Mev. Bessie Louw (62) van Bela-Bela (Warmbad) in Limpopo (Noordelike Provinsie) is een van
.talle vroue wat met die "ander kant" van HVT kennis gemaak het. Sy het byna 20 jaar lank HVT
ontvang voordat borskanker 7 jaar gelede by haar gediagnoseer is. Was dit HVT se skuld? "Die
dokters was versigtig om hulle te verbind, maar het gesê dit kon daartoe bygedra het"
Louw het op 28 'il histerektomie gehad, haar eierstokke is verwyder weens herhaalde sists toe sy
jets in die veertig was. Ná die eerste mastektomie. in 1996 is die HVT oniniddellik gestaak. "Toe.
was dit weer die warm gloede, die hoofpyn, die depressie, die droë vel. En ek het onmiddellik
begin verouder. Maar wat maak ek? Met borskanker is hormone vir jou taboe."
.' - .
Sy is bekommerd oor chroniese siektes, veral osteoporose, omdat haar ma daaraan gely het. Louw
het 'n ruk lank. een van die sogenaamde bifosfonate gebruik, maar dit later gestaak.
. .
"Dit is geweldig duur. Ek gaan nou elke jaar Vir 'n beendigtheidstoets as deel van die
kankertoetse en drink maar natuurlike goed soos ekstra kalsium. Osteoporose.is 'n verskriklike
siekte. Dit is die moeite werd om HVT net daarvoor te gebruik." •
.'Het sy 'n keuse gehad, sou sy by HVT gehou het, "Met HVT voel jy baie lekker, en jy is langer
jeugdig." .
. Haar HVT laat staan? Nooit, sê mev. Martie Pieterse (44) van Roodepoort selfs al bewys watter .
studie wat. Haar baarmoeder en eierstokke is, einde verlede jaar verwyder.
"Binne 'n week het ek begin gloede kry en begin sweet. As ek my pille net 'n dag of twee· .'
. oorslaan, begin dit weer. Ek sien eenvoudignie daarvoor kans nie." . .'. .' • . i
Vroue kan Novo Nordisk tussen. 9 vin. en 4 nm. tolvry by 0800 ; 16 941 met vrae oor dié kwessie f~~=21l-..
__ -'----:-------,---c--"'-.. ~-_-.- .._..' .'
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,Gebruik van HVT raak al hoe-meer omstrede
DIE Women's Health Initiative-studie (WHI) het hoofsaaklik ondersoek of die meeste vroue met ~ r.."'-'lL
.'n baarmoeder in die dekades ná die menopouse hormoonvervangingsterapie (HVT) moet . ~'; , (I
oorweeg omchroniese siektes soos hartsiektes, bors- en kolonkanker en beenfrakture te voorkom. I ,~;;;~~
--------i s\
Die Amerikaanse National Institute of Health (NRI) het met dié studie begin nadat die ' _.) &.
sogenaamde HERS-studie getoon het ná gebruik van sowat vier jaar beskerm HVT nie teen _ '; , c ,
.hartsiektes nie, volgens 'n beleidsdokument van die Suid-Afrikaanse VeTêDigiITgvan-~/'- ~....;...--
Verloskundiges en Ginekoloë (SAVVG). WHI moes dus kyk na die uitwerking van die '--
behandeling op die duur. .
, .
Werwmg vir die studie is al in 1993 begin, volgens die Duitse Menopousevereniging (DMV). Dit
sou lot 2005 (dus 8,5 jaar) duur. Altesame 8506 vroue het 'n spesifieke kombinasie van estrogeen
en progesteroon ontvang en 8 102 'n plasebo.
Die WHI-studie is einde Mei vanjaar beëindig weens 'n verhoogde risiko vir borskanker, veral ná
sowat vier jaar van behandeling. Dié rede het wenkbroue wêreldwyd laat lig, omdat ditalom
bekend is dat meer gevalle van borskanker voorkom met langtermyn-hormoonvervangingsterapie
(HVT). Boonop lyk dit of gewasse wat tydens HVT ontwikkel, minder kwaadaardig is en ruinder .
geneig is om te versprei.
Die groot probleem is egter dat dit lyk ofHVT nie net min beskenningteen hartsiektes bied nie..
maar ook of dit die risiko vir dié siektes kan verhoog. Dié gebrek aan beskerming is die
belangrikste bevinding vandie WHI-studie, volgens die SAVVG.
Volgens 'n artikel in die uitgawe van 17 Julie van die Journal of the American Medical
Association was die risiko vir 'n hartaanval 29% hoër onder die groep vroue wat die
lcombinasieterapie ontvang het. Beroerte het ook met 41% onder dié vroue toegeneem.
--7
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Wat ko~ore~ale kanker betref: het die stu~e egter 'n afname ~an 37%. getoon. Di,evoorkoms van [.
kanker ID die algemeen, van die endometnum en longkanker IS glad me geraak me.. . J. . /'
Nóg 'npositiewe uitslag var, die studie is dat langtermyn-HVT die voorkoms van heup- en .
. werwel:frakture beduidend verlaag het. Die kombinasie beskerm dus teenosteoporose,
Die studie het getoon die risiko's is klein: onder 10000 vroue wat die kombinasiemiddeln jaar
lank:neem, sal daar sewe meer hartaanvalle-wees, agt meer gevalle van borskanker en agtmeer
gevalle van beroerte en bloedklonte, Daar sal egter ook ses minder gevalle van kolorektale kanker .
en vyfminder heupfrakture wees, volgens die DMV.
Nadat aldie probleme egter bymekaar getel is, was daar 'n negatiewe Uitwerking onder een uit
elke honderd vroue klein, maar dit dui daarop dat die probleme meer word hoe langer HVT.
voortduur.
. . '+. . S/
Wat die skrywers wel benadruk, is dat die uitslag van die studie nie noodwendig van toepassing is V'
'.. op laer dosisse of ander kombinasies van estrogeen en progesteroon nie. Die SAVVG stem
hiermee saam. . .
Die bestudering van 'n de~de groep vroue van 10 739 wat 'n histerektomie gehad het en net met .f!/
estrogeenbehandel word, gaan steeds voort. .
Dieselfde probleme is nie in dié groep bespeur nie.
. .
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Hormoonvervangingsterapie. (HVT)ras die afgelope tyd dikwels 'n besprekingspunt in mediese .
kringe. Ná sekere studies is skielik !wolf-wolf' geroep toedaar krakies in die mondering van dié
menopousa1éáiiifvulling bespeur is. PETRO BOSMAN d,en verslag. . ..'
Ja en nee nie m~~oord .
, . '{J ":'~ .
1;~~~
v, HOKAAIegter eers, sê prof. Stephen Hough, hoofvan die departement interne geneeskunde van
.....die fakulteit gesondheidswetenskappe op die Tygerbergkampus van die Universiteit Stellenbosch,
• Daar is nie 'n eenvoudige "ja" of nee" vir hormoonaanvulling nie. Dit gaan immers oor elke vrou
.se persoonlike profiel. Vroue met gewone menopousale probleme reageer goed op HVT: Dit is '.
ook algemeen bekend dat die toediening van estrogeen wel die skelet beskerm, sê prof Hough, ,
maar die eerste krakies oor hormoonvervangingsterapie het ~ 1998 met die Hers-studie na yore
getree. ..'
'Toe isgedink vrouewat hormoonvervanging kry, is dalk slegter daaraan toe as wat eers gedink is
tenopsigte van hartbeskerming. . .
I" 'Navorsingresultate wat onlangs gepubliseer is, het betrekking op 'n kombinasie van estrogeen en
progesteroon. "Normaalweg sal45 uit 1 000 vroue wat geen medikasie gebruik nie, borskanker .: "
kry. Met hormoonvervanging skuif dit op na 47 uit 1 000. Studies met estrogeen alleen gaan nog
voort." .
--........ ,"
Elke vrou se voordeleprofiel teenoor haar nadeleprofiel moet egter opgeweeg word teen mekaar;
sê Hough. As hartsiektes ofborskanker bv. in 'n familie voorkom, verhoog die pasiënt se risiko
dalk met die toediening van hormone. Maar elke geval is uniek en moet so gehanteer word.
Liggaamsbou en risikofaktore vir osteoporose sal ook 'n rol speel.
"Die klem het geskuif na waar dokters in die verlede basies net besluit het 'n vrou sal 'n
hormoonaanvulling op 'n sekere ouderdom neem na waar bemagtigde vroue vandag saam met hul
dokter 'n ingeligte besluit kan neemoor die gebruik van hormoonvervangingsterapie," sê Hough;
Hough; wat ook die president van die nasionale osteoporose-stigting is, sê daar word egter nog .
, teen die moderne vrou gediskrimineer wat die beskikbaarheid van sommige medisyne betref ...
"Vrouegesondheid geniet nie altyd die aandag wat dit verdien nie. Sommige siekefondse en
.provinsiale hospitale wil van hul verantwoordelikheid wegskram om sekere middels aan vroue te
verskaf. Vroue kry nie altyd hul regmatige deel met byvoorbeeld osteoporosemedikasie nie;
"Provinsiale hospitale in die Wes-Kaap het die laaste-wd nie spesifieke middels gehad om " .
osteoporose te behandel nie. Onderhandeling is egter aan die gang om die onaanvaarbare situasie .'.
die hoof te bied en ons hoop ons sal met nuwe gesprek met provinsiale owerhede wel tot 'n
,.skikking kan kom." .
Verdere navrae hieroor kan gerig word aan nofsa@iafrlca.com
", ~
. _: ,:,~,
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Navorser wat medici skud, was lank in SA
Pierre Steyn
Washington. 'n Voormalige navorser van die Suid-Afrikaanse Mediese Navorsingsraad (MNR) het
hier aan die spits gestaan van 'n studie oor hormoonvervanging wat die wêreld se mediese
establishment tot in sy fondament geruk het.
Dr. Jacques Rossouw, wat in 1989 na die VSA geëmigreer het ná In lang en bitter geveg met die
destydse leierskap van die MNR, is nou waarnemende direkteur van die vroue-gesondheidsinisiatief
van die VSA se nasionale gesondheidsinstituut (NIH).
Hyen sy span navorsers het vandeesweek aangekondig dat die hormoonvervangingsbehandeling wat
tans deur meer as 6 miljoen Amerikaanse vroue ontvang word, meer skade as goed doen.
Ná jare se intensiewe navorsing het hulle bevind dat die middels, 'n kombinasie van estrogeen en
progesteroon, tot 'n klein toename in borskanker, hartaanvalle, beroertes en bloedklonte lei.
"Die resultate is van geweldige belang vir vroue. Een van die belangrikste gesondheidsbesluite wat
'n vrou moet neem, is of sy hormoonbehandeling ná haar menopouse moet kry," het Rossouw gesê.
Tot onlangs toe het die mediese owerhede hier dokters aangeraai om elke vrou wat nog nie 'n
histerektomie gehad het nie en wat menopouse bereik het, aan te moedig om die middels te neem.
Rossouw het gister aan Beeld gesê hy het nog voordat die studie begin het, die voordele van
hormoonvervanging betwyfel.
Hy het byvoorbeeld in 1998 op besoek aan Kaapstad gesê die feit dat vroue al 50 jaar aan
estrogeenbehandeling blootgestel word sonder dat die uitwerking daarvan op die hele liggaam
.behoorlik nagevors is, "grens aan misdadige en eenogige mediese praktyk".
Hormoonvervanging was egter in die vorige dekade 'n "reuse-groeibedryf". Die NIH is aanvanklik
gekritiseer toe hy in 1998 bekend gemaak het dat hy die saak gaan ondersoek, het Rossouw gesê.
Sedertdien, namate meer studies twyfel uitgespreek het oor die voordele van hormoonvervanging,
het al hoe meer wetenskaplikes begin waarsku dat vroue mooi moet dink voordat hulle die
behandeling begin.
'Rossouw, wat as een van die wêreld se voorste kenners oor vrouegesondheid gereken word, is in
Luderitz in Namibië gebore, maar het die grootste deel van sy lewe in Kaapstad deurgebring. Twee
van sy drie seuns woon en werk steeds in Kaapstad.
Rossouw het gesê hy het aanvanklik beplan om net twee jaar in die VSA deur te bring, maar die
navorsingsgeleenthede by die NIH kan nie met enige ander plek ter wêreld vergelyk word nie.
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Hormoonbehandeling nadelig, bevind span in
VSA '
PIERRE STEYN
WASHINGTON. 'n Voormalige navorser van die Suid-Afrikaanse Mediese Navorsingsraad het
hier aan die spits van 'n studie oor hormoonvervanging wat die wêreld se mediese establishment
tot in sy wese geruk:het.
Dr. Jacques Rossouw, wat in 1989 na die VSA geëmigreer het ná 'n lang en bitter geveg met die
destydse leierskap van die MNR, is nou die waarnemende direkteur van die Women's Health
Initiative van die Amerikaanse nasionale gesondheidsinstitute (NIH).
Rossouwen sy span navorsers het Dinsdag aangekondig dat die hormoonvervangings-
behandeling wat tans deur meer as ses miljoen Amerikaanse vroue gebruik word, meer skade as
goed doen.
Nájare se intensiewe navorsing het hulle bevind dat die middels, 'n kombinasie van estrogeen en ./
progesteroon, tot 'n,kleintoename in borskanker, hartaanvalle, beroertes en bloedklonte lei. v-_
"Die resultate is van geweldige belang vir vroue. Een van die belangrikste gesondheidsbesluite
wat 'n vrou moet neem is of sy post-menopousale hormoonbehandeling moet neem," het.Rossouw
gesê.
/
Tot on1angs het die mediese owerhede hier dokters aangeraai om elke vrou watnog nie 'n . '
histerektomie gehad het nie en wat menopouse bereik, aan te moedig omdie middels te gebruik,
Rossouw het gister aan Die Burger gesê hy het nog voor die studie begin het, die voordele van
hormoonvervanging betwyfel.
'7 .c;
.» ";:/~,;.j~i;,~-(!ï"\~,,-
Die Women's Health Initiative is 'n reeks kliniese toetse en waarnemingstudies waarby meer as
165 000 post-menopousale vroue betrek is.
Die navorsing oor.hormoonvervanging was net een deel van die betrokke studie.
_,,_ .......
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Wie ouer as 40 wil nie tien jaar jonger
. lyk en voel nie?
Daarom is die versoeking om hor-
moonaanvullings te neem deesdae
groot. Daar is beloftes dat dit jou
jonger kan laat voel, lyk en optree. Dit
kan die ergste ouderdomsverwante
siektes, soos osteoporose en hart-
siektes, glo afweer; ook die plooie op
jou gesig versag, jou seksdrang op-
kikker, jou spiere fermer maak en jou
geheue opskerp.
Tradisioneel verwys die term hor-
moonvervangingsterapie (Hvn na hor-
moonpreparate wat vroue in en ná die
menopouse gebruik (estrogeen en/ot
propestercon en soms ook testos-
teroon).
Volgens dr. Christiaan, skrywer van
Gesond vir 'n Leeftyd (Tatelberg-
Uitgewers, 2000), strek HVT wyer.
48 SARIE FEBRUARIE 2003
Die debat oe
hormoonvervangingsterapi
(Hvn woed voort, terw
aanvullings toenemen
gebruik word om die ang
uit oud word te haal. Ma;
dit gaan om meer as n
estrogeen en die rnenopous
JONGEF
!l11
deur LVOlA VAN DER MER
Want die produksie van 'n hele aantal
hormone neem at namate ons ouer
word - by vroue én mans. Dit lei feitlik
altyd tot die veroudering van die lig-
gaamstunksies.
Deesdae is daar hormoonvervan-
gingspreparate beskikbaar vir onder
meer estrogeen, progesteroon,
testosteroon, skildklierhormoon, de-
hidro-epiandrosteroon (DHEA), preg-
nenoloon, melatonien en groeihor-
moon (GH).
Die fontein van ewige jeug blyk dus
binne jou bereik te wees - dikwels op
die rak van jou naaste gesondheids-
winkel.
Maar daar word nog gedebatteer
of HVT so 'n goeie ding is. Een van die
vrese is dat die langtermyn-gevolge
daarvan nog onbekend is. Mense
neem dit eenvoudig nog nie lank ge-
-,
"
"\
.\,
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noeg sodat met sekerheid gesê
kan word dis veilig nie.
DIE DROOM VAN
EWIGE JEUG (SON-
DER DIE GLOEDE!)
Niks gee skynbaar beter gestalte
aan die droom van ewig jonk en
i
vroulik wees as estrogeenver-
vangingsterapie (EVT) nie. Maar
dis omstrede: dis langer as veer-
tig jaar beskikbaar en steeds wil
mense mekaar daaroor takel.
Die afname in die produksie
van estrogeen en progesteroon in
'n vrou se veertiger- en vyftiger-
jare is die oorsaak van die onge-
maklike simptome van die meno-
pouse. In die vroeë menopouse
sluit dit simptome in soos warm
gloede, gewrigspyne en slaap-
loosheid. Op die lang termyn
50 SARIE FEBRUARIE 2003
word lae estrogeenvlakke met
gesondheidsrisiko 's verbind.
HVT gee verligting van vroeë
menopousale simptome. Dit ver-
minder die risiko van kolonkanker,
verminder die effekte van
Alzheimersiekte, en verbeter
lewenskwaliteit (""do,' ,,,eer sek-
c- ..J- funKsie en slaapproblemej.
Velveroudering geskied ook
stadiger.
Volgens dr. Willem Serfontein,
'n mediese wetenskaplike van
Pretoria en skrywer van Gene-
sende Voeding (Tafelberg-
Uitgewers, 2001), het dit 'n besker-
mende effek teen osteoporose,
maar net vir sewe tot tien jaar.
Daar is eers geglo dit beskerm jou
teen ovariale kanker, maar dis ver-
keerd bewys.
Die vlieg in die salf? Dit verhoog
die risiko vir endometriale kanker
(kanker van die baarmoederbin-
newand) en ook van bloedklonte
ginekoloog van Johannesburg, sê
die mediaberigte bied nie die volle
prentjie nie. Die WHI-studie verwys.
na 'n spesifieke middel, .Prempro, 1
wat jare reeds die stanaaardvorm
van HVT in Amerika is. Plaaslik
word <:lit onder die naam Prempak
bemark. Clit is sintetiese estrogeen
van perde-1Jrien, gekombineer met
progestien, 'n veranderde vorm
van progesteroon.
Daar is egter anoer HVT-pro-
dukte in verskillende kombinasies
- die uitkoms is dus enders. Die
nuwe neiging is lae dosisse HVT-
produkte wat as "natuurlike" of
bio-identiese estrogeen geklassi-
fiseer word.
"Elke vrou moet haar unieke
situasie saam met haar dokter on-
der die loep neem. Nie alle post-
menopousale vroue het HVT nodig
nie. Vir dié wat dit wel moet neem,
is daar veilige terapeutiese keuses.
Na vyf jaar moet die risiko's en ./
(veral in die eerste jaar en as jy voordele jaarliks teen mekaar
rook). Die risiko vir borskanker styg ---opgeweeg word," sê hy.
met tot 35% by vroue wat dit Maar dr. Serfontein sê kanker is
langer as tien jaar gebruik. Dit kan kanker. Dit het min met individuele
onder meer migraine en ander pasiënte te doen.
hoofpyne vererger, en gewigstoe- Volgens hom is daar maniere om
name, waterretensie, galstene en . die voordele van estrogeen-terapie te
borsteerheid veroorsaak. Geen behou, terwyl die nadele uitgeskakel
wonder nie dat sowat 50% van word. Dit sluit in die gebruik van
vroue HVT ná 'n jaar los weens fito- of plant-estrogeen, soos
newe-effekte of die vrees vir kaoke.
op die lang termyn.
Die debat oor EVT het onlangs
nuwe momentum gekry. Die
Amerikaanse Women's Health
Inisiative Study (WHI) moes die
mate van beskerming ontleed wat
kornbinasie-Hvf (estrogeen en
progestien, of sintetiese proges-
teroon) op die lang termyn bied.
Die studie is ná vyf jaar gestaak.
Nie net was daar 'n klein toename
in die risiko van borskanker nie; die
risiko vir hartaanvalle het met 41%
verhoog. Aan die positiewe kant
was daar 'n afname van 37% in
kolorektale kanker en 'n aansienlike
verlaging in heup- en werwelfrak-
ture. (Die deel van die studie waar
net estrogeen gebruik is, word
voortgesit.j
soja-ekstrak en swart slangwortel
(black cohosh), die neem van hor-
monale voorlopers soos DHEA en
pregnenoloon, die gebruik van es-
triol ('n natuurlike estrogeen),. en
ook 'n topikale pro-gesteroon-
room om progestien te vervang.
Dr. Christiaan waarsku dat jy
nie tegelykertyd 'n estrogeen- en
isoflavoon-preparaat moet neem
nie. Baie vroue kla dan van warm
gloede.
'Meer inligting oor die natuurlike be-
nadering tot menopouse: Kruie met
Geneeskrag deur dr. Arien van der
Merwe (Tafelberg-Uitgewers, 2002).
MENEER,MAAK
NIKS JOU MEER
OPGEWONDE NIE?
Dr. Theo Kopenhager, 'n ouderdom - swaarmoedig, met 'n
Meneer, is jy so om en byaftree-
... :
\\ ..
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-,,1 niks maak jou meer
kr;Jlrwonde nie?
Prof. Riana'Sornman van die
afdeling andrologie, Departement
Urologie aan die Universiteit van
Pretoria, sê mans se testes-
teroon-vlakke begin ná 30 gelei-
delik daal. Simptome kom al meer
ná 45 voor, soos buierigheid, 'n
verlies aan dryfkrag, depressie en
'n gevoel van "moenie met my
karring nie". Seksuele vermoëns
neem af en dis gewoonlik die
dryfveer wat mans hulp laat soek.
Testosteroon speelook 'n be-
langrike rol om spiermassa en
beendigtheid te behou - dit kan
verband hou met osteoporose by
ouer mans,
Daar is lank geglo testos-
teroon-aanvullings kan jou risiko
vir prostaatkanker en kardio-
vaskulêre siektes verhoog. Die
jongste navorsing toon dat
testosteroon dalk juis kardio-
vaskulêre funksies beskerm. Dpar
is ook geen bewyse dat dit
prostaatkanker by gesonde mans
tiewe effek hê Op jou ener-
gievlakke, libido, gec,eue, im-
muunstelsel, stresvlakke, fyn
plooitjies en rumatiekpyn. Dit kan
hartsiektes voorkom, liggaamsvt>
verminder en jou teen sekere
kankers beskerm.
Diere-eksperimente wil dit laat
lyk of dit jou ook langer kan laat
lewe, In een studie het DHEA-
aanvullings rotte se lewensver-
wagting met tot 50% vermeerder,
Newe-effekte van oordosering
kan insluit haarverlies, geirnteerd-
heid, agg ressiwiteit, aknee en
menstruele veranderinge. Daar is
ook kommer dat hoë dosisse le-
werskade by sommige pasiënte
kan veroorsaak.
Volgens dr. Serfontein is daar
gevrees dat dit die risiko vir
prostaatkanker kan laat toeneem,
maar die meeste studies-toon dis
nie die geval nie. Daar is selfs
aanduidings dat dit jou daarteen
kan beskerm, Mans met
prostaatkanker het dikwels 'n
geskiedenis van baie lae DHEA-
vlakke in hul jong dae.
Die veiligheid van DHEA in es-
trogeen -afhanklike borskanker is
DHEA - GOED VIR nog nie duidelik nie.
DIE LIBIDO Hy sê die maksimum dosis
Dis 'n steroïedhormoon wat deur wissel van mens tot mens - van
die byniere vervaardig word, is 'n 15-75 mg p/d in drie verskillende
skaplikes wat glo dis in werk-
likheid stygende estrogepflvlakke
wat prostaatkank= veroorsaak.
Tensy die r"siem onderdruk
woro .reip testosteroonaan-
,,'Ings net vir 'n kort tydperk.
Testosteroon-aanvufmqs is op
voorskrif beskikbaar in die vorm
van inspuitings en pille, maar an-
der oorsake van onder meer lae
libido en moegheid moet eers uit-
geskakel word. Die behandeling is
duur en siekefondse betaal
gewoonlik nie daarvoor nie. Jy
moet dit die res van jou lewe
neem en ook gereeld jou testos-
teroon-vlakke laat toets.
By vroue val die produksie van
testosteroon ná die menopouse,
hoewel nie so vinnig soos estro-
geen nie. 'n Simptoom is 'n ver-
laging in libido. Testosteroon-aan-
vullings kan oormatige harlqheid
en aknee veroorsaak Maar dr.
Christiaan sê as dit omsigtig ge-
doen en 'n lae dosis geneem
word, kan dit wondere vir jou
lewensenergie en libido beteken,
Gesels met jou ginekoloog of
huisdokter daaroor.
~REI]IIE~:V9il 100% GOED
kan veroorsaak nie. 8~$jf\O$U~tF\l\(V©j ~ iii:JA [g~~ u~~~~~(D!FJ(.QIlW$~~
Mans wat prostaatkanker het,
moet dit egter vermy. Prostaat- ~Jj@~';H1~[k,l(\QD~~';;:J 'i~Uii\~lli~~g~]:,êJ.'j(D;EJ
kankerselle verskil van die nor-
male selle waaruit dit ontwikkel en
groei makliker in die teenwoor-
digheid van testosteroon. Voor jy
testosteroon-aanvullings neem,
moet jy eers 'n bloedtoets (PSA)
en rektale ondersoek ondergaan
om te bepaal of daar nie kanker-
agtige selle is nie. Dit moet bo die
ouderdom van 40 jaarliks herhaal
word.
Daar is 'n ander kinkel in die
kabel. Volgens dr. Serfontein
word testosteroon by mans bo 40
in estrogeen omgesit (deur 'n
spesifieke ensiem). Daar is weten-
.~",;."
voorloper vir hormone soos estro-
geen, testosteroon en proges-
teroon, en het 'n uitwerking op
die meeste liggaamsorgane.
Dr. Serfontein sê DHEA-vlakke
daal skerp met die ouderdom. Op
90 het die gemiddelde mens net
10% van 'n twintigjarige s'n. Die
dalende vlakke is nou gekoppel
aan die agteruitgang van die im-
muunstelsel en die verouderings-
proses in die algemeen.
DHEA-aanvullings kan 'n posi-
dosisse. Laat toets jou DHEA-
vlakke voor jy aanvullings begin
neem en herhaal die toetse elke
drie maande.
KLOP VLUGVOOS-
HEID EN SLAAP-
PROBLEME
Die hormoon melatonien, wat deur
die pineaalklier in die brein
afgeskei word, reguleer onder
meer die immuunstelsel, vrugbaar
heid en slaappatrone. >
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f!ll!E~~f$~VOEL 100% GOED
Aanvullings word o.m. gebruik vir
vlugvOOUleid en slaapversteurings.
Dr. ChriSi'O'ln sê slaap speel 'n
belangrike rol by, I .
""'f"J ewendhetd:
dit kan bv. hormoonpro(J.. '
\.:.'~Ie ver-
. beter. (Sy boek oor slaap, é;",-.,
Smart, Rollerbird-uitgewers, ver-
skyn in Maart.)
Volgens dr. Serfontein is daar
sterk bewyse dat melatonien-aan-
vullings teenverouderingsterapie
met 'n wye omvang is en baie
gesondheidsvoordele het. Dis ook
r·
voordelig in die behandeling van
sekere kankers, in kombinasie
met konvensionele behandel-
ingsmetodes soos chemo- en
radiote-rapie.
Dit het nie newe-effekte nie.
Mense wat dit moet vermy, sluit in
pasiënte met leukemie, limfoom-
en ander kankers van die immuun-
stelsel, outo-immuunsiektes soos
lupus en rurnatoïede artritis, eie,
stokkanker, swanger vroue, vroue
wat swanger wil raak (hoë dosisse
kan dalk 'n voorbehoedmiddel
wees), en mense jonger as dertig.
Dr. Christiaan sê die algemeen-
~"'"
ste dosering is 3 mg so twee uur
voor slaaptyd. Moenie dit meer as
vyf keer per week neem nie, om-
dat dit die funksie van die
pineac:!klier kan onderdruk. Daar is
nie 'n toets in Suid-Afrika beskik-
. ''lr wat jou melatonien-vlakke
kan i.,
''lI nie.
JONGER
- METWOEMh
Volgens dr. Serfontein is die,
dele van menslike groeihormoon-
aanvullings (mGH) goed nagevors.
Dit het 'n positiewe effek op feitlik
elke orgaan en sel in die liggaam.
Dis 'n verjongingskuur vir die vel
en bene, gee nuwe woema aan
die hart, lewer, longe en niere en
vernuwe ander liggaamsfunksies.
Dit bou spierweefsel, verbeter die
immuunstelsel, beheer stresskade
en verminder liggaamsvet. Die
tempo van herstet hang af van hoe
laag die GH-vlakke in die eerste
plek was.
Daar kan wel newe-effekte
wees. Volgens 'n studie wat on-
langs in die Journal of the
American Medical Association
gepubliseer is, het bejaarde proef-
voudige dieetgewoontes doen: iil
verlaag bv. jou insulienvlakke deur ~
suikeragtige kosse (soos vrugte en ~
verfynde koolhidrate) 2-3 uur voor ~
slaaptyd te vermy. Vermy die oor- ~
matige inname van kalsium. Neem
aanvullings soos die aminosure 1-
triptofaan (5-10 g p/d), en 1-
arginien (sowat 1-5 g p/d) op 'n
leërnaáq
BETER GEHEUE
ho1:enoloon is die voorloper van
teroon 81 poos DHEA, testos-
getoon dit ver&en: Studies het
kognitiewe funksies.' qeheus en
Die dosis is 30 mg sogg.,.
Nie almal is opgewonde oor alt.-
gewildheid van hormone as teen-
verouderingsmiddels nie. Die
Amerikaanse Nasionale Instituut vir
Veroudering sê in 'n verklaring
daar is nie genoeg wetenskaplike
navorsing wat toon dat HVT enige
voordele inhou nie. Natuurlike hor-
moonproduksie verskil boonop
van mens tot mens. Dis onmoont-
lik om 'n enkele veilige dosis van
'n bepaalde hormoon vir 'n hele
bevolking te bepaal.
persone wat GH geneem het Dr. Christiaan sê die ideaal is
komplikasies soos karpaletonnel- dat 'n profiel van die hormoon-
sindroom, gewrigspyn, geswelde stelsel saamgestel en lae dosisse
ledemate, diabetes en ander
bloedsuikerversteurings getoon.
Die newe-effekte het verdwyn toe
die behandeling gestaak is.
Volgens dr. Christiaan is die simp-
tome deur té hoë dosisse veroor-
saak.
Dis ook onprakties om te ge-
bruik. Dr. Christiaan sê GH moet
gereeld ingespuit word en dis
duur Ná 'n Jaar of wat begin die
liggaam daaraan gewoond raak
en moet die dosis vermeerder
word. Gereelde bloedtoetse is
nodig om die GH-vlakke in jou lig-
gaam te bepaal.
Volgens dr. Serfontein kan
sulke inspuitings die produksie van
jou natuurlike GH onderdruk. veral
as dit oor 'n lang tydperk gebruik
word. Dis beter om die produksie
daarvan op 'n natuurlike rnanier te
stimuleer. Jy kan dit met een-
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van 'n verskeidenheid van hor-
mone dan toegedien word.
Betreklike goedkoop speeksel-
toetse kan oorsee gedoen word,
maar is nie plaaslik beskikbaar
nie.
Voordat jy hormoonaanvullings
neem, besoek jou dokter vir 'n
volledige mediese ondersoek en
bloedtoetse om te bepaal of jy
tekorte het. Weeg die risiko's en
die voordele daarvan teen mekaar
op.
En gebruik dit onder dokters-
toesig.
Dr. Serfontein beklemtoon dat
jy nie net op "jeug-eliksers" kan
staatmaak vir lewenskwaliteit op
jou oudag nie. Dit verg 'n holis-
tiese benadering, insluitende 'n
gebalanseerde dieet, oefening,
vermindering van stresvlakke en
'n doelom te lewe. 11!
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\\H,ormone Rep~acementTherapy refieves the' n@sty, , \ '.,
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, 'menopausal women, inclUding~ \ an anti-oestrogen. These are very
® Heart disease: several suggest-~ promising drugs that can prevent
ed that post-menopausal women on \1 vertebral fractures, but have not yet
oestrogen have about han the mei- been shown to prevent h ip trae-
, ',' , ~tmce of Eearf disease compared) tures," he says. '"
THERE'" nothing to get the with those not taking hormones. " 'The Women's Health lnitiativehOrlnOne,sin a knot quite like <!,li) Mental deterioratton, includ- study, by former South African, the debate around hormone ing Alzheimer's Disease: several researcher Jacques Rossouw" threwreplacement therapy (HRT). small, short-term trials suggest that the cat among the pigeons.
But if you're the woman facing the oestrogen improves the memory of The entire study took in 27 000 .
question of whether or not to post-menopausal women. One study healthy, post-menopausal women, ~:;.
take the drugs, the final decision is in the early 1990sreported that BRT h a lf of who m wer era n d0m ly .
unfortunately going to have to be enhanced the mental fundion of assigned to HRT and the other half
yours. ' women with mild to moderate symp- to a placebo. But in one part of th i ,"
Fortunately there's plenty 'If good toms of Alzheimer's Disease. " study a group of 17,000women with
advice to be had, so women today - ' @ Colon caneert. a large study a uterus were divided into half;who
and their doctors - should examine reported that oestrogen users had a took a combined hormone (oestrogen
the options and not see BRT as the 29% lower risk of dying from colon' and progesterone), and, the other
simple answer to being happier, liv- cancer than non-users. For those on half a placebo. The researchers want- ,.!
ing longer or getting fewer heart oestrogen for 10 years and longer, ed to study the relationship between
attacks. the ri:sk was reduced by 55%. ' hormone therapy and its possible
Specific indicatieris and goodjudg- ® Ageing skin: Claims were made benefits for heart disease and hip
ment regarding the risks and bene- generally that HRT helped preserve fractures, and its possible risk for
fits of HRT are essential, says Pro- skin elasticity by maintaining breast cancer, endometrial cancer
fessor Stephen Hough, head of the ' and blood clots. '
department of internal medicine at In July last year the NIH halted
the University of Stellenbosch. the trial after only five years, cone
Interviewed in the latest edition eluding that the risks for the study
.of Tygerland, the publication of the" group on combined therapy out-
faculty of health sciences, Hough weighed the benefits. '
pointed to the turnabout that had "The risks included a very small, .
taken place since the Women's , but statistically Significant increased 'Z.;
Health Initiative long-term study, ' risk of breast cancer, coronary heart .d
sponsored by the United Sta tes disease, stroke and blood clots," ,
National Institute of Health. Hough explains.
The study, on combined oestrogen A separate part of the trial, on the
and progesterone use in healthy, use of oestrogen alone in women
post-menopausal women, was halted who have had a hysterectomy, is
last year; citing small but signifi- continuing because researchers have
cant increased risks of breast cancer apparently not seen similar. risks in
and coronary heart disease. these women. '
These developments resulted in Sciwhat does all this mean for the
worldwide anxiety and confusion ' average woman on HRT?
among women, many of whom firm- Where heart disease is concerned,
ly believed that HRT was a panacea Hough, says, the study has proved
for menopausal miseries, heart dis, beyond .doubt that -protection against
ease', osteoporosis, mental deterio- heart disease is not a reality when
ration, colon cancer and ageing skin. women use combination therapy
BRT, touted as "the closest thing in (oestrogen and progesterone), as was
modern medicine to an elixir of preViously believed. ,
youth", had revealed a dárk side. So if a woman is using I-LT<Tonly to
Hougf· through the debate, protect against heart disease, she
It S IS no answer. to to examine' other ?pt!ons:
"
"..
Stellenbosch University http://scholar.sun.ac.za
•I
among women, rnany Ui WUUlU HUH-
ly believed that HRT was a panacea
for menopausal miseries, heart dis-
ease, osteoporosis, mental deterio-
ration, colon cancer and ageing skin.
HRT, touted as "the closest thing in
modern medicine to .an elixir of
youth", had revealed a dark side.
Hough, cutting through the debate,
says it's clear there is no. answer to
ft': rul women, arid that a prescription
for HRT can no longer be handed
out to every woman starting
menopause.
D
However it's still the best treat-
ment available for the symptoms of
menopause and is effective for· the
prevention: and even treatment, of
osteoporosis.
So why hormone replacement
herapy?
Hough explains that menopause
starts with oestrogen withdrawal
from the body, the decline resulting
in symptoms which vary from hot
flushes, heart palpitations, uro-gen-
ital problems, vaginal dryness, loss
of libido and mood swings. .
About 80% of all women develop
symptoms of menopause and the old-
est use of HRT is to relieve these
symptoms.
Late menopause can be complicat-
ed by more serious, long-term prob-
lems like osteoporosis, a disease
characterised by low bone mass and
structural changes in the bones,
leaving them more fragile and open
to fractures, typically of the wrists,
spine and hips.
Fr om birth onwards, Hough
explains, bone mass increases,
reaching a peak at about 25 years
after which it starts to decline.
In women there is a dramatic
decline when the body stops pro-
ducing oestrogen during late
menopause, which may result in low
bone density or changes in the qual-
ity of bone, leading to osteoporotic
fractures.
To. prove the seriousness of the
condition, Hough emphasises that
osteoporosis affects one in every
four post-menopausal, Westernised
--women tn S('juth Africa. One of every
. five women with a hip fracture dies
within a year of the event, and half
fail to regain their capacity to live a
full, independent life.
"Until recently, there has been a
degree of uncertainty about the
effects of oestrogen on bone, but late-
ly randomised, controlled studies
have shown beyond doubt that the
hormone prevents bone loss and
fractures of the spine and hip, no
matter what route of administration
is used - be it in the form of pills,
patches, implants or inhalants," he
says.
But many short-term and observa-
tionál studies through the yeats
have indicated oestrogen may also
have other benefits. for post-------------------
'Women must
ask themselves
why they wtallmt
to be armHRT~
....Professo!'
Stephen Hough
collagen that keeps the skin look-
ing wrinkle-free.
So what about the claim that HRT
is a modern-day miracle?
The first indications that it isn't
came in the 1970s when several stud-
ies revealed that women taking the
hormone had an increased risk of
cancer of the endometrium (uterine
cancer), and Hough confirms that
the risk is indeed significantly
increased in women taking only
oestrogen replacement therapy.
However, in women-who still have
a uterus, this risk is virtually elim-
inated when progesterone is com-
bined with oestrogen.
.Studies at the same time also sug-
gested a slightly increased risk of
breast cancer, the most common can-
eerIn women. But the HRT breast
cancer risk was so small when com-
pared to the risks associated with
obesity, regular alcohol use or a fam-
ily history of breast cancer, that
doctors usually weighed this small
risk against the proposed long-term
benefits of HRT.
Pointing to a range of new drugs
developed during the last decade to
eliminate the risks of HRT and
retain the benefits of the therapy
for the prevention and treatment of
some of the symptoms of menopause,
Hough says' these new drugs -
known as selective oestrogen recep-
tor modulators, or Serms - produce
similar effects on the bone to oestro-
gen but do not bind to cells in the
uterus and the breast.
"They have an effect similar to
oestrogen in most tissue, but in the
breast and endometrium they act as
Hough says, the study has pj
beyond doubt that protection a~
heart disease is not a reality
women use combination the
(oestrogen and 'progesterone), a
previously belleved.
So if a woman is using HRT 0
protect against heart disease
needs to examine other option
'.(r~~tiG:1..~:; wtio have hail ti
terectomy and are using oest
therapy only, are doing much 1
and the study continues. To t
would say, carryon with the 1
py," Hough advises.
Thrombo-embolism is arealit
has been shown to be high
patients on HRT. So if a worn
HRT is going to be irnmobil is
for instance sitting on an aerc
for 10 to 15 hours, he would f
her to stop taking the horme
few days previously. .
As far as cancer is concerned
are a few important indicator
In terms of the endometrial (
risk, Hough says that women
uterus, using only oestroger
have a much higher risk as
endometrium will get thickr
thicker. Any post-menop
woman who has not had a hy!
tomy must use progesterone t
er with oestrogen.
In terms of colon cancer, the :
most common cancer, Hougl
the risk for women on HRT
nificantly reduced.
In breast cancer, compreh
research has shown that four
every 100women will develop
cancer if followed up to age 7
HRT used for five years de
change that statistic. But if it
for many years - say 10 to ]
says there are about six to eig
breast cancer Cases per 1
patients who are followed
age 70.
Some final advice?
Hough says the bottom line
while hormone therapy is s
acceptable option for trr
menopausal symptoms ant
tures, the decision for a v
considering whether to USE
and for how 'long, has beco
more complex.
She must ask herself wl
wants to be on HRT, what b
she'll enjoy and how her ti:
certain conditions will incre
HRT.
Hough says the patient rr
able to make an informed de
and' her doctor must provi
with information that will all
to do that.
Then she must be closely fe
up to ensure the benefits and
tially harmful side-effects ar
tified sooner rather than latt
"It is a situation that requir
mon sense," he says.
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men, including: . an anti-oestrogen. These are very /)
18e: several suggest-'\ promising drugs that. can prevent 'u,
nopausal women on vertebral fractures, but have not yet -v
about half the mei- j been shown to prevent hip trae, -~
. disease compared) tures," he says. I
:aking hormones. . The Women's Health Initiative
erioration, includ- study, by former South African • .:=
"s Disease: several researcher Jacques Rossouw, threw V)
n trials suggest that the cat among the pigeons. , ' 'i
oves the memory of The entire study took in 27 000 -,
1women. One study healthy, post-menopausal women, ~
'S reported that HRT half of whom were r an domlv N>
nental function of assigned to HRT and the other half \ -
d to moderate symp- to a placebo. But in one part of the ~
rer's Disease. study a group of 17000women with .
cer: a large study a uterus were divided into half, who ..)
strogen users had a took a combined hormone (oestrogen
Jf dying from colon and progesterone), and the other ~
-users, For those on half a placebo. The researchers want-.«
I years and longer, ed to study the relationship between ~
uced by 55%. . hormone therapy and its possible '\l
: Claims were made benefits for heart disease and hip '; I'
RT helped preserve fractures, and its possible ris.k for -,
- by maintaining breast cancer, endometrial cancer ~
and blood clots. ~<- - -
In July last year the NIH halted .
the trial after only five years, con- . ~
eluding that the risks for the study ~':)
group on combined therapy out- ''-:)
weighed the benefits.
"The risks included a very small, ?:I
but statistically significant increased <~
, risk of breast cancer, coronary heart .J
disease, stroke and blood clots," .
Hough explains,
A separate part of the trial, on the
use of oestrogen alone. in women
who have had a hysterectomy, is
continuing because researchers have
apparently not seen similar risks in
these women.
So what does all this mean for the
average woman on HRT?
Where heart disease is concerned,
Hough says, the study has proved
beyond .doubt that protection against
heart disease is not a reality when
women use combination therapy
(oestrogen and progesterone), as was
previously believed, .
So if a woman is using HRT only to
protect against heart disease, she
needs to examine other opticus.
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.s~,wás I, untll'lt was all spelled out to me by the eminent and highly-resp~
PI'Ofe$sorDavid Archer"; an obstebidi;1n and gym:lecolOgist from Eastem Virginia
MedlcalSCh~I, ln Norfolk; Vlrglilla,America, .
· . Archer hes reen in~oIY~ In the issue of menopause fOr 15 years, and is also past
· .•president of the NQrth Ainerlcan Menopause Society. As eélltor of the quarterly
. publication Menopausal Medicine, he's also .well qualified to discuss, In layman terms
fo(pei:iple.llke myself; eVêryaspect of hormoneS,.oestrogen, menopause and all
things related. ... ' ' . I••
Bro.ught out te;! ~A bY.~harma.c~UtiCal com.pan ..'N.avo Nordls.k speak at th~ 4~ SA ';..-1' '.
,-MenQPll~~ Society C':Ingress rn purban, he tack!. . . my and contentious I~:=======:::;t::::::;. ofHRT ,anêfttl'e>llnk'With-b~st'cancer-Wlth~eEtFaerdJtlaP{-CladtV.------ I
It'boilS down to epidemiology, he said. Epidemlology.is when experts look at the
asSociation of things relating to a disease. '. .
In other words, HRT.tioes noteeusebreast cancer, although It may be linked to it.
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.Not that you might not be diagnosed with breast eeneer while you're on HRT- you
· , might - but HRT itself will not cause thé cancer.
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Die waarheid oor BVT
VALDA JANSEN
DIE media het onlangs wêreldwyd op loop gegaan oor die voortydige afstel en "skokkende
resultate" van 'n studie oor die risiko's en voordele van hormoonvervangingsterapie (HVT) by
post-menopousale vroue.
Onlangse uitslae van 'n Women's Health Initiative (WHI)-studie beweer dat HVT die risiko van
borskanker en hartsiektes kan verhoog. Ook die gesaghebbende tydskrifTime het die uitslae
uitgebasuin.
Vroue die wêreld oor wat reeds die terapie ontvang, sowel as vroue wat die behandeling oorweeg,
het bekommerd geraak.
Die WHI-studie het veral gekonsentreer op die risiko van kardiovaskulêre siektes, bors- en
kolonkanker en beenfraktures by post-menopousale vroue wat HVT oor 'n lang tydperk gebruik.
Hierdie studie, wat deur die Nasionale Gesondheidsinstituut in die VSA begin is, is vyfjaar
gelede van stapel gestuur en sou agtjaar duur. In Mei vanjaar is een deel van die studie voortydig
gestop, ná bewyse gevind is dat die risiko's meer as die voordeleis. Daar is bevind dat sommige
vroue wat HVT in 'n kombinasie van estrogeen en progestien (vir vroue wat nie 'n histerektomie
gehad het nie) gekry het, 'n groter kans het om borskanker te ontwikkel. .
Die media het ook die volgende feite oor die studie gegnoreer: die WHI-studie het nie betrekking
op lae dosisse van kombinasie-medisyne nie en neem ook nie ander formules vir mondelikse
estrogeen en progestien in ag nie.
In 1993 is die medisyne wat deur die WHI gekies is, wêreldwyd gebruik. 'n Onlangse benadering
is om eerder lae dosisse HVT -produkte te gebruik, wat as natuurlike estrogeen geklassifiseer
word. Verskillende mediese instansies het tot hul redding gekom deur dié vrese te besweer.
In Suid-Afrika het die SA Menopouse-vereniging onlangs op sy kongres in Durban die uitslae van
die WHI-studie in die regte konteks geplaasmet wat reeds oor HVT en vroue se gesondheid
bekend is.
Simptome van die menopouse is die gevolg van die afname in estrogeen-produksie op die
ouderdom van 50 tot 60 jaar. Vroeë simptome, soos warm gloede, hartkloppings en slapeloosheid
verdwyn geleidelik. Lae estrogeenvlakke lei tot 'n groter risiko van hartaanvalle, beroerte en
osteoporose wat tot beenfrakture kan lei.
Hoewel sommige van die vroeë simptome later verdwyn, word die kans op kardiovaskulêre
siektes en osteoporose verhoog.
Die vervanging van estrogeen deur HVT is die doeltreffendste behandeling vir die vroeë
simptome van die menopouse en kan ook beenvermindering en die kans op osteoporose voorkom.
Daar bestaan genoeg bewyse dat HVT die lewensgehalte van vroue ná die menopouse verbeter.
Maar ander langtermyn-uitwerkings van HVT is nie so duidelik nie. Terwyl daar genoeg rede is
om te glo dat HVT help om kardiovaskulêre kwale te voorkom, was die resultate van verskillende
navorsingstudies nie konsekwent nie.
Toe die uitslae van hierdie groep ontleed is, is soortgelyke toenames in risiko vasgestel vir
kardiovaskulêre siektes. Maar aan die ander kant is vasgestel dat die kans op kolonkanker en
beenfraktures as gevolg van osteoporose met HVT -gebruik afneem.
http://152.111.1.251/argieflberigte/dieburger/2002/09/18/11/5.html 1/15/2004
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'n Ander groep vroue in die studie wat slegs estrogeen sonder die progestien ontvang het, het geen
toename in enige gesondheidsrisiko's getoon nie en hierdie deel van die studie gaan dus voort.Die
gesondheidsvoordele vir hierdie groep vroue sal oar drie jaar bekend wees. .
Die media het grootliks gekonsentreer op persentasies vir die toename ingesondheidsrisiko vii"
vroue wat die kombinasie-HVT ontvang het. Hierdie getalle is misleidend omdat dit nie die ware
risiko-toename weerspieël nie. Eintlik is die bykomende risiko vir borskanker en hartsiektes by
vroue wat kombinasie-HVT ontvang, baie klein.
Dit is belangrik om in gedagte te hou dat die risiko van borskanker vir alle vroue in elk geval met
die ouderdom toeneem, ongeag ofhulle HVT gebruik of nie. Prof. Alistair MacLennan,
hoofredakteur van Climacteric, die amptelike tydskrifvan die Internasionale Menopouse-
vereniging, verduidelik dat die klein toename in risiko wat die WHI-studie met HVT-behandeling
getoon het, gelykstaande is aan een ekstra kankergeval per 200 vroue oor tienjaar. Om twee
standaard- alkoholiese drankies per dag te drink, of die eerste swangerskap van 20 na 30 jaar oud
uit te stel, hou dieselfde risiko in om borskanker te kry.
Die waarneming dat HVT nie daartoe bydra om hartsiektes te voorkom nie, was 'n verrassende
uitslag. Omdat die vroue wat aan die WHI-studie (gemiddeld 63 jaar) deelgeneem het, ouer was
as dié aan wie HVT normaalweg voorgeskryf sal word, is dit logies dat die risiko van hartaanvalle
en beroerte groter was.
In Suid-Afrika word HVT nie voorgeskryfvir die :voorkoming of behan deling van
kardiovaskulêre siektes nie. Hierdie siektes moet eerder beheer word deur toepaslike leefstyl-
aanpassings (byvoorbeeld deur op te hou rook) en medisyne. .
Die voordele van HVT met betrekking tot verligting van simptome en vérbeterde lewensgehalte.is·
reeds aangeteken.
Ná die bekendmaking van die WHI- uitslae beveel die SA Menopouse-vereniging die volgende
aan:
Vir die meeste vroue wat deur die menopouse gaan, is die korttermynvoordele van HVT meer as
die risiko's. Die gebruik van HVT oor langer tydperke behoort deur elke vrou individueeloorweeg
te word. Dit is egter belangrik dat alle vroue ingelig word oor die resultate van die WHI en ander
gepubliseerde studies sodat hulle 'n ingeligte besluit oor hul toekomstige gesondheid kan neem
wanneer hormoonvervangingsterapie oorweeg word.
Vroue wat reeds HVT ontvang, moet dit nie summier stopsit nie, maar dit eers met hul dokter
bespreek.
"Vroue moenie paniekbevange raak nie," het dr. Theo Kopenhager gesê. Kopenhager is 'n
eredosent en eksaminator aan die departement ginekologie by Wits se mediese skool. Vir die
meeste vroue hou HVT meer voordele as risiko's in. Geen ander terapie is so doeltreffend om
menopousale simptome te beheer nie (waaronder warm gloede, moegheid en hoofpyne). HVT
voorkom en behandel beenverlies en osteoporose en help ook om die volgende te voorkom:
kolonkanker, oog-degenerasie, kognitiewe afname en Alzheimer se siekte.
http://152.111.1.251/argieflberigte/dieburger/2002/09/18/11/5.html 1/15/2004
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SHAPE YOUR LIFE
Herb of the month: Italian parsley
(Petroselinum crispum Italian)
It's time to start boosting your immune system for winter, which is what
makes parsley such a good idea right now. We're talking vitamins A, C, E
and iron, as well as antioxidant properties. Try getting two table-
. spoons of chopped, fresh parsley each day - sprinkle on salads,
add it to meat, pasta or cheese sauces at the end of cooking, or
juice it up in a blender with apple or tomato juice. A cup of parsley
. tea is also very refreshing, and helps treat kidney and bladder infections.
iThe flat-leaf Italian parsley is even easier to grow than the moss curled
~ variety, and it has a more distinctive taste. It needs full sun or partial
~ shade, and does best in rich soil that is kept moist. Plant as a border for
~8 roses and it will keep pests away while enjoying the water that's lavished on
ti
it the roses. More information: 012-8081044 or www.herb.co.za
.",.
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Shake your booty .J!'
Biodanza and Nia are two of the stars dancin&,JrrShapes eyes. We"ve featured both
dance-based disciplines in the past. and bOJ-li'are gaining fans every week .
• Catch up with Carolina Churba (left). t~€ Biodanza queen of SA. on Wednesday
evenings at the Parktown North M~8dist Church Hall (64 7th Avenue, Parktown
North) from 6.30 to 8.30pm. C0780; inquiries: Carolina on 011-8846403 or
biodanza@netactive.co.za " ,.0'
• Kathy Wolstenholme, who '6ught the smash-hit Nia to South Africa, is opening her
own studio at the RiverCOin Observatory, Cape Town, on May 4. There'll be classes
every day, with up to, being able to be accomodated in the wonderful, newly reno-
vated space. For d Hs,call Kathy on 021-6743747or e-mail: kwolstenholme@zanet.co.uk
Johannesburg's (ngto get Nia soon, too, with a series of classes at Planet Fitness gyms
uly. For Hscontact: charmaine.lifestyle@planetfitness.co.za
?,
HRT gets a double whammy
Hot on the heels of the question mark
about the safety of hormone replace-
ment therapy are suggestions that the
treatment may offer'no real benefit to
postmenopausal women.
The New EnglandJournal of Medicine
reports that further research shows •
virtually no improvement in their quality'
of life: women taking the drug were no'
less depressed, more energetic or had
more sexual satisfaction or restful sleep
than a placebo group. Until last year,
before the first report appeared about
,_?~g~associated with
HRT,it was the most widely prescribed
drugs regime. Sales dropped by 50%
when studies revealed that the treatment
could mean increased risks. "This is addi-
tional information showing that the
oestrogen mystique is not what it was
cracked up to be," said Dr Deborah
Grady in an accompanying editorial.
. Dr Andrew Newham, a member of Shape's
advisory board said: "Hormones must be
taken for the right reason and oestrogen
for severe menopausal symptoms is still
the most effective treatment - one must
just be very selective who one gives it to.
In the correctly chosen women it could
give a dramatic improvement. However,
there are a lot of vague symptoms associ-
ated with that time in a women's life, and
hormones are too often prescribed unnec-
essarily for non-hormone related issues.
"There has been a big growth in plant-
based oestrogens (phyto-oestrogens),
which are showing promising results
especially for treatment of menopausal
symptoms," he says.
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Rene Lotter
From:
Sent:
To:
Subject:
Vicky Zigras. .
Wednesday, October 29,200311:14 AM
Rene Lotter
HRT Therapy stories
Dear Rene
. . ., . . .
I could only find 1 story on e-news. It's a Reuters or eNN piece done on 2002107/10. You're welcome to corrie and view it
upstairs:
Doctors have issued a new warning against the danqers of hormone replacement therapy. for women.
Earlier this week, a US major study of its effects was cancelled.
Results showed an increased risk of heart disease, breast cancer and other chronic illnesses ..
(PAUSE)
SUPERNew York/USA
The study examined the effects of combined hormone replacement therapy on nearly 17 thousand healthy women.
But the risks were so high that the US government called an abrupt halt to the trial.
They also issued a warning to doctors and patients.
SUPERJacques Rossouw/ Doctor
UPSOUND: The therapy increases the risk for heart attack or stroke. Additionally it increases the risk for breast cancer and blood clots.
The study found that HRT does lower the incidence of hip fractures and colon cancer.
But it raised the number of strokes by 41 percent, heart attacks by 29 percent, and breast cancer cases by 26 percent.
This presents a second blowto HRT.
Last week, doctors confirmed that estrogen and progestin combined does not protect menopausal women from heart disease.
For years, estrogen was touted as a healthy replacement for hormones that were lost at menopause.
Drug companies promoted HRT for the prevention of osteoporosis
And said it could keep women young, healthy and attractive.
But the latest findings have forced millions of women to rethink their treatment options.
SUPER
Patricia Whitsett
UPSOUND: It does kind of take you aback when you think something is helping you that it also might be hurting you.
1
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Coverage of rep6rtirig on HRT in South African newspapers, magazines and
television 1-1ay2002 until November 2003
Publication Date Author Headline Angle
; ;':.'
; l· ... :
Appendix r::
Research results published in medical journals
In September 2002, the South African Medical Journal reports as follows on
the Women-'"""S!1eaIthInltlatlve 'I"ltldlIigS. :. : .. .~., .\ C
The principal results from the Women's health initiative (WHI)
randomisedcontrolled tria (RTC) published on 17 July 2002 have evoked a
widespread response in the medical and laypress. For instance, time magazine
of 22 July 2002 carried a 7-page article entltled 'The tiuth about hormones"
with the subtitle "A large federally-funded study provides definitive proef
that oestrogen and progestin are not age-defying wonder drugs. What's a
woman to do?" ' f
As expected patients are alarmed and their doctors face a dilemma. Clearly
the study in question needs to be put in perspective. This editorial
addresses the pertinent findings and suggests management guidelines.
The overall goals of the WHO are to test methods of reducing the risk for
cardiovascular disease, breast cance, colorectoral cancer and osteoporotic
fractures in women. Many other health outcomes are being monitored as well.
It is the largest and most expensive research study even funded by the
National Institute of Health (NIH) with a budget of $628 000 000 over the
IS-year period 1992-1997. It includes a randomised trial of about 64 000
women and an observational study of about 100 000 women in the age range
50-79 years, of diverse race/ethnicity and socia economic status. The three
branches of the randomised trial are designed to test hypotheses concerning
the effects of disease incidence of 9i) dietary modification (ii) hormone
replacement and (iii) calcium/vitamin D. Women may participate in one, two
or three branches of the trial.
Almost all observational epidemiological studies find that oestrogen
replacement therapy (ERT) reduces the risk of coronary heart disease (CHO).
However, there is conc~rn that a tendency for healthier women to use HRT may
make it appear that the beneficial effect is greater than it really is.
Moereover, the effects of progestin and oestrogen replacement together are
less certain, because this combination of hormone has not been used for as
long a period of time as oestrogen on its own.
The principal results of the WHI paper concerning the risks and benefits of
oestrogen plus progestin in healthy post-menopausal women are summarised
below. The trial included 16 608 postmenopausal women who were randomised
to receive either one daily tablet containing conjugated equine oestrogen
(CEE) 0.625 mg and medroxyprogesterone acetate (MPA) 2.5 mg (treatment group
- N=8 506) or a matching placebo (control group - N=8 102 This primary
prevention study was due to run for 8.5 years but was halted at an average
follow-up of 5.2 years because the number of cases of breast canéer had
reached a pre-specified safety limit. Moreover, the global index that
summated important aspects of health benefits versus risks,consisting of the
earliest occurrence of CHD, invasive breast cancer, stroke, pulmonary
'embolism (PE) endometrical cancer, colorecial cancer, hip fracture, or death
due to other causes, revealed a hazard ratio of 1.15.
As, absolute risks statistics ~re easier to apply to clinical practice, these
arE~\olitrrne(rDe:lów.··For'TD'-rrOO women taking such HRT' for- áy~red
with those not~taking it, there would be an additional 8 cases of invasive
breast cancer ~38 vs 30), 7 heart attacks (37 vs 30), 8 strokes (29 vs 21)
and 8 pulmonary embolisms (15 vs 7) However there would also be 6 fewer
bowel cancers (10 vs. 16) and 5 fewer hip fractures (10 vs 15)
Overall mortlity was not increased with therapy.
The small increase in the number of patients with breast cancer did not
appear in the first 4 yars of use and accords with previous population
studies. After 5 years of this combined HRT the increased risk of breast
cancer was less than 1 in 1000. Par~nthetically, studies to date show no
increase in deaths from breast cancer in association with HRT.
In'V\fiewof fli'~raily favourable biological effects of oestrogen on the
cardiovascular sstem, the ~ack-of b~nefit on coronaray heart disease is
.~;~~'isurprising. The Kaplan Meier estimates of cumulative hazards for CHD
t , indicate that the differ.ence 'between treatme.nt groups began to'develop soon
after randomisation. Although 'the'WHI trial was a primary prevention study------.~.......______ .._. ._
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in predominantly healthy women, aged 50 to 79 years, 7,7% had priqr
cardiovascular disease. Moreover, there were seme factors that may have
increased the harmful effects caused by HRT. Ihe women enrolled in the stu~y
had a mean age of 63 years, with two-thirds being over 60. on average, the
women were overweight, and one third were obese. Fifty per cent were
previous or current cigarette smokers when they entered the study. One third
had received treatment for high blood pressure, and over 10% had raised
cholesterol levels requiring medication.
The WHI is the first trial with definitive ata supporting the ability of
postmenopausal hormones to prevent fractures at the hip vertebrae and other
sites.
It needs to be emphasised that the WHI trial arm consisting of conjugated
equine oestrogen only, for women with hysterectomies, has not been stopped
as the balance of risks and benefits in the unopposed oestrogen component,
at interim analyses, remains uncertain. The planned end of the latter trial
is March 2005, by which time the average follow-up will be about 8.5 years.
It is also important to note that the paper reporting the first WHI results
did not consider the proven benefits for menopausal symptom control e.g hot
flushes and also did not report the effects of HRT on uinary and vaginal
health.
Overall uality of life measures were not reported. In particular it has not
~y~t reported on the effect of HRT on brain function and dementia. It ~
vt'nerefore does not allow assessment o-f-tne"'bverali~bala:nce-oT all risks and
benefits of long-term HRT. Nevertheless is does indicate that the particular
combination utilised should not be used for long-term disease pr even't.Lon in
postmenopausal women because the benefits are not sufficient-to justify the
risks of such use. Although this conclusion could potentially apply to all
oestrogen/progestin combination hormone products, there are currently no
large randomised clinical trials (ReTs) that definitely prove a better
long-term effect associated with utilisation of other formulations or
routes. This must become a research priority, especlally as tnerm2tabolic
effects of different regimes are differentm which may have an effect on
their cardiovascular and possibly other effects. ,--------- _
The relevance of the WHO findings to the use of the particular HRT regimen
in short-term treatment to the use of the particular HRT regimen in
short-term treatment of symptoms in women at the time of menopause is less
certain.
However, treatment should n9_tbe_initiated for the sole purpose of '
prevention 'ó f -cardlO'va-s6ilardiseas'e. For' those already on 'such-treatment,
it is mandatory that they are informed of the WHI findings, and those who
elect to ontinue on it should probably limit utilisation to 4 years. Those
who choose to discontinue HRT or to convert to other preparations or routes
should probably be weaned off gradually. Above all, indiviualisation and
patient information are paramount.
Professor AH maclennan 9personal communication, 24 july 2002) makes the
following helpful points. Most women initiate HRT for symptom control. For
the first 4 years the serious risks may be few. After 4-5 years, if there
are no other indications to continue HRT, it may be reasonable to wean the
patient off HRT and try without it. Up to 40% of women previously' on HRT may
experience a recurrence of sufficient symptoms to warrant further years of
treatment.
A decision to continue HRT after 4-5 years is currently understandably
difficult when it brings potential risks as well as potential benefits. It
is to be hoped that more information 0 help in making these decisions wil
come from other ongoing WHI trials and another long-term trial abbreviated
as WISDOM (Women's International Study of Long Duration oestrogen after
menopause) the latter, begun in 1999, is being run in the UK, Australia and
New Zealand, and will eventually recruit a total of 22 Q90 women aged 50-69
years.
February 13, 2003 NEJM
In May 2002, the Women's Health Initiative (WHI) trial of daily combined
therapy with estrogen and progestin was terminated early. The reason for
stopping was an increased risk of breast cancer (and evidence of greater
overall risk than benefit) in the hormone-therapy group. Far more
surprising, however, was the associated increase in the risk of myocardial
infarction. An expectation of coronary benefit had been a major reason for
many women's decisions to use postmenopausal hormone therapy.
Earlier reports had failed to show improvement in cardiovascular outcomes in
9
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postmenopausal ~omen with known cardiovascular disease who were ttea~ed with
con:1.:gated equ i.r;eestrogen either alone or i:-!comb ine t i cn with
medroxyprogesterone. But i~ was still c~nsicered plausinle that heal~hy
women No~ld benefit. Several observational studies involving women wi~ho~~
coronary disease had shown roughly a halving of the risk of myocardial
infarction among hormone users. These findings might have been explained at
least in part by the tendency of healthier ~omen to use this therapy.
However, physiological data - such as improvement in lipid profiles and
measures of endothelial function with estrogen therapy - suggested
mechanisms for potential oenefit.
The results of the WHI left many women with more questions than answers. How
great are the risks of such therapy? Should women who are currently taking
estrogen and progestin stop immediately? What about hormonal formulations
other than that studied in the WHI (0.625 mg of conjugated equine estrogen
and 2.5 mg of medroxyprogesterone [Prempra, Wyeth-Ayerst])?
In reality, the absolute risks associated with daily combined
estrogen-progestin therapy are small (see Table
<http://content.nejm.org/cgi/contefl:t/full/348/7/579>). For example, the 29
percent increase ip the risk of coronary heart disease and th~ 26 percent
increase in the risk of invasive breast cancer associated witfi hormone
therapy in the WHI translate to 4 additional coronary events and 4 !
additional breast cancers for every 1000 women followed f or an average of ~,,·{/t
5.2.years. Thus, the argument against using postmenopausal hormone therapy "'g::i(
for the prevention of chronic diseases is not that the likelihQod of harm i3/! .
highi but rather that the potential harm outweighs the potential benefit. I.
This does not mean that postmenopausal hormone therapy should never be used.
Postmenopausal symptoms - such as hot flashes and vaginal dryness or
discomfort - remain a valid indication in the absence of contra indications
such as a history of venous thromboembolism or coronary disease. For
symptoms of genital atrophy alone, local estrogen or nonhormonal lubricants
may be sufficient and should be considered. Although there are other
possible treatments for vasomotor symptoms - for example, selective
serotonin-reuptake inhibitors - hormone therapy is very effective and still_
reasonable as first-line treatment. Because vasornóf.óf ..-sympf·oms··are generally
translent,S"fior":r':::tërrn--usë--TIó-.r:-·no more than two to three years) is all that
is generally needed, and such use carries few risks. Using the minimal dose
of estrogen that' controls symptoms (e.g.; 0.3 mg rather than 0.625 mg of
conjugated estrogen) makes sense, although there are no long-term data
indicating that a lower dose reduces risk.
What about women who are using postmenopausal estrogen-progestin therapy for
reasons other than control of symptoms? On the basis of available data,
these women should be advised to stop. Long-term use cannot routinely be
encouraged for the protsction of bone, given the availability of alternative
therapies, and there are no data from large clinical trials to support the
belief that long-term therapy will help women preserve cognitive function or
maintain a youthful appearance. .
That said, there is tio urgency to stop hormone therapy abruptly. In women
whose symptoms recur after stopping, therapy can be gradually tapered (by
reducing the frequency of administration, the d.ose, or both) over a period
of weeks to months. For a small number of women - those with persistent
symptoms and reduced quality of life - continued treatment may be justified,
as long as they understand thé potential risks and the alternatives.
The findings of the WHI and other trials do not rule out the possibility
that some postmenopausal women might derive cardiovascular benefit from
hormone therapy. In this issue of the Journal (pages 645-650), Grodstein et
al. hypothesize that benefit might be more likely in younger women who are
treated from the time of menopause; however, as the authors acknowledge,
this hypothesis is unproved and unlikely to be tested. Post hoc analyses of
clinical-trial data suggest that certain polymorphisms - for example, in the
gene for prothrombin or that for estrogen receptor - might predispose women
to cardiovascular harm or benefit from hormone therapy. Nonetheless, our
current ab~lity to identify "good candidates" for hormone therapy is too
rudimentary to support differential prescribing. Thus, the prudent approach
is to avoid hormone therapy for the purpose of long-term prevention of
disease.
The WHI findings have led some younger women who use oral contraceptives or
who use hormone therapy after premature menopauSe to wonder whether they
should stop. Studies of hormone therapy in w~men 50 years of age or older,
however, cannot be generalized tb these groups.
In respons~.~o the WHI, other hormonal regimens or prepárations have been
10
Stellenbosch University http://scholar.sun.ac.za
touted as alternóLives to conjugated estrogen with medroxyprogesterone.
Estrogen therapy alone (without a progestin) is not reco~mended unless a
woman has had a hysterectomy, because it is associated with increased risks
of endometrial hyperplasia and cancer. More information about the 10ng-te~T
effects of estrogen alone after hysterectomy should be forthcoming from a~
ongoing part of the WHI study. Different formulations (including "natural"
estrogens or progesterone) or transdermal administration has also been
suggested. However, their long-term effects have simply not been studied. o~
the basis of available data, the Food and Drug Administration recently
recommended that labeling for all postmenopausal estrogen and
estrogen-progestin products include a boxed warning emphasizing the
associated risks of coronary disease, stroke, and breast cancer.
What should postmenopausal women do now? Women older than 65 years of age or
younger women with other risk factors for osteoporosis should have their
bone mineral density measured. Women should routinely be advised to consume
adequate calcium and vitamin D and to engage in weight-bearing exercise. For
women who have osteoporosis, the bisphosphonates alendronate and risedronate
substantially reduce the risk ~t both hip and vertebral fractures. The
selective estrogen-receptor modulator raloxifene (discussed in this issue of
the Journal [pages 618-629]) also reduces the risk of vertebral fracture,
although it has not been shown to reduce the risk of hip fracture. In
contrast to estrogen, it appears to reduce the risk of invasive breast
cancer but does not improve (and may cause) menopausal symptoms. Ra.Lox i f ene
also increases the risk of venous thromboembolism, although its effects on
cardiovascular disease remain uncertain.
To reduce cardiovascular risk, coronary risk factors should be assessed,
including reevaluation of the lipid profile, which may worsen after the
cessation of hormone therapy. A healthful diet, exercise, and smoking
cessation should be encouraged; medications including statins and
antihypertensive agents should be used in appropriate patients. The
combination of these approaches is much more likely than estrogen-progestin
therapy to optimize health and longevity in postmenopausal women.
Source Information
From the Department of Medicine, Brigham and Women's Hospital, Boston
(R.G.D.) .
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In September 2002, the South African Medical Journal reports as follows on
the Womefl-'s Healtn Inltlative flIiCUtlgS. :_, , .. ,....' --, C
The principal results from the Women's healtn initiative (WHI)
randomisedcontrolled tria (RTC) published on 17 July 2002 have evoked a
widespread response in the medical and laypress. For instance, time magazine
of 22 July 2002 carried a 7-page article entltled 'The truth about hormones"
with the subtitle "A large federally-funded study provides definitive proof
that oestrogen and progestin are not age-defying wonder drugs. What's a
woman to do?"
As expected patients are alarmed and thei::::-doctors face a dilemma. Clearly
the study in question needs to be put in perspective. This editorial
addresses the pertinent findings and suggests mana~ement guidelines.
The overall goals of the WHO are to test methods of-reducing th~ risk for
cardiova~cular disease, breast cance, colorectoral cancer and osteoporotic
fracture~ in women. Many other health outcomes are being monitored ás well.
It is the largest and most expensive research study even funded by the
National Institute of Health (NIH) with a budget of $628 000 000 over the
1S-year period 1992-1997. It includes a randomised trial of about 64 000
women and an observational study of about 100 000 women in the age range
50-79 years, of diverse race/ethnicity and socio economic status. The three
branches of the randomised trial are designed to test hypotheses concerning
the effects of disease incidence of 9i) dietary modification (ii) hormone
replacement and (iii) calcium/vitamin O. Women may participate in one, two
or three branches of the trial. .
Almost all observational epidemiological studies find that oestrogen
replacement therapy (ERT) reduces the risk of coronary heart disease (CHO).
However, there is conc~rn that a tendency for healthier women to use HRT may
make it appear that the beneficial effect is greater than it really is.
Moereover, the effects of progestin and oestrogen replacement together are
less certain, because this combination cf ho:::monehas not been used for as
long a period of time as oestrogen on its own.
The principal results of the WHI paper concerning the risks and benefits of
oestrogen plus progestin in healthy post-menopausal women are summarised
below. The trial included 16 608 postmenopausal women who were randomised
to receive either one daily tablet containing conjugated equine oestrogen
(CEE) 0.625 mg and medroxyprogesterone acetate (MPA) 2.S mg (treatment group
- N=8 506) or a matching placebo (control group - N=8 102 This primary
prevention study was due to run for 8.5 years but was halted at an average
follow-up of 5.2 years because the number of cases of breast cancer had
reached a pre-specified safety limit. Moreover, the global index that
summated important aspects of health benefits versus risks, consisting of the
earliest occurrence of CHO, invasive breast cancer, stroke, pulmonary
'embolism (PE) endometrical cancer, colorecial cancer, hip fracture, or death
due to other causes, revealed a hazard ratio of 1.15.
As. absolute risks statis~ics are easier to apply to clinical practice, these
ar~trYnêaDeioW-;""Fo'r 'llr-ëJO 0 women taking such HRT -for- ay~red
with those not~taking it, there would be an additional 8 cases of invasive
breast cancer ~8 vs 30), 7 heart attacks (37 vs 30), 8 strokes (29 vs 21)
and 8 pulmonary embolisms (15 vs 7) However there would also be 6 fewer
bowel cancers (10 vs_ 16) and 5 fewer hip fractures (10 vs 15)
Overall mortlity was not increased with therapy.
The small increase in the number of patients with breast cancer did not
appear in the first 4 yars of use and accords with previous population
studies. After 5 years of this combined HRT the increased risk of breast
cancer ~as less than 1 in 1000. Parenthetically, studies to date show no
" lncrease in de a t.h s .f r om br e a s t; cancer in association with HRT.
In-vfew of fi'le~rally favourable biological effects o'f oestrogen on the
cardiovascular sstem, the .Lack- of benefit on coronoray heart disease is
'''':;~~~',sutpri~ing.The Kaplan Meier estimates of cumulative hazards. for CHD
-,indicate that the d.if.f.er.erice':between treatment groups began to'develop soon
after randomisation. Although'thê'WHI trial was 'a primary prevention study
...____-"'-""" .----...___ .._~:---
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in predominantly healthy women, aged 50 to 79 years, 7,7% had priqr
cardiovascular disease. Moreover, there were some factors that may have
increased the harmful effects caused by HRT. The women enrolled in the study
had a mean age of 63 years, with two-thirds being over 60. on average, the
women were overweight, and one third were obese. Fifty per cent were
previous or current cigarette smokers when they entered the study. One third
had received treatment for high blood pressure, and over 10% had raised
cholesterol levels requiring medication.
The WHI is the first trial with definitive ata supporting the ability of
postmenopausal hormones to prevent fractures at the hip vertebrae and other
sites.
It needs to be emphasised that the WHI trial arm consisting of conjugated
equine oestrogen only, for women with hysterectomies, has not been stopped
as the balance of risks and benefits in the unopposed oestrogen component,
at interim analyses, remains uncertain. The planned end of the latter trial
is March 2005, by which time the average follow-up will be about 8.5 years.
It is also important to note that the paper reporting the first WHI results
did not consider the proven benefits for menopausal symptom control e.g hot
flushes and also did not report the effects of HRT on uinary and vaginal
health.
Overall uality of life measures were not reported. In particular it has not
1~~t reported on the effect of HRT on brain function and dementia. It ~
vt'nerefore does not allow assessment of -tFie-ë:5veralr-bá Lance"ó'f all risks and
benefits of long-term HRT. Nevertheless is does indicate that the particular
combination utilised should not be used for long-term disease preven't i.on in
postmenopausal women because the benefits are not sufficient. to justify the
risks of such use. Although this conclusion could potentially apply to all
oestrogen/progestin combination hormone products, there are currently no
large randomised clinical trials (RCTs) that definitely prove a better
long-term effect associated with utilisation of other formulations or
routes. This must become a research priority, especlally as the metabolic
effects of different regimes are differentm which may have an effect on
their cardiovascular and possibly other effects. -,----- ~
The relevance of the WHO findings to the use of the particular HRT regimen
in short-term treatment to the use of the particular HRT regimen in
short-term treatment of symptoms in women at the time of menopause is less
certain.
However, treatment should 'n9_tbe_initiated for the sole purpose of
prevention ()f--cardió\ra-scularéfisease. 'For't.hose aLready on such--treatment,
it is mandatory that they are informed of the WHI findings, and those who
elect to ontinue on it should probably limit utilisation to 4 years. Those
who choose to discontinue HRT or to convert to other preparations or routes
should probably be weaned off gradually. Above all, indiviualisation and
patient information are paramount.
Professor AH maclennan 9personal communication, 24 july 2002) makes the
following helpful points. Most women initiate HRT for symptom control. For
the first 4 years the serious risks may be few. After 4-5 years, if there
are no other indications to continue HRT, it may be reasonable to wean the
patient off HRT and try without it. Up to 40% of women previously· on HRT may
experience a recurrence of sufficient symptoms to warrant further years of
treatment.
A decision to continue HRT after 4-5 years is currently understandably
difficult when it brings potential risks as well as potential benefits. It
is to be hoped that more information 0 help in making these decisions wil
come from other ongoing WHI trials and another long-term trial abbreviated
as WISDOM (Women's International Study of Long Duration oestrogen after
menopause) the latter, begun in 1999, is being run in the UK, Australia and
New Zealand, and will eventually recruit a total of 22 Q90 women aged 50-69
years.
". ~I11'" r \ A \. U' !\ \ - I \. " I '
February 13, 2003 NEJM ttl \-_~~-{!/~ '{jl/'- -h, ,'. / '
In May 2002, the Women's Health Initiative (WHI) trial of daily combined
therapy with estrogen and progestin was terminated early. The reason for
stopping was an increased risk of breast cancer (and evidence of greater
overall risk than benefit) in the hormone-therapy group. Far more
surprising, however, was the associated increase in the risk of myocardial
infarction. An expectation of coronary benefit had been a major reason for
many women's decisions to use postmenopausal hormone therapy.
Earlier reports had failed to show improvement in cardiovascular outcomes in
9
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postme~opausal ~omen with known cardiovascular disease who were ttea~ed with
con~ugated equi~e estrcge~ either alone ~r i~ combination with
medroxyprogesterone. But it was still c~nsiéered plausible that healthy
women ~ould benefit. Several observational s~udies involving women wi~ho~t
coronary disease had shown roughly a halving of the risk of myocardial
infarction among hormone users. These findings might have been explained a~
least in part by the tendency of healthier women to use this therapy.
However, physiological data - such as improvement in lipid profiles and
measures of endothelial function with estrogen therapy - suggested
mechanisms for potential benefit.
The results of the WHI left many women with more questions than answers. How
great are the risks of such therapy? Should women who are currently taking
estrogen and progestin stop immediately? What about hormonal formulations
other than that studied in the WHI (0.625 mg of conjugated equine estrogen
and 2.5 mg of medroxyprogesterone [Prempra, Wyeth-Ayerst])?
In reality, the absolute risks associated with daily combined
estrogen-progestin therapy are small (see Table
<http://content.nejm.org/cgi/cont~ht/full/348/7/579>). For example, the 29
percent increase in the risk of coronary heart disease and the 26 percent
increase in the risk of invasive breast cancer associated with hormone
therapy in the WHI translate to 4 additional coronary events and 4 J
addi tional breast cancers for every 1000 women followed 'for an average of ~~.y:.z,
5.2 years. Thus, the argument against using postmenopausal hormone therapy ~~~
for the prevention of chronic diseases is not that the likelihQod of harm is/ !
high, but rather that the potential harm outweighs the potential benefit ..
This does not mean that postmenopausal hormone therapy should never be used.
Postmenopausal symptoms - such as hot flashes and vaginal dryness or
discomfort - remain a valid indication in the absence of contra indications
such as a history of venous thromboembolism or coronary disease. For
symptoms of genital atrophy alone, local estrogen or nonhormonal lubricants
may be sufficient and should be considered. Although there are other
possible treatments for vasomotor symptoms - for example, selective
serotonin-reuptake inhibitors - hormone therapy is very effective and still_
reasonable as first-line treatment. Because vasom-óTórsympEo'ms' are gërierally
€ranslent, shor'F'::tërrn"'us-e~--(for'no more than two to three years) is all that
is generally needed, and such use carries few risks. Using the minimal dose
of estrogen that' controls symptoms (e.g.; 0.3 mg rather than 0.625 mg of
conjugated estrogen) makes sense, although there are no long-term data
indicating that a lower dose reduces risk.
What about women who are using postmenopausal estrogen-progestin therapy for
reasons other than control of symptoms? On the basis of available data,
these women should be advised to stop. Long-term use cannot routinely be
encouraged for the prot'~ction of bone, given the availability of alternative
therapies, and there are no data from large clinical trials to support the
belief that long-term therapy will help women preserve cognitive function or
maintain a youthful appearance. ,
That said, there is no urgency to stop hormone therapy abruptly. In women
whose symptoms recur after stopping, therapy can be gradually tapered (by
reducing the frequency of administration, the dose, or both) over a period
of weeks to months. For a small number of women - those with persistent
symptoms and reduced quality of life - continued treatment may be justified,
as long as they understand the potential risks and the alternatives.
The findings of the WHI and other trials do not rule out the possibility
that some postmenopausal women might derive cardiovascular benefit from
hormone therapy. In this issue of the Journal (pages 645-650), Grodstein et
al. hypothesize that benefit might be more likely in younger women who are
treated from the time of menopause; however, as the authors acknowledge,
this hypothesis is unproved and unlikely to be tested. Post hoc analyses of
clinical-trial data suggest that certain polymorphisms - for example, in the
gene for prothrombin or that for estrogen receptor - might predispose women
to cardiovascular harm or benefit from hormone therapy. Nonetheless, ou~
current ability to identify "good candidates" for hormone therapy is too
rudimentary to support differential preséribing. Thus, the prudent approach
is to avoid hormone therapy for the purpose of long-term prevention of
disease.
The WHI findings have led some younger women who use oral contraceptives or
who use hormone therapy after premature menopause to wonder whether they
should stop. Studies of hormone therapy in women 50 years of age or older,
howéver, cannot be generalized to these groups.
In respons~ ~o the WHI, other hormonal regimens or preparations have been
10
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touted as alternatives to conjugated estrogen with medroxyprogesterone.
Estrogen therapy alone (without a progestin) is not recommended unless a
woman has had a hysterectomy, because it is associated with increased risks
of endometrial hyperplasia and cancer. More information about the long-term
effects of estrogen alone after hysterectomy should be forthcoming from an
ongoing part of the WHI study. Different formulations (including "natural"
estrogens or progesterone) or transdermal administration has also been
suggested. However, their long-term effects have simply not been studied. On
the basis of available data, the Food and Drug Administration recently
recommended that labeling for all postmenopausal estrogen and
estrogen-progestin products include a boxed warning emphasizing the
associated risks of coronary disease, stroke, and breast cancer.
What should postmenopausal women do now? Women older than 65 years of age or
younger women with other risk factors for osteoporosis should have their
bone mineral density measured. Women should routinely be advised to consume
adequate calcium and vitamin D and to engage in weight-bearing exercise. For
women who have osteoporosis, the bisphosphonates alendronate and risedronate
substantially reduce the risk of both hip and vertebral fractures. The
selective estrogen-receptor modulator raloxifene (discussed in this issue of
the Journal [pages 618-629]) also reduces the risk of vertebral fracture,
although it has not been shown to reduce the risk of hip fracture. In
contrast to estrogen, it appears to reduce the risk of invasive breast
cancer but does not improve (and may cause) menopausal symptoms. RaLox i fene
also increases the risk of venous thrombo~mbolism, although its effects on
cardiovascular disease remain uncertain.
To reduce cardiovascular risk, coronary risk factors should be assessed,
including reevaluation of the lipid profile, which may worsen after the
cessation of hormone therapy. A healthful diet, exercise, and smoking
cessation should be encouraged; medications including statins and
antihypertensive agents should be used in appropriate patients. The
combination of these approaches is much more likely than estrogen-progestin
therapy to optimize health and longevity in postmenopausal women.
Source Information
From the Department of Medicine, Brigham and Women's Hospital, Boston
(R.G.D.) .
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Heart disease 7 1.29 (+29%)
Stroke 8 1.41 (+41%)
Pulmonary embolism 8 2.13 (+100%)
Breast cancer 8 1.26 (+26%)
Hip fractures (osteoporosis) 5 0.66 (-33%)
0.63 (-37%)
The South African Society of
Obstetricians and Gynaecologists (SASOG)!JI .
and The South African Menopause Society (SAMS)!2]
recommendations post- WHI study
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Contemporary Issues in Ob/Gyn & Women's Health
Reflections on the WHI Findings: Ávoiding a Pill Scare and Taking Sensible Steps
- Forward
Paul D. Blumenthal, MD, MPH
Medscape General Medicine 4(3),2002. © 2002 Medscape
Posted 07/18/2002
A little more than 25 years ago, the heretofore complacent world of estrogen replacement
therapy (ERT) was rocked by papers indicating that unopposed estrogen, when provided
over a long period of time to postmenopausal women, resulted in an increased risk of
endometrial cancer.[1,2jThis amounted to a "pill scare," which more commonly results
after the publication of a study finding some adverse event in connection with oral
contraceptives. Patients called their physicians in panic, the media was filled with fear-
mongering articles, prescriptions for exogenous estrogen plummeted, and clinicians went
to great lengths to provide symptomatic postmenopausal women with anything but an
estrogen-containing compound. Similar to what happens in a contraceptive pill scare,
women who were candidates for ERT even in the face of the newly reported results were
denied access by their providers.
In the case of a contraceptive pill scare, what usually results is an increase in subsequent
rates of unintended pregnancy and abortion. In the menopause setting, an ERT/hormone
replacement therapy (HRT) pill scare is likely to mean that women with menopausal
symptoms who could be helped through this life phase by low-dose, relatively short-term
hormone therapy, which has not been implicated as being risky or dangerous, will be
shifted away from the most effective means of treatment toward less effective modalities.
This may satisfy a risk-averse medical community. However, clinicians, the media, and
the general public should all be aware of the variety of effective alternative hormone
regimens that are actually available.
To be sure, the Women's Health Initiative (WHI) results are noteworthy, and changes in
clinical practice are indeed both likely and warranted. But health professionals,
healthcare providers, the lay public, and the media need not panic. The media in
particular need to put these results into perspective and avoid the temptation to create
even more controversy and consternation than is necessary. No doubt, this week's top
story will be replaced by a new crisis before you can say "hormone replacement therapy,"
but the crisis in confidence oroduced bv renortinz that is desizned more to attract
Stellenbosch University http://scholar.sun.ac.za
attention than to provide guidance will last for years.
In addition, as with any good study, the results presented this week generate more
questions than hard answers, and both clinicians and the media need to be responsible in
profiling the implications of the WHI results to their patients and to the public,
respectively. The commentaries appearing in this journal by Dr. Randolph, Dr.
Notelovitz, and Dr. Kaunitz are exactly what is required to provide the necessary
perspective (absolute as opposed to relative risk) and to identify solutions (lower dose,
different progestin, more counseling) instead of simply amplifying the problem.
References
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WHI Findings Summary
Estrogen plus Progestin Effects OrJ Bone Density and the Risk of
Fractures
In the October 1 issue of the Journal of the American Medical Association (JAMA),
WHI published the final fracture results for the Estrogen plus Progestin (E+P) study.
The updated results include information on risk factors for fracture, additional fracture
cases, and the bone density results for women in this part of the study.
The updated analysis shows that after an average of 5.6 years, 733 (8.6%) women in
the E+P group and 896 (11.1%) women taking placebo (inactive) pills experienced a
fracture.
• Overall, there was a 24% reduction in all fractures and a 33% reduction in hip
fractures in women assigned to E+P. '-
• Hip bone density increased 3.7% after 3 years of taking E+P compared to
0.14% in the placebo group.
E+P reduced the risk of fracture to a similar degree in women who were considered to
be at high or low risk of fracture.
WHI reported in July 2002 that the overall risks of E+P outweighed the benefits,
including the fracture benefits. This new report examined whether the balance of risks
and benefits, summarized in a global index, differed in women considered to be at
high or low risk of fracture. The global index is a number that represents the
combined risks and benefits for the major outcomes studied in WH!. There was no
evidence of an overall benefit. Even in the group of women at increased risk of
fracture, who would benefit most from the prevention of fractures, the risks of E+P
outweigh the benefits.
In conclusion, treatment with E+P should not be recommended for the prevention and
treatment of osteoporosis in women who don't have menopausal symptoms. Other
medicines for osteoporosis should be considered. If E+P is prescribed to prevent
osteoporosis, women need to be informed of the risks of taking E+P .
• Abstract of sG_i_~nljficpaper in tb~ Jo_Yrmu.Qf th~_Am_~fican_M_edical
~ss_Qciation
http://www .whi. org/findings/ summary_bone .asp
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WHI Findings Summary
Estrogen plus Progestin and Risk of Coronary Heart Disease
In the August 7 issue of the New England Journal of Medicine, WHI published the
final coronary heart disease (CHO) results for the Estrogen plus Progestin (E+P)
study. The findings suggest that E+P does not protect the heart and may even
increase the risk of coronary heart disease (CHO).
In final analyses, E+P use was associated with:
• A 24% overall increase in the risk of CHO (6 more heart attacks annually per
10,000 women using E+P)
• An 81% increased risk of CHO in the first year after starting E+P
Women who had higher baseline low-density lipoprotein (LOL) cholesterol levels at
the beginning of the study were at particularly high risk of CHO with E+P use. No
other factors significantly changed the risk of CHO while using E+P.
In conclusion, E+P does not protect the heart and may increase the risk of CHO
among generally healthy postmenopausal women, especially during the first year
after beginning hormones. E+P should not be started or continued to prevent heart
disease.
http://www. whi.org/findings/summary _chd.asp
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WHI Findings Summary
Estrogen plus Progestin Effects on ~reast Cancer and Mammograms
WHI study findings on the risk of breast cancer in women taking combined estrogen
plus progestin (E+P) were published in the July 2002 issue of the Journal of the
American Medical Association (JAMA). The E+P study continues to be analyzed.
Updated results (June 25 issue of JAMA) include data on additional breast cancer
cases, their characteristics, and mammogram results for women in the study.
The 2002 report showed that more women taking E+P developed breast cancer than
those taking placebo (inactive) pills. This updated analysis shows that after an
average of 5.6 years, 245 of the 8,506 E+P women and 185 of the 8,102 women on
placebo developed breast cancer. Of the total cancers, 349 cases were invasive, a
type of breast cancer with a greater chance of spreading to other parts of the body.
The conclusions below are based on the invasive breast cancer group.
• The increased risk of breast cancer due to E+P was eight additional cases of
breast cancer for every 10,000 women over one year
• Overall, there was a 24% increase in the risk for breast cancer due to E+P
The breast cancers in the E+P group had similar characteristics (looked the same
under a microscope) to those in the placebo group. However, the tumors in the E+P
group tended to be larger and more advanced (had spread to the lymph nodes or
elsewhere in the body). A more advanced stage is usually associated with poorer
outcome. At this time, no direct statements can be made about the prognosis of the
breast cancer found in women taking E+P until more follow-up information is
collected. .
After even one year, quite a few more women had abnormal mammograms in the
E+P group (9.4%) compared to the placebo group (5.4%); this pattern continued until
the study ended. An abnormal mammogram is a breast X-ray that results in a
recommendation for additional medical evaluation (most often, a shorter time between
mammograms, but sometimes, a breast biopsy or other tests). Although we have
known from other studies that E+P use increases the density of breast tissue on
mammograms, the increase in abnormal mammograms with E+P use seen in this
study is a new finding.
Further WHI studies are being done to learn what happens to breast cancer rates and
mammograms after E+P use is stopped.
• Abstract of sc!~ntific paper in the Journal of the American M~gical
Asso~iation
http://www .whi. org/findings/ summary_be .asp
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WHI Findings Summary
Effects of Estrogen plus Progestin on Stroke in the Women's Health
Initiative
JAMA May 28, 2003
While the world continues to discuss the J_!!Iy_~_O_Q_~_li"mtingsfrom the WHI EstrQgen
Plus Progestin Study, WHI investigators are busy analyzing the data in much more
detail. Study findings on the risk of stroke in women taking combined estrogen plus
progestin (E+P) were published in the May 28, 2003 issue of the Journal of the
American Medical Association (JAMA). These updated results include data on
additional strokes, information on types of stroke, and data on risk factors for stroke.
As reported earlier, women taking active E+P developed more strokes than did those
taking placebo (inactive) pills. This updated analysis showed that after an average of
5.6 years, 151 (1.8%) of the 8506 women on estrogen plus progestin and 107 (1.3%)
of the 8102 women on placebo developed strokes. We can describe these same
findings in several other ways:
• For every 10,000 women followed for 1 year, we would expect to see 31 strokes
in women on E+P compared to 24 in women on placebo.
• The excess risk of stroke due to E+P was 7 strokes for every 10,000 women
over one year.
• There is a 31% increase in the risk for stroke due to E+P.
Most of these strokes were caused by blood clots in the brain. This is the type of
stroke affected by E+P. The less common type of stroke, caused by bleeding into the
brain, did not seem to be affected by E+P. The increased risk of stroke due to E+P
was seen in all groups of women studied, including those closest to the menopausal
change and those with symptoms like hot flashes. The authors conclude that
combined E+P should not be used to prevent cardiovascular diseases. The authors
confirmed several risk factors for stroke that women can control: high blood pressure,
smoking, and diabetes. They also suggest that exercise and taking vitamin C
supplements reduce risk for stroke. Although the health benefits of exercise have
been generally accepted, the benefits of vitamin C in reducing stroke risk will need to
be confirmed by other randomized clinical trials. Further work is being done within
WHI to learn more about the ways in which E+P affects cardiovascular disease .
• Ab~_tract Qf scientific_~per in Journal of the American Medical Association
http://www,whi.org/findings/summary_stroke.asp
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